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Chapter 
I ntroduction 
1.1 Chirality 
Knowledge about the spatial arrangement and chirality of organic molecules plays a dominant 
role in modem chemistry Especially, the widespread recognition of the importance of using chiral, 
bioactive compounds in enantiopure pure form, is an important incentive for scientific activities in 
this area As the molecular environment in living organisms is chiral', interactions with bioactive 
chiral substances are predominantly based on chiral recognition It should be noted however, that it 
is still common practice to administer medicines with chiral ingredients as racemates There are 
numerous examples of differences in physiological action in pairs of enantiomers A few are listed 
in Figure 1-1 
HOOC 
COOH HOOC 
N H l
 Asparagine N H 2 
COOH 
bitter (S) ·*- 1 —»• (R) sweet 
H 0 \ T - ^ \ ^ \ < '
C 0 0 H H O O C 
H o J U NH2 D o p a 
anti-Parkinson (S) ·*— 5 — 
nor 
(R) toxic 
OH 
4 α xv Q4^°°<H@ Limonene 
lemon (R) ·*— 2 —•· (S) orange 
0
 О Thalidomide О О 
teratogen (S) •*— 6 —»• (R) sedative 
О О 
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f 
OH HO 
N.. .Ν 
I I 
H 0
^ Ethambutol ^OH 
tuberculostatic (S,S) •*— 7 —»• (R,R) blindness 
"™Ί0ι 
iBu ¡Bu 
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(Et)2N N(Et)2 
DARVON X ? ' ^O^ NOVRAD 
analgesic (R S) •*— 8 —*• (S R) antitussive 
Figure 1-1. Pairs of enantiomers with different physiological actions 
Dissimilar taste is observed for enantiomers of asparagine 1. The natural enantiomer of 
asparagine 1 tastes bitter whereas the opposite enantiomer is sweet2. Different smell properties are 
noticed for limonene 2 and carvone 3 enantiomers. The analgesic and antiinflammatory activity of 
Ibuprofen 4 resides in the (S)-enantiomer whilst the other enantiomer is inactive3. A well-known 
and grievous example of a drug where the distomer causes serious side-effects is thalidomide 6 
(also known as Softenon), which was developed as racemate in the 1960s and sold as a sedative. 
Later on it became clear that the (R)-enantiomer is an effective sedative but that the (S)-enantiomer 
is teratogenic and causes fetal abnormalities4. The enantiomers of propoxyphene 8 show completely 
different activities. One enantiomer has analgesic properties, whereas its optical antipode is an 
antitussive devoid of analgesic activity. Both drugs are marketed by Eli Lilly as DARVON and 
NOVRADc reflecting their mirror image relationship5. 
These examples show clearly the great importance of synthesizing chiral pharmaceuticals in 
enantiomerically pure form The current trend is that chiral products (e.g. DOPA 5) are being 
developed and marketed as single, enantiopure isomers. Legislation in Europe and USA, i.e. the 
Food and Drug Administration (FDA), now enforces a rational development of chiral drugs taking 
different actions of optical isomers into account. The FDA also stated that the use of single isomers 
may be advantageous. Formal guidelines were issued in 1992-19936 However, there is uncertainty 
about whether and when agencies will approve single isomers that are already approved as 
racemates; the so-called racemic switch. Industry observers stated that FDA reviewers have not 
decided on a clear policy for dealing with racemic switches7. 
1.2 Synthesis of Enantiopure Compounds 
In principle three methods for the synthesis of enantiopure' compounds are available which in 
this section are briefly described: 
1. (catalytic) asymmetric synthesis 
2. synthesis from the chiral pool 
3. resolution of racemates 
/ 
Synthesis 
'Chiral Pool' 
Prochiral Substrates 
Asymmetric Synthesis 
\ 
Enantiopure Compound 1 
\ 
Res Dlution 
\ 
Racemates 
Figure 1-2. Synthetic methods to enantiopure compounds. 
' Occasionaly the term 'optically pure' is used in stead of'enantiopure' or 'enantiomerically pure' 
Introduction 
Enantiopure compounds can be synthesized from prochiral substrates by asymmetric 
synthesis. Introducing chirality in such a synthesis requires an enantiopure agent or auxiliary. 
Reactions using enzymes or synthetic enantioselective catalysts are gaining great 
.mportance8910"1213 
The chiral pool refers to readily available optically pure products and their derivatives (e.g. 
sugars, amino acids, alkaloids and penicillins). Many of these products are obtainable from natural 
sources or from large scale industrial processes and are usually inexpensive. A wide range of 
selective synthetic methods is available to elaborate these molecules without affecting the optical 
purity. Substrates from the chiral pool can serve as basis for the preparation of new optically pure 
compounds which in turn can be added to the chiral pool8"4 " 
Resolution of racemates is a classic but still very useful method to obtain optically active 
compounds. There are essentially three methods for the resolution of racemates, viz. 
(1) chromatographic separation employing homochiral stationary phases. In the 1980s, 
separation with high pressure liquid chromatography (HPLC) became common practice also 
stimulated by the growing number of commercially available homochiral stationary phases'6 HPLC 
is attractive as it is performed at room temperature and in principle has the potential for larger scale 
preparative separations. There are also reports on separations using gas chromatography", but this 
method is limited by the high operating temperatures and requirement of sufficiently volatile 
substrates. In recent years there is a growing interest in separating racemates by capillary zone 
electrophoresis, which appears to be a very versatile method in the determination of enantiomeric 
excess (ее)'8. 
(ii) Kinetic resolution, whereby the difference in reaction rate between two enantiomers and 
an optically pure reagent (an enzyme or chemical reagent) results in an enantiomeric enrichment of 
the starting material and/or the reaction product8"9202122. 
(iii) Resolution of a racemate by selective crystallization, which can be subdivided in two 
groups: the direct crystallization of enantiomers and the crystallization of diastereomers. These 
methods are described in more detail in section 1.3 and 1.4. 
In spite of the revolutionary advances in (catalytic) asymmetric synthesis, the (kinetic) 
resolution of racemates still remains the most important method for the industrial synthesis of 
optically pure compounds, simply because it is economically the most attractive method. 
1.3 Resolution of Racemates by Direct Crystallization 
Resolution of a racemate by crystallization techniques can be performed by two methods, viz. 
direct crystallization from a mixture of enantiomers and separation of enantiomers by formation of 
diastereomers, the latter method will be discussed in section 1.4. Resolution of racemates by direct 
crystallization of one of the enantiomers is the simplest method, as no additional chiral substrates or 
reagents are required. However, from an operational point of view many difficulties can be 
encountered. Whether a racemate can be resolved by this direct method depends on the type of 
racemate. A racemate is defined as an equimolar mixture of two enantiomers regardless of the 
3 
physical state25 Crystalline racemates may belong to three different classes, which are characterized 
by their binary (melting) phase diagrams (see Figure 1-3)24'25. A racemic compound (type a) consists 
of the two enantiomers in equal amounts and in a regular pattern within a single crystal and 
therefore crystallization of the racemate results only in racemic material. This type of racemate is 
the most common one. About 80-90% of chiral organic compounds exist in this form26. Only about 
10-20% exist in the form of a conglomerate27 (type b) which is a mechanical mixture of crystals of 
the pure enantiomers and therefore separable by direct crystallization. Fortunately, many simple 
salts of organic acids or bases consist as conglomerates, thus enhancing the value of this method. In 
a solid solution (type c) two enantiomers coexist in an unordered manner in the crystal. This type of 
racemates, which is very rare, is also called a pseudoracemate. Crystallization of a pseudoracemate 
has almost no influence on the composition and optical enrichment is usually low. The above 
classification of racemates does not imply that every chiral organic compound exist in only one 
crystal form. Polymorphs, compounds which can exist in more than one crystalline form, are well-
known Examples are known where crystals with different morphology can interconvert by changes 
in temperature or pressure28 
IT 
\, 
R 
(b) 
Xo5 SR Xos SR Xo5 S 
(a)  (c) 
Figure 1-3. Binary phase diagrams of the three types of racemates. racemic compound (a), 
conglomerate (b), solid solution (c): ideal (1), with a maximum (2) and with a 
minimum (3). Τ is the temperature and χ the molar fraction 
From the above description of racemates it is clear that resolution through direct 
crystallization is only possible with conglomerates. They can be separated by manual sorting29 
(crystal picking) which was performed by Pasteur more then one century ago10 A more widely 
applied method is preferential crystallization, also called resolution by entrainment811'2 This 
method involves seeding a supersaturated solution of the conglomerate with one enantiomer, 
inducing crystallization of that enantiomer. Direct crystallization of conglomerates is, for example, 
applied on an industrial scale for the a-methyl-DOPA derivative 9" and chloramphenicol 
intermediate 10" (Figure 1-4). Preferential crystallization can be improved and facilitated by using 
chiral solvents and additives35. Operational stability can sometimes be low because of uncontrolled 
crystallization from the supersaturated solutions caused by foreign crystallization nuclei. 
Nevertheless, many examples, also in industry, are known. For instance, practically all natural 
amino acids are resolvable by preferential crystallization either directly or as salt with an achiral 
agentj6. Also racemic amines can be resolved by direct crystallization of their salts with achiral 
acids For example, a-methylbenzylamine 11 is resolved by preferential crystallization of its 
4 
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cinnamic acid salt'7 and norfenfluramine 12 by preferential crystallization of its salt with several 
achiral acids3" Likewise, racemic carboxylic acids can be resolved directly by crystallization of 
their salts with achiral amines Naproxen 13, for example, is resolved by preferential crystallization 
as its benzylamine salt39 
CbN
v 
1.4 Resolution by Diastereomer Crystallization 
The most frequently applied method for separation of a mixture of enantiomers involves 
formation of a pair of diastereomers with an optically pure resolving agent In contrast to 
enantiomers. diastereomers have different physical properties and can be separated by 
chromatography or by crystallization techniques This method was first performed by Pasteur40 
more than one century ago and is referred to as classical resolution when applied to diastereomenc 
salts 
2(+/-)-A + 2(+)-B *- (+)-A(+)-B + (-)-A(+)-B 
p-salt n-salt 
Scheme 1-1. Classical resolution (A is the substrate, В is the resolving agent) 
When a racemic acid A reacts with an optically pure base В a mixture of two diastereomenc 
salts results (Scheme 1-1) The p-salt (positive) denotes the salt resulting from the enantiomers with 
the same sign of optical rotation and n-salt (negative) from those with opposite signs In practice, 
classical resolution usually involves formation of diastereomenc salts between acids and bases and 
subsequent selective crystallization of one of the stereoisomers based on solubility differences In 
principle, the resolving agent can readily be recycled by acid-base extractions When both 
enantiomers of the resolving agent are available, also both enantiomers of the resolved substrate are 
obtainable, because resolutions with opposite enantiomers proceeds in the same manner This is 
known as the Marckwald principle41 
When a racemic acid is resolvable by an optically pure amine, it is fairly common that this 
same racemic amine may be resolved by the optically pure acid This process is known as reciprocal 
resolution and although this statement is not entirely legitimate, "in general, one may embark upon 
reciprocal resolution with optimism", as stated by Jacques, Collet and Wilen41b 
The main problem in developing a resolution process for a racemate via diastereomenc 
crystallization involves the search for a suitable resolving agent At present, no suitable method is 
5 
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available for the prediction of a resolving agent for a given racemate42 A large number of 
resolutions has been collected by Wilen43 and N e w m a n " , unfortunately however, this collection has 
not been updated Recently, resolutions using the resolvants mandelic acid 25 and a -
methvlbenzy lamine 11 were collected by Yamakawa Chemical Industry45 Eliel and Wilen46 tried to 
arrange resolving agents according to substrate type Common resolving agent are depicted in 
Figure 1-5 and include compounds from the chiral pool ( e g brucine 14. tartaric acid 20) and 
synthetic resolving agents ( e g cx-methylbenzylamine 11, 2-amino-l-butanol 23) The cyclic 
phosphoric acids 28 constitute a relatively new class of synthetic resolving agents 42c47 
Chiral Pool 
14 Brucine (X=OMe) 
15 Strychnine (X=H) 
16 Quinine (X=OMe) 18 19 
17 Cinchonodine (X=H) Dehydroabiethylamine Ephedrine 
HOOC. ^ V V - S O . H 
20 21 22 
Tartatnc acid Malic acid 10-Camphor sulfonic acid 
HO OH 
^ < 
HOOC COOH 
COO H 
OH 
CO. NHT NH·, 
11 23 24 
a-Methylbenzylamine 2-amino-l-butanol Amphetamine 
OH 
0 ^ COOH £Q COOH о^ ^соон τ 
25 26 27 
Mandelic acid Hydratropic acid Phenoxypropionic acid Cyclic phosphoric acid 
Figure 1-5. C o m m o n l y used resolving agents 
A resolution may be improved by using less than one equivalent of the resolving agent 
Theoretically, a resolution should be possible with only half an equivalent of resolving agent This 
method is known as ' the method of half quantit ies ' and involves the crystallization of one 
6 
Introduction 
enantiomer as a diastereomeric salt whereas the other enantiomer remains in solution. This method 
was already described more than one century ago by Marckwald48 and practical optimum conditions 
are in most cases found by using ca. 0.7 equivalent of resolving agent. The 'method of Pope and 
Peachy"" (Scheme 1-2) is a modification using half an equivalent of resolving agent along with a 
half-quantity of achiral acid or base. The achiral acid or base is added to neutralize the excess of 
racemate. Recently, the mechanism of resolution by this method was studied50. 
(i) 2(+/-)-A + (+)-B 
(Ü) 2(+/-)-B + (+)-A 
KOH 
HCl 
(+)-A.(+)-B + (-)-A".K + H20 
(solid) * (solution) 
(+)-B.(+)-A + (-)-BH CL" 
(solid) * (solution) 
Scheme 1-2. Resolution by the method of Pope and Peachy. 
(i. method by using base, ii. method by using acid) 
Binary phase diagrams of systems consisting of two diastereomeric salts are similarly 
constructed as those for mixtures of enantiomers (see section 1.3). The only difference in these 
diagrams is that they are not symmetric (Figure 1-6)". In contrast with racemates, mixtures of 
diastereomers usually form eutectic mixtures (the equivalent of a conglomerate). The formation of 
addition compounds (double salts, equivalent to racemic compounds) is very exceptional. However, 
the occurrence of solid solutions of mixtures of diastereomers is less rare than it is for racemates. 
The shape of the phase diagram is of fundamental importance for a successful resolution. It 
determines whether or not a mixture can be resolved, the course and the maximum yield of that 
resolution51" " 
Xo.5 η ρ x«5 η ρ Xos 
(a) (b) (с) 
Figure 1-6. Binary phase diagrams of mixtures of diastereomers: (a) addition compound 
(double salts); (b) eutectic mixture; (c) solid solution. Τ is the temperature, ρ and η are 
the pure diastereomers, χ is the molar fraction and x
eu
 is the eutectic composition. 
The maximum yield of an optically pure diastereomer Ρ in the resolution of an eutectic 
mixture (1:1) is given by RE/ΡΕ (Figure l-7a) and the maximum theoretical yield of 50% is 
approached when the eutectic (E) is close to N. A favorable binary phase diagram of an eutectic 
mixture is therefore one with an eutectic near one of the ends of the diagram. The maximum yield 
of optically pure Ρ in a purification or resolution of an eutectic mixture with composition M is 
given by ME/ΡΕ. Optical enrichment of a racemic compound is only possible in the domain PE' or 
7 
Chapter 1 
E"N (Figure 1 -7b), because crystallization in the range E'RE" results'in racemic material The 
maximum yield of optically pure Ρ in the purification of a racemic compound with composition M' 
is given by M'E'/PE' and the yield increases if M'-> R and decreases if M'-> E' The highest 
vield of optically pure Ρ is therefore obtained with conglomerates (E'=I=E") 
PE-
-ME- ?W 
-M'E'· 
-E'RE11 * 
-E"N--
M N M' E' N R E' 
(a) (b) 
Figure 1-7. Binary phase diagram of an eutectic mixture (a) and a racemic compound (b) Τ is the 
temperature, Ρ and N are the pure diastereomers, R is the racemic composition and E 
E and E' ' are eutectic compositions 
The quality of a resolution can be described adequately by the parameter S, first introduced by 
Fogassv'3 S is obtained by the equation 
S = k t 
•к,, (1-1) 0 5 Co 
where к is the chemical yield (k=2 for 100% yield) t the optical purity (t=l for 100% ее), kp and kn 
the solubility of the p-salt and η-salt respectively and C0 the initial concentration of substrate in the 
solution The range of S is from 0 to 1 0 for no resolution (t=0) and 1 for maximum resolution 
(k=t=l) Calculating S from к and t has the disadvantage that the obtained S-values are highly 
dependent on the experimental conditions A better method for calculating S is to use the measured 
solubilities kp and kn of the ρ and n-salt
42a
 The best method however, is to use the solubilities of the 
diastereomenc salts under experimental resolution conditions, which can be obtained from the 
eutectic point in the ternary phase diagram 
The ultimate goal in the study of resolutions is the rational design of resolutions, ι e to 
correlate molecular structure with resolving capability Although considerable progress has been 
made in the rational design of drugs by computer assisted molecular modeling (CAMM) of drug-
receptor interactions, rational design of resolutions is far more complex because it includes the 
prediction of crystal packing and finding correlations between properties of resolving agents and 
resolution processes A study of classical resolutions using cyclic phosphoric acids 28 was 
performed at the University of Nijmegen in order to find correlations between physical properties of 
the diastereomenc salts and calculated S-valuesJ2lc In other recent studies Fogassy et al attempted 
to correlate crystal structures of diastereomenc salts with resolution processes" Also the roles of 
Introduction 
solvates and solvents were investigated". Thus far, useful results with some predicting value have 
only been obtained for structurally related series of compounds 
A topic of recent interest is resolution through chiral inclusion compounds 5 0". Selectivity of 
this process depends among others on relative stability of the diastereomeric complexes formed, 
topological compatibility and flexibility. Two broad classes of inclusion compounds can be 
identified, viz. cavitates (e.g. cyclodextrins, crown ethers) and clathrates (e g. urea, tno-o-
thymotide). This method broadens the scope of resolution of racemates by crystallization techniques 
because more classes of substrates can be applied. 
1.5 Resolution with In Situ Racemization: 
Asymmetric Transformation and Dynamic Kinetic Resolution 
As mentioned in section 1.2, resolution is still the most attractive method for the industrial 
production of enantiopure compounds. The main disadvantage of resolution is the maximum 
theoretical yield of 50%. Therefore, racemization of the unwanted isomer is of great concern. An 
economically favorable process can be obtained if a resolution by selective crystallization is 
accompanied by an in situ racemization/epimerization of the unwanted enantiomer/diastereomer, 
allowing a theoretical yield of 100%. Such a process is referred to as crystallization-induced 
asymmetric transformation (Scheme 1-3)58 
a (+/-)-A (+)-A щ= (solution) 
preferential 
crystallization 
(-)-A 
(solution) 
(+)-A (solid)T 
5D (+/-)-A (+)-B 
[ i s t o r d e r ] 
(+)-A.(+)-B - » (-)-A.(+)-B 
(p-salt, solution) (η-salt, solution) 
crystallization ( 2nd order] 
(+)-A.(+)-B 
(p-salt, solid)* 
Scheme 1-3. Crystallization-induced asymmetric transformation of: (I) mixture of enantiomers 
(only conglomerates), (II) mixture of diastereomers. (A is the substrate and В the 
resolving agent) 
Crystallization-induced asymmetric transformations are possible for both racemates (I) and 
mixtures of diastereomers (II). However, the former are relatively rare because the racemate has to 
exist in the form of a conglomerate. Two equilibrating enantiomers of a conglomerate in solution 
are present in equal amounts because there are no differences in physical properties. When this 
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equilibrium exists in a supersaturated solution, crystals of one isomer can be obtained after seeding 
the solution with crystals of the desired enantiomer In the case of mixtures of diastereomers there is 
a fundamental difference between a first- and second-order process A pair of equilibrating 
diastereomers, formed from a resolving agent В and an optically labile racemic substrate A, can 
have unequal quantities at equilibrium in solution because they have different physical properties 
Such a thermodynamic equilibrium in which one of the diastereomers is present in excess is referred 
to as a first-order asymmetric transformation In a second-order asymmetric transformation this 
equilibrium in a supersaturated solution is continuously displaced by crystallization of only one of 
the diastereomers until 100% of this pure isomer is obtained It should be noted that there is no 
relationship between the diastereomer present in excess in the first-order process 
(thermodynamically the most stable isomer) and the diastereomer crystallizing in the second-order 
process (isomer with lowest solubility) A literature survey of crystallization-induced asymmetric 
transformation is presented in section 2 2 
If a kinetic resolution is accompanied by an in situ racemization of the unwanted enantiomer, 
the process is called a dynamic kinetic resolution (Scheme 1-4) In this process, a racemic substrate 
S reacts with unequal rate constants (k(+) s » k(, s) to an optically enriched product (+)-P in the 
presence of a nonracemic catalyst (reagent) or enzyme However, the substrate (with the remaining 
(-)-S in excess) is racemized under the reaction conditions allowing a maximum yield of more then 
50% When the rate of racemization of substrate S is sufficient high with respect to the rate of 
reaction (k
mv
 > k(+) s » k( ( s ), enantiopure product (+)-P can be produced in 100% yield Recent 
reviews concerning dynamic kinetic resolutions are published by Noyori59 and Ward60 
k(+)-S 
— ^ — (+)-P 
кщ > k(+)_S s> \.)A 
k
-^* (-)-P 
Scheme 1-4. Dynamic kinetic resolution (S is the substrate and Ρ is the product, 
k(+) s and Ц ) s are the reaction rates and k,nv is the inversion rate 
First- or second-order asymmetric transformations and dynamic kinetic resolutions are 
distinguished by two characteristics, viz asymmetric transformations are thermodynamically 
controlled in contrast to dynamic kinetic resolutions which are kinetically controlled Furthermore. 
onl> changes in stereochemistry of a substrate occur in asymmetric transformations, whilst dvnamic 
kinetic resolutions include stereochemical and structural changes by reaction with a nonracemic 
reagent Therefore, substrate and product are different in dynamic kinetic resolutions and identical 
in asymmetric transformations 
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An asymmetric transformation or dynamic kinetic resolution is achieved when the following 
equation is valid 
-X- f^
 + 50 100 I. 2 
where y is the yield (%) and ее the enantiomeric excess (%) In other words, when one enantiomer 
is obtained in a total amount greater than 50% 
1.6 Aim and Outline of the thesis 
The major drawback of the classical resolution of racemates is that the unwanted isomer is 
also obtained and in at least the same amount as the desired single isomer Such a resolution process 
will be highly improved when an in situ racemization of the unwanted isomer could be achieved In 
other words, the conversion of a conventional resolution into an asymmetric transformation is an 
interesting challenge In this thesis attention is focused on the racemization process of a series of a-
substituted carboxylic acids with the aim to design an asymmetric transformation for these 
compounds 
In Chapter 1 an introduction on enantiopure compounds and their synthesis is presented In 
addition, a brief overview of resolution techniques with or without in situ racemization is given 
Chapter 2 deals with a literature survey of asymmetric transformations, showing that known 
examples are mainly the result of accidental discoveries" An exception is the crystallization-
induced asymmetric transformation of amino acids which is well studied an applied in industry and 
covering the major part of the literature Therefore, there is a clear need for a more rational design 
of asymmetric transformations applicable to a broad range of compounds Racemization is of 
essential importance in the design of an asymmetric transformation Despite this fact racemization 
has drawn little scientific attention A systematic investigation of the available (patent-)hterature 
has also been made in Chapter 261 
Chapter 3 describes the racemization of mandelic acid and derivatives61 It is concluded that 
racemization by base is the most promising method From a kinetic study the conclusion is drawn 
that base-catalyzed racemization is very effective when performing the reaction in the melt Based 
upon this result it was attempted to perform a crystallization-induced asymmetric transformation of 
mandelic acid by combination of a resolution and base-catalyzed racemization in the melt61 
Chapter 4 deals with the racemization of α-arylpropionic acids, also in the melt, and describes 
the crystallization-induced asymmetric transformation of Ibuprofen and hydratropic acid61"'' In this 
chapter important parameters of crystallization-induced asymmetric transformation are more 
systematically investigated and optimized 
Chapter 5 describes new resolving bases for mandelic acid and Ibuprofen, which are qualified 
by their binary phase diagrams In Chapter 6 the prediction of the efficiency of resolution based on 
arbitrary conglomerate samples is presented This method is shown to be useful for a quick selection 
and qualification of resolution processes Chapter 7 deals with the anhydride-mediated racemization 
of α-substituted carboxylic acids This thesis is concluded with a summary in Dutch and English 
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Chapter 
L iterature Survey: Racemization and Asymmetric Transformation 
2.1 Introduction 
An essential feature of economically attractive resolution processes is that the unwanted 
enantiomer can be recycled In principle three methods are available 
• use of the unwanted enantiomer for other purposes 
• inversion into the desired enantiomer 
• racemization to the starting racemic material 
Realistic possibilities involve the use of racemization, preferably simultaneous with the 
resolution and thus allowing a theoretical yield of 100% of a single stereoisomer Despite this 
importance, racemization has drawn little attention in the scientific literature' A more systematic 
investigation is therefore in place In this Chapter a summary of a literature review2 is presented 
Also resolutions involving in situ racemization, commonly known as asymmetric transformations, 
are not very well documented The only recent review is in Japanese3 This Chapter (section 2 3) 
gives a comprehensive review of crystallization-induced asymmetric transformations of both 
enantiomers and diastereomers 
2.2 Racemization of Optically Active Organic Compounds 
The literature describing racemization as the main topic is scarce, mainly focuses on amino 
acids and related compounds and often deals with the avoidance of racemization, e g in protein 
synthesis In the development of an industrial resolution procedure the racemization of the 
unwanted enantiomer often is one of the most difficult obstacles in achieving an economic process 
In many cases rather harsh conditions are necessary, leading to decomposition, or the substrate has 
to be modified to make racemization possible 
(R) +==* (S) (R) (S) ^ = = ± r (S) (S) 
Racemization Epimerization 
ki=k-i ki*k.i 
Figure 2-1. Racemization and epimerization 
Racemization is defined as the irreversible formation of a racemate from a pure enantiomer 
and is always associated with the total loss of optical activity Therefore, compounds which 
15 
Chapter 2 
racemize easily are referred to as optically labile The inversion of one stereocenter in a compound 
containing several stereocenters is called an epimenzation This leads to change but usually not to 
complete loss of optical activity if at least one stereocenter in the substrate remains unaffected 
Because of this change in optical rotation, epimenzation is also referred to as mutarotation, 
especially in the case of carbohydrates 
2.2.1 Kinetics of Racemization 
The driving force of the racemization process can be predominantly attributed to the increase 
of entropy caused by the mixing of the two enantiomers Although differences in interaction 
between enantiomers (R-R, or S-S vs R-S interactions) may lead to a non-zero enthalpy 
contribution, this can usually be ignored, thus Δΰ° ~ RT 1η(Ά) This corresponds to -0 41 kcal/mol 
(-1 7 kJ/mol) at 25°C 
Two different definitions for the rate of racemization have been reported" The rate of 
racemization can be described either as the rate of interconversion of enantiomers, or as the rate of 
formation of the racemate The interconversion of enantiomers can be described by reversible first-
order kinetics5 (equation 2-1) 
(R) « j " » (S) 
k-i 
--^ = k,[R]-kl[S] (2-1) 
where [S] and [R] are the concentrations of the enantiomers S and R, k, and к , are the 
interconversion constants for the R and S enantiomer respectively, and t is the time Initially, when 
one of the enantiomers dominates, there is a chiral medium present and k, * к , In the solid state 
this difference may be substantial, however, in a solution the difference will be negligible and it 
may be assumed that k,=k ,=k If the racemization starts from a pure enantiomer R, the elaboration 
of this first-order differential with the conditions [R]<r[R]t=[S]t is 
Wo In : 2kt (2-2) 
_2[Ä],-[Ä]0_ 
where [R]0 is the concentration of enantiomer R at time zero and [R], at time t 
Racemization can also be described as the formation of a racemate from a pure enantiomer in 
an irreversible first-order reaction (equation 2-3) 
2 (R) k ' » (RS) 
d[R] 
~dT = k'[R] (2"3) 
With the condition [R]0-[R]t=2[RS], this equation can be transformed to 
In Wo = k't (2-4) [R)0-2[RSl 
where [RS]t is the concentration of the racemate at time t and k' is the racemization constant When 
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the racemization process is followed by the loss of optical activity, equation 2-4 can be transformed 
to 
In к I (2-5) 
where a 0 is the optical rotation at time zero and a, at time t 
It should be noted that k'=2k, implying that the rate of racemization equals to twice the rate of 
interconversion of enantiomers 
Another frequently used variable to describe racemization or epimenzation is the racemization 
half-life t , (also denoted as τ) which is the time required to obtain a mixture with an enantiomeric 
excess of 50% Calculated from equation 2-2 this results in 
ln2 
and from equation 2-4 in 
M
 ( M > 
,.-ψ 
2.2.2 Racemization Methods 
Considering the literature in the period 1967-1996, nine methods of racemization can be 
distinguished, and the substrates used in these racemizations can be devided into nine classes of 
compounds Counting the number of papers on the respective methods, as applied to the selected 
classes of compounds provides a useful overview of the scope and limitations of racemization 
techniques (Table 2-1) Several conclusions from this classification can be drawn 
Based on classes of compounds 
• a-Aminocarboxylic acids and derivatives Almost half of the total number of papers deals with 
amino acids or derivatives, demonstrating the industrial importance of these compounds Base 
and enzyme-catalyzed racemizations and racemizations with a Schiff base intermediate are of 
equal importance and are responsible for 80% of the cases Acid catalyzed and thermal 
racemization are of lesser interest 
• a-Alkylcarboxylic acids and derivatives About 17% of the reports deals with racemization of 
α-alkylcarboxylic derivatives These references pertain mainly to profens and chrysanthemic 
acids (both industrially important compounds) which are usually racemized by base (52%) or 
acid (24%) catalysis Some examples using thermal or enzymatic racemization are reported 
• q-Oxycarboxylic acids and derivatives Approximately 11% of the studied literature refers to a-
hydroxy and α-alkoxycarboxylic acids or derivatives, mostly involving base-catalyzed 
racemization (60%) Enzyme-catalyzed racemization (21%) is also of some importance, but can 
be attributed exclusively to the use of mandehc acid racemase 
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Table 2-1. Classification Matrix of Racemization by Methods and Classes of Compounds'. 
Racemization Method 
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492 
a) The numbers in this matrix refer to the number of reports on the indicated item in the period 1967-1996 
• α-Substituted nitrites· Racemization of chiral nitriles is of minor importance Substrates bearing 
an α-hydrogen are usually racemized by base. In the absence of an α-hydrogen, racemization is 
possible by nucleophilic substitution with cyanide. 
• Amines: Racemization of chiral amines is generally performed by oxidation-reduction (60%), or 
by base catalysis (30%) 
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• Alcohols and Oxv-compounds. Only 2% of the references deals with chiral alcohols, alkoxides, 
acetates and ethers. Thermal, base-catalyzed and enzyme-catalyzed racemization have been 
reported. 
• Halides' Like alcohols, only a few examples of racemization of chiral halides are known (2%) 
Racemization via reversible substitution seems to be the best procedure, followed by base 
catalysis. More reports on racemization of halides are encountered in the literature about 
dynamic kinetic resolutions, e.g. the base-catalyzed racemization of a-halocarboxylic 
derivatives. 
• Rotamers: Racemization of rotamers (usually biaryls) is performed thermally and is in some 
cases catalyzed by additives. 
Based on racemization methods' 
• Base-catalyzed racemization: Almost one third of the reports refer to base-catalyzed 
racemizations. It is by far the most important method of racemization of enantiopure organic 
compounds, its scope is large and it can be applied to almost all compounds bearing an acidic 
hydrogen at the chiral center. 
• Schiff-base mediated racemization: Racemization via Schiff bases are only feasible for 
compounds bearing a free primary amino group at the chiral center. Nevertheless, this 
racemization procedure has been very extensively studied and is important in industry because of 
its application to the racemization of amino acids. 
• Enzyme-catalyzed racemization: Of the total number of references. 15% deals with enzyme-
catalyzed racemizations. The scope of racemization by racemases is still limited, and mainly 
restricted to amino acids and derivatives (75%) and to α-hydroxycarboxylic acids and derivatives 
(15%). Efforts are reported to apply enzyme-catalyzed racemization to other classes of 
compounds. 
• Thermal racemization: The scope of thermal racemization (14%) is wide and it is an industrially 
attractive method because it is simple and cheap. The main problem with this method is usually 
decomposition of the substrate when high temperatures have to be applied. Good substrates for 
thermal racemization are compounds which racemize by rotation or deformation of bonds 
(biaryls), by pyramidal inversion or by rearrangement of bonds; these account for more than 50% 
of the examples of thermal racemization. 
• Acid-catalyzed racemization: The scope of acid-catalyzed racemizations is more limited than that 
of base-catalyzed reactions and is usually restricted to compounds capable of some form of keto-
enol tautomerism α-Substituted carboxylic acids and derivatives account for 87% of the 
substrates used. 
• Oxidation-reduction · Only 8% of the total number of references deals with racemization by 
redox reactions. Of these, 80% refer to racemization of chiral amines. Some racemization 
procedures are rather complex (multistep), and therefore industrially not attractive. Chiral 
alcohols also appear to be good substrates for this racemization approach. 
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• Nucleophihc substitution Racemization of chiral substrates by nucleophihc substitution or 
addition-elimination sequences (3% of the total) is restricted to chiral hahdes and nitnles This 
method, requires that the substituent at the chiral center is a good leaving group as well as a good 
nucleophile An advantage of this method is that it can be used for compounds lacking a 
hydrogen at the stereocenter 
• Racemization via an intermediate meso-compound Racemization in which the asymmetric 
center itself is not involved is possible by making two of the functionalities attached to the 
stereocenter equal, resulting in an achiral meso-compound A few examples (2% of the total) of 
this method are known and mainly involve dicarboxylic acid derivatives or diacetates This 
method can be applied to compounds without a hydrogen at the chiral center 
• Photochemical racemization Racemization by photochemical reactions appears to be a method 
of little value Only a few examples are known (1%) and are all related to cyclopropane 
derivatives (chrysanthemic derivatives) 
To convert an enantiomencally enriched mixture into a racemic mixture two approaches are 
available, the simplest being the addition of the other enantiomer Obviously this will be used only 
under special circumstances, such as during the measurement of phase diagrams or in the 
development of methods for the determination of an enantiomeric excess Otherwise it is necessary 
to invert an enantiomer into its mirror image by physical or chemical methods The classification 
matrix presented (Table 2-1) will be used for a treatment of the various methods of racemization 
2.2.3 Thermal Racemization 
Many optically active compounds can be racemized by simply heating them to an appropriate 
temperature without any additional reagents The main requirement for the success of this method is 
that the substrate must have a sufficient thermal stability under the conditions used Therefore, the 
scope of this method is limited Racemization at temperatures close to or below room temperature is 
often referred to as spontaneous racemization 
Thermal racemization can occur by various mechanisms Several compounds without a 
specific chiral center racemize by rotation about a bond Other mechanisms involving no bond 
breaking are the simultaneous deformation of several bonds and the inversion of heteroatom chiral 
centers At higher energy levels pathways involving the breaking or rearrangement of bonds such as 
tautomensm, retro-Diels-Alder/Diels-Alder, and radical processes can occur For acids and bases 
thermal racemization may take place but, depending on the compound, this may also be considered 
as an (auto-)catalytic process 
Compounds bearing a keto function in an α-position to a chiral center can racemize through a 
keto-enol equilibrium Thermal racemizations of a-alkyl substituted carboxylic derivatives 
according to this mechanism are summarized in Table 2-2 Naproxen 4a is racemized in t-BuOH at 
140°C' and Ibuprofen 5 is racemized at 220°C'° 
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Table 2-2. Thermal Racemization of α-Alkyl Substituted Carboxyl Derivatives 
LQ 
о 
la(R|=CI R2=OH) 
Jb(R,=R2=CL) 
OH 
(R=i-Pr cyclo-Pr) 
(X,Y=Hal, H alkyl, 
alkoxy CH2Hal, O-Cn-O) 
COOH 
COOH 
MeO 
COOR 
4a (R=H) 
4b (R=Me,Et) Jjt COOH 
Entry Compound Racemization conditions Yield (%)a Ref 
1 
2 
3 
4 
5 
6 
la 
lb 
2 
3 
4a 
5 
inert solvents (hydrocarbons), T>150°C, N 2 , 3-12 h 
inert solvents (hydrocarbons), T>150°C, N 2 , 3-12 h 
liquid or vapor phase, T=200-350°C, inert atmosphere 
200°C, 1 hour 
t-BuOH, autoclave, 140°C, 22 h 
heating in the melt, 220°C 
η r 
η г 
nr 
99 
nr 
η r 
6 
6 
7 
8 
9 
10 
a) η r = not reported 
The industrially important thermal racemizations of amino acids and their derivatives without 
any catalyst proceed relatively difficult, especially in aqueous solutions These racemizations are 
performed at high temperatures and often under pressure" The attractiveness of such methods is 
that they are relatively cheap and therefore industrially attractive The critical feature of thermally 
racemizing amino acids and derivatives is its performance with a minimum amount of product 
decomposition 
2.2.4 Base-catalyzed Racemization 
Base-catalyzed racemization is a well-known and probably the most frequently used method 
for racemization or epimenzation of optically pure compounds It usually involves the removal of a 
hydrogen from the chiral center to form a carbanion This carbanion must be stabilized by adjacent 
groups such as keto, mtrile, nitro or other functionalities (Scheme 2-1 A), or by a reversible 
elimination of a ß-substituent (Scheme 2-IB) 
Θ 
base 
Θ 
γ 
,© 
X=C(0) CN N02 etc 
base 
Η 
.Θ 
Scheme 2-1. Mechanisms for the base-catalyzed racemization 
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Base-catalyzed racemizations often require the preparation of a derivative with an enhanced 
acidity From an industrial point of view this is undesirable as it introduces additional reaction steps 
unless the denvatization is reversible and can be performed in situ 
A generally accepted mechanism for the acid and base-catalyzed racemization of amino acids 
is outlined in Scheme 2-2 i ; The racemization is consistent with a SE1 mechanism and shows a 
Hammel relation with ß=l 15 for arylglycines at pH=10 A pH profile study showed general base 
catalysis and first-order kinetics13 Factors influencing the acidity of the α-hydrogen of amino acids, 
and thus the rate of racemization, are the electronegativity of the substituent R, decrease of the 
negative charge of the carboxylate and substitution at the carboxylic and amino site14 
Base-catalyzed 
R' 
NH2 N H 2 
H TOO® R - ^ C O O ® 
© θ 
,© NH3 NH3 
Aud-catalyzed 1 ^ в Т ™ - п ^ Я 4 
R4-COOH R
 H Y
 R
 ° .. 
Η OH OH 
© © 
Scheme 2-2. Acid- and base-catalyzed racemization of amino acids 
In a kinetic isotope study of the racemization of optically active phenone 39a, it was found 
that the racemization proceeds with a rate equal to the rate of enohzat ion following a S
r
l 
mechanism ' 5 The kinetics of the base catalyzed racemizations of chiral ketones 39b have been 
studied at different basicities '6 
Me Me 
6a(R-Ph) ° ° 
6b (R=Ar) 
Scheme 2-3. 
Racemizations of α-alkyl or ct-aryl substituted carboxylic acids, eslers or related compounds 
are collected in Table 2-3 A general method to racemize profens naproxen 4a, Ibuprofen 5, 
hydratropic acid 7 (R=H) and ketoprofen 8 is by heating with hydroxides (entry 1,5,9.11,14) or 
amines in inert solvents (entry 1.2,8) Naproxen 4a and Ibuprofen 5 can be racemized in a saturated 
NaOCl-solution, in which NaOCl probably acts as a base (entry 4) The unwanted isomer of 
naproxen 4a in resolution processes can be racemized by heating the salt of naproxen and an 
optically active amine in the mother liquid (entry 6,7,10) Profens can also be racemized by in situ 
conversion to a mixed anhydride under basic conditions (entry 3,12) or by heating with a strongly 
basic ion exchange resin (entry 13) 
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Table 2-3. Base-catalyzed Racemization of α-Alkyl or a-Aryl Substituted 
Carboxylic Acids, Esters and Related Compounds. 
О 
MeO 
COOR 
4a (R= 
4b (R= 
=H) 
=Me.Et) 
О 
(Qi 
Et 
ÎS, COOR 
9a(R=H) 
.COOH COOH 
9b(R=Ft) 
Entry Compound Conditions of Racemization Yield (%)a Ref 
4a 
4a 
4a 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
4a 
4a 
4a 
4b 
4a, 5 
la 
5 
5 
5 
7 (R=H) 
7 
8 
9a 
9b 
9b 
10 
11 
NaOH, KOH. H 20, heating 
heating mother liquid of resolution with optically active amine 
in DMF/H20=95/5, 115°C, 24 h 
heating mother liquid of resolution with 1-p-tolyl-ethy lamine, 
autoclave, 150°C,N2, 12 h 
DBU, DBN or DABCO in inert polar solvent, 80-100°C, 3-9 h 
NaOR, KOR, inert polar solvent, T>100°C, >24 h 
heating mother liquid of resolution with MBA, inert solvent, 
80-150°C, 5-48 h 
NaOH, KOH, 2-ethoxyethanol, reflux, 5 h 
saturated NaOCl-solution, H 20, 80°C, 1-24 h 
50% aqueous KOH solution, 136°C, 5 h. 
NaOH/2-propanol or Et3N/octane, reflux, 15 h 
Et3N, H20, 1% MBA, ΔΡ, 120°C, 4h 
0.1 eq. Ac 2 0, NaOAc, /PrOAc, reflux, 18 h 
Ac 20, pyridine, reflux 
strong basic ion exchange resin, anhydrous 
NaOH, methyhiobutylketone, 70-100°C 
half-life t,/; =1350 h (EtOH, 27°C) 
t,/;=80 h (EtOH, 27°C), t,/2=24 h (EtOH, 47°C) 
NaOEt, EtOH,-10°C 
amine, heating, organic solvent 
heating mother liquid of resolution with quinine, NaOEt 
n.r 
n.r. 
>90 
17 
18 
>90 
>90 
n.r 
95 
>90 
98 
n.r. 
n.r. 
n.r. 
n.r 
n.r. 
n.r 
n.r. 
η г. 
n.r. 
η г. 
n.r. 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
32 
32 
33 
34 
a) η г = not reported 
^ ^ 13 
Figure 2-2. 
A study of the solvent control in the racemization of nitriles 12 and 13 (Figure 2-2) and their 
amide and ester analogues showed a large increase in the racemization rate (-factor 10 ) going from 
MeOH to DMSO. The kinetics of these reactions were studied by hydrogen-deuterium exchange'5 
and the results explained by different solvation of the base and the substrate in the solvents used A 
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similar study of the isotope effect on the racemization of 2-phenylpropionitnle 12 by NaOMe at 
10°C showed an increasing racemization rate with increasing concentration of DMSO in 
DMSO/MeOH solutions16 A kinetic isotope study of nitnles 12 and 14 in the reaction with the 
bases KOMe and KOtBu in deuterated methanol /e/7-butyl alcohol and DMSO, showed either 
retention inversion, isoinversion or racemization depending on the substrate, solvent and base 
used'7 Racemization of the nitnle derivative of naproxen 15 was accomplished by a strong basic ion 
exchange resin (OH ) in an organic solvent38 
Table 2-4. Racemization of α-Hydroxy Acids, Esters, Ketones and Related Compounds 
OH OH OH 
ft-ST * 'COUR r p f l - - . COOK Н О О С ^ у С О О Н F , C ^ Y ° Y ^ | 
l4^16a(R=H) ^ ¿ J 17a (R=H) ОН О k ^ 0=l^^)=0 
I6b(R=Et) 17b(R=Et) 18 19 
OAr 
/ L EtOOC 
H,C^COOR 
X /4__ O^ COOH 0=< " i n ] 
^ ^ C O O E l C > = 0 O ^ O ^ ^ 
20 21 
О 
22a (R=H) 
22b (R-Ac) 
23 
* COOtBu 
24 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Substrate 
16a 
16b 
17a 
17b 
18 
19 
20 
21 
22a 
22a 
22b 
23 
(0-24 
Reaction Conditions 
alkali metal hydroxides, water or alcohol 
Na, toluene, 25°C, 5 h 
ΔΤ, base (e g NaOAc, pyridine, El3N), Ac 2 0 
NaH, toluene, reflux 
alkali, H 2 0 , reflux, 5-8 h, via weio-lartanc acid 
PPh3, dialkyl azodicarboxylate, DBU or DBN 
NaOR, KOR or DBU, anhydrous inert solvents 
NaOEt in EtOH 
NaOR, KOR, DBU, DBN, RT-120°C, 
with or without solvent 
NaOHorKOH, 145°C 
Ba(OH)2, NaOMe, K 2 C0 3 , NaOAc, 
heating of anhydrous solutions 
NaOH or KOH, H 2 0 , 140-160°C, 5 h 
Et3N, CHjCN, 0-50°C 
Yield 
(%)a 
n r 
44 
η r 
87 
η r 
69 
n r 
n r 
n r 
η r 
> 9 0 
90 
88 
Racemization 
(%)a 
100 
100 
n r 
100 
η r 
100 
100 
100 
100 
100 
100 
100 
100 
Ref 
51 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
a) η r = not reported 
The results of the racemization of α-hydroxy acids, esters, ketones and related compound are 
collected in Table 2-4 Mandehc acid 16a was racemized by refluxing or heating with alkali metal 
hvdroxides dissolved in water or alcohol" The velocity and mechanism of racemization reactions 
was studied, and it was concluded that the base-catalyzed racemization of 16a is faster than the 
acid-catalyzed reaction Racemization reactions were studied in aqueous solutions at pH 1-12 in the 
temperature range of 25-100°C No racemization was observed in acidic solutions (less than 
pH=ll 2 at 96°C) Parameters affecting the first-order racemization constant are the temperature 
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and the concentration of base5' The tautomeric equilibrium of mandelic acid 16a was studied and a 
pKE of 15 4 was measured for the acid and 22 0 for the carboxylate" 
2.2.5 Acid-catalyzed Racemization 
Compared to base-catalyzed racemizations the scope of acid-catalyzed racemizations is 
somewhat limited Usually two pathways are recognized The most frequently encountered pathway 
for acid-catalyzed racemization is the protonation of a doubly bonded heteroatom in an a-position 
to a chiral center, followed by abstraction of a hydrogen from the chiral center (Scheme 2-4A), 
representing keto-enol tautomensm if the heteroatom is oxygen, and îmine-enamine tautomensm 
tor nitrogen This mechanism is conceptually similar to base-catalyzed racemization The 
protonated heteroatom enhances the acidity of the α-proton to such an extent that even a very weak 
base can initiate deprotonation 
Η Η 
f¥ì \ с 
[
—> J — A + Η 
Scheme 2-4. Mechanisms for acid-catalyzed racemization 
(Bransted as well as Lewis-type acids) 
Acid-catalyzed racemization is also possible if a substituent is present at a chiral center which 
upon protonation, is converted into a good leaving group This leads to the reversible formation of a 
carbocation which is planar (unless constrained in some manner) resulting in racemization (Scheme 
2-4B) The carbocation must be stabilized by other functionalities otherwise rearrangement can 
occur easily, leading to unwanted side reactions The need for a substituent that can act as a leaving 
group combined with the need for a cation-stabilizing functionality is more restricting than in base-
catalyzed racemizations, where only an anion-stabilizing group has to be present, but this 
mechanism is also possible with compounds lacking a hydrogen attached to the chiral center 
R, R, © 
И ^ -
HOOC COOR „ 
25 H 
R, R, r A I S 
У W 
HOOC COOR HOOC COOR 
26 27 
Scheme 2-5. Indirect acid-catalyzed racemizations 
Although most of the acid-catalyzed racemizations proceed by one of the general mechanisms 
depicted in Scheme 2-4 there are also some reactions known where no chiral center is involved, but 
25 
J-AH • X 
*=4 >*o + R 0 H = s = b : )—( 
О ^ RDDT ГППН 
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where symmetnzation is achieved in a different manner Examples of such racemizations are shown 
in Scheme 2-5 Dicarboxylic acid monoesters, such as compounds 25, 26 and 27 undergo acid-
catalyzed transestenfication As these reactions proceed via a symmetrical and achiral intermediate 
racemization is achieved without affecting any chiral center directly'4 
Acid-catalyzed racemization of amino acids is probably the most extensively studied type of 
racemization The reason is that amino acids can be very easily racemized (according to the general 
approach shown in Scheme 2-4A), after in situ conversion to îmines (Schiff bases)55 using a broad 
variety of aldehydes and ketones This method is of major importance for the industrial synthesis of 
enanliopure amino acids and is treated in detail in section 2 2 6 Most, if not all, free amino acids 
can be racemized under acidic conditions The dependence of the rate of racemization on the pH has 
been studied and turned out to be complex, viz depending on no less than six rate constants56 Acid-
catalyzed racemization requires strong acids and temperatures well above 100°C" Racemization of 
alanine, valine, leucine and phenylalanine at 142°C proceeds slowest at pH's between 1 and 356 
Estenfication of the acid, or conversion of the amine into an amide are frequently used to facilitate 
the racemization under acidic conditions5' 
R R· 
N=< \ X 
28 О 29 R ' О 30 
Figure 2-3 
Amino acid amides are often racemized in the presence of anhydrides or ketenes The in situ 
formation ot azlactones 28, which racemize readily under acidic conditions, greatly facilitates 
racemization The ease of racemization of azlactones is mainly due to the formation of an aromatic 
ring system101 Often an anhydride is formed which has to be hydrolyzed subsequently with an 
aqueous base The use of relatively large amounts of anhydride and the formation of salts makes 
this reaction somewhat less attractive from an industrial point of view Conditions for racemization 
of V-acyl amino acids in the presence of anhydride are generally much milder than for unsubstituted 
amino acids5' Also, cyclic derivatives of amino acids such as 29, ι e ìmidazolidines (X=N) 
oxazolidines (X=0) and thiazohnes (X=S) racemize very easily under acidic and basic conditions60 
Compounds with a hydroxy function attached to a chiral center may be racemized by the 
mechanism shown in Scheme 2-4B In practice however, this type of reaction is not often found 
Unwanted side reactions can be prevented only if the carbocation formed is sufficiently stabilized or 
is unable to undergo rearrangement Compounds with the hydroxy group adjacent to a carbonyl 
moiety are rather racemized by keto-enol tautomensm than by the formation of a carbocation 
Mandehc acid 16a could be partially racemized by treatment with talc, which has acidic as well as 
basic sites6' D-Tartanc acid 18 was racemized in the presence of mejo-tartanc acid to give 74% of 
DL-tartaric acid In the absence of the meso acid only 50% racemization was observed62 
,.COOH 
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α-Alkyl and a-arylcarboxylic acids can be racemized under acidic conditions 
Dibenzothiepine 30 racemizes in acetic acid with 4N HCl at 140°C in 12 h in nearly quantitative 
yield63 The carboxylic acid la (Table 2-2) racemizes in the melt in the presence of a catalytic 
amount of sulfuric acid (140°C, 2h) or p-toluenesulfonic acid (220°C. 1 h)64 Naproxen 4a can be 
racemized by refluxing in acetic anhydride" 
2.2.6 Racemization via Schiff Bases 
Denvatization of a functional group connected to a chiral center is a well-known method to 
affect the optical lability The increased leaving ability of an exchangeable group or the enhanced 
acidity of an attached proton allows mild racemization conditions which can often be combined 
with a resolution process The aldehyde or ketone catalyzed racemization of amino acids and 
derivatives via Schiff base intermediates is the most prominent example of this method, and 
proceeds by initial protonation of the îmine followed by proton abstraction by the acetate anion 
(Scheme 2-6) This mechanism was confirmed by kinetic studies of the hydrogen-deuterium 
exchange of Schiff bases66 
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Scheme 2-6. Racemization of amino acids via the corresponding Schiff base 
A more detailed survey of the patent and scientific literature shows that virtually every amino 
acid has been used in a Schiff base-promoted racemization or crystallization-induced asymmetric 
transformation (see also section 2 3 1b and 2 3 3b) In more general terms 
• all amino acids and simple esters or amides can be used provided an α-proton is present and the 
amino-group is not protected 
• for Schiff base formation aromatic aldehydes like salicylaldehyde or pyndoxal are preferred but 
also aliphatic aldehydes and even simple ketones can be used 
• in most examples a catalytic amount of aldehyde (1-10%) is sufficient, excess is often applied for 
different reasons 
• the aldehyde (or ketone) can also be used as solvent or cosolvent 
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• the aldehyde can be activated by additional substituents, ι e nitro groups in aromatic aldehydes 
or made water soluble through sulfonic acid functions 
• immobilization of the aldehyde can be used to simplify down stream processing 
• in most cases additional acid or base is used to set up the required equilibrium system 
• resolving acids as well as bases can be applied together with the racemization catalyst 
• simple solvents like water, acetic acid, alcohols and ketones can be used, preferably one of the 
reactants is used in excess to serve as solvent 
• reaction conditions are mostly mild, using reflux (50-100°C) and high concentrations (5-20%) 
• yields are generally good to excellent (70-100%) 
2.2.7 Enzyme-catalyzed Racemizations67 
An increasing number of enzymes and related biocatalytic systems appear in the literature 
describing racemizations, sometimes in combination with kinetic resolution The substrates used in 
these reactions have two common features 
• the chiral center bears a proton 
• adjacent to the chiral center is a carbonyl group or a related acidity enhancing substituent 
Amino acids, α-hydroxy acids and related structures cover almost all examples known to date 
The enzymes, mostly known as racemases, often need a cofactor like pyndoxyl phosphate (PLP) or 
a bivalent metal ion to function properly As far as investigated the enzymes accept both 
enantiomers as substrate A simple classification according to reaction mechanism has been given 
by Gallo, Tanner and Knowles" Depending on the number of bases from the active site involved in 
the racemization a 'one-base system' or a 'two-base system' has been distinguished Positively 
identified 'one-base' enzymes are a-amino-e-caprolactam racemase, various alanine racemases and 
probably also the racemases for arginine, threonine and serine They need PLP as cofactor which is 
used to form a Schiff base with the amino group enhancing the acidity of the adjacent proton6', in 
fact the same mechanism as given in section 2 3 3 4 Identified two-base' racemases are proline 
mandehc acid, aspartic acid and glutamic acid racemase They do not need PLP as cofactor6' The 
precise mechanism of the 'two-base system', concerted or stepwise, is still a matter of debate™ The 
nomenclature of the various racemases is rather erratic and sometimes misleading Often the 
racemase is named after the first substrate studied, not necessary the most suitable substrate 
Racemization of mandehc acid 16a by mandelate racemase, isolated from Pseudomonas 
putida, is well studied This racemase is rather stable and easy to isolate" A divalent metal ion, 
preferably Mg is indispensable for optimal activity, and substrate specificity is limited Substituents 
in the phenyl ring are accepted, although not more than one is allowed Lactic acids are not 
accepted, although 2-hydroxy-but-3-enecarboxyhc acid is a suitable substrate72 Reaction 
mechanism and crystal structures have been studied recently™ " 
(R)-Naproxen (R)-4a was racemized by microorganism These microorganism may be a 
fungus (e g Exophala wilhansu) or a bacterium (e g Rhodococcus) and whole cells or enzymes 
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extracted from these cells may be used A kinetic resolution to enantiopure enantiomers was 
observed for racemic naproxen 4a, racemic Ibuprofen 5 and racemic phenylglycine using Exophiala 
wilhansii' Also a complete inversion of (R)-4a to (S)-4a was performed using an inverting enzyme 
system (fungus or bacterium)" 
2.2.8 Racemization via Redox and Radical Reactions 
Oxidations and reductions can be used to perform racemizations Oxidation removes a 
hydrogen from an asymmetric carbon, generating an intermediate species with a planar geometry 
Reduction or hydrogénation restores the original hybridization state in a non-stereoselective way, 
thus generating a racemate (Scheme 2-7) Racemization via hydrogen abstraction can also be 
realized by radical reactions The most efficient process is obtained when an equilibrium exists 
between the oxidized and reduced forms of the substrate in a single step In many reactions using 
catalytic hydrogénation such an equilibrium exists, as the catalysts lowers the transition state These 
methods are especially suitable when the asymmetric carbon in the substrate is activated by aryl 
groups Ibuprofen 5 racemizes slowly at 190-200°C under hydrogen atmosphere in the presence of 
palladium or carbon catalyst (Scheme 2-8)76 Other examples of single-step racemizations involve 
activated and unactivated amines2 
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Scheme 2-7. Racemization via redox reactions 
Racemization can also be achieved by performing the oxidation and the reduction in separate 
steps This usually involves some form of chemical oxidation where no equilibrium exists This 
approach has been applied to several optically active amines In the first step an ïmine or immonium 
species is generated Reduction in the second step leads back to the amine2 
Oxidation can be used as a method for racemization of components with two adjacent centers 
of chirality Suitable candidates are, for example, optically active a-aminoalcohols 31 Oxidation 
destroys chirality of one stereocenter, thereby creating a carbonyl function Racemization of the 
second stereocenter now can occur under enohzation condition The resulting racemate then has to 
be reduced (diastereoselectively) to the original component as a racemate It is evident that with a 
diastereoselective reduction at hand this is a useful strategy for conversion of one diastereomer into 
racemic mixtures of the other diastereomer An example of this methodology is the racemization of 
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enantiopure diltiazem precursor (-)-32 by oxidation with benzophenone and enolization by KOtBu 
at reflux After stereoselective reduction with NaBH4, racemic threo 32 is obtained in 70%". 
H2 (200-400 psi) 
COOH Pd(5%onC) , r^SynCCX)H Qi» 00" ^ S S - Xjg» 
(R)-5/(S)-5=84/16 (R)-5/(S)-5=6I/39 
R2 
OH 
.R, 
N(R3)2 
31 
Scheme 2-8. Redox racemization. 
2.2.9 Miscellaneous Racemization Methods 
Most of the racemization procedures are characterized by disconnection and reconnection or 
substitution of one of the groups directly bound to the center of chirality. However, racemization 
techniques have been described in which the bonds in the asymmetric center are not involved. This 
can be accomplished by rotation about bonds or by making two of the functionalities at the 
stereocenter equal to give an achiral (meso) compound. After restoring the two original 
functionalities in a non-stereoselective way, a racemate is generated. Malonic acid half-ester (-)-33, 
an unwanted isomer in a resolution process, is racemized by esterification to an achiral diester and 
subsequent hydrolysis to the racemic half-ester in an overall yield of 23% (Scheme 2-9)78. It is clear 
that the value of this approach depends on the preferred resolution route for preparation of 
enantiopure compounds like 33. As soon as methods are available for enantioselective mono-
hydrolysis of the achiral diesters these will be far more attractive than the combination of resolution 
of a racemate and racemization of the unwanted isomer. Some meso- and prochiral diesters are 
suitable substrates for an enzyme-catalyzed enantioselective hydrolysis to enantiopure half-ester in 
yields up to 100% (meso trick)79. Other less popular methods for racemization of enantiopure 
compounds are the racemization of cyanohydrins via equilibrating condensation reactions, 
photochemical racemization and racemization via addition-elimination reactions2. 
I (EtO)2S02 I I 
— 1 4 , COOEt K2CO3 — I COOEt KOH^ — I COOEt 
V\ acetone * X ЕЮН X . 
PhCH 2 -0 COOH reflux PhCH 2 -0 COOEt PhCH 2 -0 COOH 
(-)-33 (+/-)-33 
Scheme 2-9. Racemization of a malonic half-ester. 
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2.3 Asymmetric Transformations (Definitions) 
Different terms are used for resolution processes with in situ racemization which gives rise to 
much confusion The first example of an asymmetric transformation is in fact the decrease of optical 
rotation of D-glucose in aqueous solution This was called 'mutarotation' by Lowry8U in 1899 The 
term asymmetric transformation' was first used by Leuchs and Wutke91 in 1913 to describe a 
classical resolution with in situ racemization A thermodynamic equilibrium of diastereomers in 
solution in which one of the diastereomers is present in excess, was called an 'asymmetric catalytic 
racemization' by McKenzie'2 in 1925 In 1932, the same process was called an 'asymmetrische 
Umlagerung erster Art' by Kuhn83 which was incorrectly translated to 'first-order asymmetric 
transformation' Kuhn also introduced 'second-order asymmetric transformation' for cases like that 
of Leuchs In 1942 Jamison and Turner94 redefined 'first-order asymmetric transformation' as a 
thermodynamic equilibrium of diastereomers in solution in which one of the diastereomers is 
present in excess, whereas in a 'second-order asymmetric transformation' two phases are present 
and usually involves a crystallization from a solution with in situ racemization Mislow85 used the 
term 'enantiomenzation' to describe first-order asymmetric transformations Jacques, Collet and 
Wilen introduced in 1981 the term 'crystallization-induced asymmetric transformation to describe 
second-order asymmetric transformations for both enantiomers and diastereomers86 In 1984 
Duhamel87 coined the term 'deracemization' to describe asymmetric protonations of enolates which 
are kinetically controlled and therefore not asymmetric transformations Nevertheless 
deracemization is being used to describe crystallization-induced asymmetric transformation of 
enantiomers88 and second-order asymmetric transformation is also used to describe dynamic kinetic 
resolutions89 Other terms are 'optical activation', 'asymmetnzation' and 'total spontaneous 
resolution' 'Asymmetric transformation' is also used to define several other asymmetric processes 
like the selective animation of racemic acids with enantiopure amines'" 
In this thesis the term crystallization-induced asymmetric transformation' is used for second-
order asymmetric transformations, because it can be used for both enantiomers and diastereomers 
"First-order asymmetric transformations' is used to define thermodynamic equilibration of 
diastereomers in solution in which one of the diastereomers is present in excess 
2.3.1 Crystallization-induced Asymmetric Transformation of Enantiomers 
Enantiomers can undergo a crystallization-induced asymmetric transformation if a preferential 
crystallization is accompanied by an in situ racemization This method can be applied provided the 
enantiomer exists as a conglomerate (see section 1 3) As only about 10% of the enantiomers fulfill 
this condition, not many examples of such processes are known A subdivision of the different 
processes can be made on the basis of the racemization method used 
a Thermal Racemization 
A combination of thermal racemization and resolution is achieved for binaphthyls 34 These 
compounds form polymorphic crystals, and racemate and conglomerate can coexist in a wide range 
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of temperatures. Derivative 34a forms a stable racemate between room temperature and 197CC, and 
a conglomerate in the range 197-204°C. In this case a crystallization-induced asymmetric 
transformation can be performed at 204°C by a solid-melt-solid conversion, or by a solid-solid 
conversion at 197°C". For Ι,Γ-binaphthyl 34b the temperature ranges are room temperature to 
145°C (racemate) and 145-158°C (conglomerate)92 A crystallization-induced asymmetric 
transformation was carried out with a heterohelicene by careful crystallization from benzene at 
room temperature This was possible because of spontaneous racemization at room temperature91. 
Тгі-0-thymotide 35 forms crystalline conglomerates by inclusion of solvent molecules and under 
thermal racemization conditions an asymmetric transformation was observed94. The chiral 
quaternary ammonium iodine 36 forms a conglomerate and racemizes thermally by bond 
dissociation and re-association. Under slow crystallization (several months) an asymmetric 
transformation was noticed in which the mother liquid remains racemic95. 
X 
34a (X=NH2) 35 36 
34b (X=H) 
Figure 2-4. Asymmetric transformation induced by thermal racemization. 
b Racemization Promoted by Schiff Bases 
The racemization of amino acids via Schiff base formation is well studied and can be 
performed in acidic solutions with a catalytic amount of aldehyde (e.g. salicylaldehyde)96. The 
racemization mechanism is depicted in Scheme 2-660. This method is very efficient for /j-hydroxy-
phenylglycine using an achiral aromatic sulfonic salt of the racemic amino acid in a supersaturated 
solution of acetic acid, acetic anhydride and a catalytic amount of aldehyde. This resulted in the 
isolation of enantiopure amino acid in 69%'" The same method also works for alanine98. 
с Enolization-catalyzed Racemization 
Asymmetric transformation of the methyl and ethyl ester of naproxen 4b (Table 2-2), which 
form conglomerates, was performed in a supersaturated solution of racemic 4b and a base (e.g 
DBN) in methanol or ethanol. Crystallization with seeding gave enantiopure (R)-4b in yields of 63-
87%99. 
In the synthesis of cephalosporins the search for a conglomerate resulted in mandelic acid 
derivative 24 (Table 2-4). Preferential crystallization under basic conditions was carried out in a 
saturated diethyl ketone solution with a catalytic amount of DBU and seeding. An asymmetric 
transformation resulted and (S)-24 was isolated in 80% yield and 84% ее'00. 
С 
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Racemization of jV-acyl amino acids is accelerated by intramolecular formation of azlactones 
(oxazolmones) and subsequent deprotonation101 This racemization method is applied in the 
asymmetric transformation of DL-N-acyl amino acids 37a-c in heated solutions of Ac20 in CHC13 
or AcOH Optically enriched 37a-c were isolated in yields of 66-94% and ee's of 10-40%lü2 
An asymmetric transformation of ct-aminocaprolactam (ACL) 38 could be achieved by 
forming a diastereomenc complex with NiCl2 The reaction was carried out by treating racemic 38 
with anhydrous NiCl2 in an alcohol solution and subsequently seeding of the supersaturated solution 
with enantiopure (l-ACL)3NiCl2 EtOH at temperatures ranging from room temperature to 120°C In 
situ epimenzation was initiated by a basic catalyst (Ni(OH)2 or Ni(OR)2) and enantiopure ACL 38 
was isolated in yields up to 86%103 Asymmetric transformation of chiral ketones 39 and 40 was 
observed by crystallization under base-catalyzed enolization conditions104 
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R COOH 
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37b Leu (R' Me) 
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Figure 2-5. Enohzation-catalyzed asymmetric transformation of racemates 
d Racemization by Reversible Ring-Opening and Closure 
It has been suggested that racemization of oxazolebenzodiazepinone 41 occurs via reversible 
ring opening to an achiral quaternary iminium salt intermediate (Scheme 2-10) After seeding a 
supersaturated methanolic solution of racemic 23 with one of its pure enantiomers at room 
temperature, a crystallization-induced asymmetric transformation was observed and optically pure 
(S)-23 was isolated in a yield exceeding 70%"" 
О 
Br &k~ 
О 
Crystallization 
N — • (S)-41 
' F v F υ v F 
(R)-41 (S)-41 
Scheme 2-10. Racemization and asymmetnc transformation of oxazolebenzodiazepinone 
2.3.2 First-order Asymmetric Transformation of Diastereomers 
Because diastereomers have different physical properties, the ratio of a pair of diastereomers 
can be unequal to 1 1 in a thermodynamic equilibrium This is called a first-order asymmetric 
transformation One of the first examples is the mutarotation of glucose in aqueous solutions Under 
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neutral conditions and after equilibration the solution consists of 36% of a-D-glucose and 64% of 
ß-D-glucose Selective crystallization of the a - or ß-isomer is possible106 
A first-order asymmetric transformation of menthone 42 by base-catalyzed racemization 
resulted after thermodynamic equilibration in a solution of NaOMe/MeOH in a ratio of (-)-42 (+)-
42=70 30"" (-)-Menthyl mandelate 43 epimenzed in a solution of КОН/ЕЮН and equilibrated to a 
ratio of (S)-43 (R)-43=54 46'°' The complexation of amino acid thioester 44 with an enantiopure 
amine was studied A first-order asymmetric transformation was observed with ee's up to 76% 
under influence of a base (eg Ft3N) in refluxing сус1оЬехапе/СН2СІ2=3/110' Base-catalyzed 
epimenzation (ι e hydroxide) of chiral cobalt complexes of amino acids also resulled in first-order 
asymmetric transformations"0 Ee's up to 20% was observed using a combination of Schiff base 
promoted epimenzation and chiral cobalt complexes'" In a similar method chiral copper complexes 
of dipeptides were used in which enantiopure products were isolated in 63-76% yield"1 
A first-order asymmetric transformation was observed during the asymmetric Ullmann 
reaction to non-racemic biaryls 45a and 45b Initially, in the Ullmann reaction to biaryl 45a a S R 
ratio of 62 38 was observed, which under thermodynamic equilibrating conditions in solution 
changed to S R=93 7 Refluxing racemic 45b in DMF with Cu(0)/Cu(I,II) for two days resulted in a 
R S ratio of 3 1 while refluxing in DMF without a catalyst gave a ratio of R S=l 3"3 
Me~ ^Ме 
42 Me 
MeO 
MeO MeO OMe OMe 
45a 
Figure 2-6. Substrates for first-order asymmetric transformations 
A photo-induced first-order asymmetric transformation of cyclopropane derivative 46 was 
observed From enantiopure 2'-(R)-46 or 2'-(S)-46 the same ratios were attained The isomenzation 
follows a ring-opening mechanism and is initiated by radicals Different diastereomenc ratios were 
obtained depending on the triplet-energy of the sensitizer and therefore, the energy transfer from the 
sensitizer to 46 is probably the key step for the isomenzation"4 
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Scheme 2-11. First and second-order asymmetric transformation 
of chlorobromomethanesulfonic acid. 
A first and second-order asymmetric transformation was found for chlorobromo-
methanesulfonic acid 47 under influence of an enantiopure aminoalcohol (Scheme 2-11). Under 
equilibration conditions in acetone the diastereomers were present in a ratio of (S)-47:(R)-47=81 9 
In a saturated solution of acetone, after seeding with enantiopure material, crystallization of one 
diastereomer resulted and enantiopure (R)-47 was isolated in 75% yield"5 (note that this is the 
diastereomer least present in solution). 
2 .3 .3 Crysta l l izat ion- induced A s y m m e t r i c Transformat ion of D ias t ereomers 
A useful classification can be made on the basis of the racemization method employed as 
shown in section 2.3.1 for enantiomers. 
a Thermal Racemization 
Compounds whose chirality depends on the hindered rotation about a single bond can very 
often be simply racemized by heating to a sufficiently high temperature. This behavior is frequently 
observed for substituted biaryls (e.g. biphenyls, binaphthyls). Therefore, these compounds are 
receptive for crystallization-induced asymmetric transformations. 
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Figure 2-7. Crystallization-induced asymmetric transformation of biaryls. 
The influence of substituents on the optical stability of biphenyl 48 was studied 
Crystallization-induced asymmetric transformations were found during the formation of brucine 
salts"6. Also for biphenyl 49 a complete asymmetric transformation was observed during salt 
formation with brucine"7. The bridged biphenylcarboxylic acid 50 racemized in o-xylene at 50°C 
(t,/;=53 min) and an asymmetric transformation of 50 was observed via diastereomenc salt formation 
with quinidine"8. Racemization of binaphthyls 51a-c was spontaneous and a transformation was 
attained during diastereomeric complexation with CuCI2-sparteine or CuC^-MBA"
9
 1,1 '-ВІ-2-
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naphthol 51a could also be racemized in the melt which likewise can be extended to a 
crystallization-induced asymmetric transformation by complexation with chiral diamines1"0. 
b Racemization Promoted by Schijf Bases 
The racemization of amino acids promoted by Schiff bases (Scheme 2-6) in combination with 
a resolution is the most prominent example of crystallization-induced asymmetric transformation. 
The enhanced acidity of the α-proton in Schiff bases allows mild reaction conditions. The reaction 
can be carried out with a catalytic amount of aldehyde and generally high yields and ee's are 
obtained. This method is also applied in industry. For almost every amino acid an asymmetric 
transformation is known. A few representative examples are shown in Scheme 2-12. 
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(R)-56 C O O H (S)-56 C O O H ( + ) - T A (S)-57 
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Scheme 2-12. Asymmetric transformation of amino acids promoted by Schiff bases 
Well-known is the asymmetric transformation of phenylglycine 52 which under influence of a 
catalytic amount of salicylaldehyde in acetic acid resulted in the isolation of enantiopure (S)-52 in 
70% yield96""'21. p-Hydroxyphenylglycine underwent a transformation by a catalytic amount of 
salicylaldehyde in acetic acid and enantiopure 1-phenyl-ethanesulfonic acid or a-bromo-
camphorsulfonie acid as resolving agent. This resulted in the synthesis of enantiopure p-
hydroxyphenylglycine with yields exceeding 90%97b 122. A nice example is the crystallization-
induced asymmetric transformation of proline 53, which involves a complete inversion Under the 
same conditions an asymmetric transformation of racemic 2-pipendinecarboxylic acid was carried 
out'23. A complete inversion is also known for histidine'24. In the synthesis of enantiopure 
homocysteine 55 and cysteine 57, a transformation of l,3-thiazane-4-carboxyhc acid 54 and 4-
thiazohdinecarboxylic acid 56 respectively was used. In these reactions enantiopure 54 and 56 were 
obtained in yields of 83-90% by reaction with salicylaldehyde in acetic acid, employing tartaric acid 
as the resolving agent125. Application of the crystallization-induced asymmetric transformation 
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induced by Schiff base racemization is not restricted to amino acids but can also be applied to 
amino acid esters and amides This was demonstrated by the asymmetric transformation of p-
hydroxy-phenylglycinates66 andp-hydroxy-phenylglycine amides126 
Racemizations via Schiff bases are frequently used in the industrial synthesis of optically 
active compounds This is illustrated in the synthesis of the CCK-antogonist 59, which involves an 
asymmetric transformation of a benzodiazepinone 58 (Scheme 2-13)127 In the synthesis of 
aspoxicillen, two transformations to enantiopure D-p-hydroxy-phenylglycine and D-aspartic acid 
were used in yields of 90%12' 
CH3 
(+)-CSA ~ 
ArCHO 
RT 
Scheme 2-13. Asymmetric transformation of a benzodiazepinone promoted by a Schiff base 
A quantitative approach of the crystallization-induced asymmetric transformation of 
phenylglycine and phenylglycinates was reported and it was found that substrate, solvent and 
carbonyl compound are of equal importance in effecting an asymmetric transformation12' 
с Base-catalyzed Racemization 
The acidity of the α-proton in amino acids 60 can be promoted by conversion to 
imidazohdines 61 via an lminoether coupling with a diamine These optically labile compounds can 
undergo crystallization-induced asymmetric transformations under weakly basic conditions 
(Scheme 2-14) Starting from alanine (R=Me) and under influence of enantiopure (S)-2-
(aminomethyl)pyrrolidine, enantiopure alanine was isolated in yields exceeding 50%no 
60-(S) 
Scheme 2-14. Asymmetric transformation of imidazohdines 
A new class of crystallization-induced asymmetric transformation was introduced by reaction 
of TV-acetyl-p-hydroxy-phenylglycine 62a with an excess enantiopure resolution base a-
methylbenzyl-amine (MBA) in a hexanol/cumene solution at 130°C (Scheme 2-14)'3' Enantiopure 
amino acid derivative (R)-62a was isolated in 90% yield and the in situ racemization is initiated by 
the excess MBA A study of the racemization rate of /V-acetyl-amino acids showed an inductive 
effect of the side chain of amino acids following a Hammet-relation131 An asymmetric 
transformation of 62a was also observed employing 2-4 eq (R)-2-amino-l-butanol in 1-
butanol/toluene in 87% yield and 85% ее'32, and for ,V-acetyl-phenylglycine 62b with 2 eq (R)-
MBA in butanol/xylene in 95% yield and 100% ее1" 
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Scheme 2-15. Base-catalyzed asymmetric transformation of TV-acetyl-phenylglycines 
Treatment of racemic 63 with one equivalent (S)-MBA at room temperature gave enantiopure 
(S)-63 in 97% yield1" Enantiopure butync acid derivative 9a135 and mdanone derivative 64 were 
isolated from the racemic acids in 90-95% by treatment with brucine A transformation of 
hydrocarbostynl derivative 65 was observed by combination of enohzation and resolution with 
quinidine Enantiopure 65 was isolated in 96% yield136 Optically enriched malomc acid derivative 
66 was isolated in almost quantitative yield from the racemic compound by the action of different 
alkaloids117 
A crystallization-induced asymmetric transformation of ß-lactam derivative 67 was attained 
during the asymmetric synthesis of cephalexin (Scheme 2-16) In situ epimenzation of N-
nitrosoimidazohdinyl derivative 67 was achieved by base under slow crystallization and gave 
enantiopure 67 in 76% yield which subsequently has been converted to enantiopure cephalexin138 A 
crystallization-induced asymmetric transformation of 68 was encountered in the asymmetric 
synthesis of ß-lactams139 In situ epimenzation occurs at the phenylglycine ester site in the molecule 
under influence of Et3N in diethyl ether 
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Scheme 2-16. Crystallization-induced asymmetric transformation of ß-lactams 
An asymmetric transformation was observed with covalent diastereomers of 69 (Scheme 2-
17) In situ epimenzation was induced by a catalytic amount of DBN at 25-60°C in a mixture of 
ethyl acetate/hexane, and under crystallization conditions enantiopure 69 was isolated and converted 
into the enantiomencally pure ethyl ester (a compound with analgesic and antiinflammatory 
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activity)1". Also for deltamethnn 70, a pyrethroid insecticide, a crystallization-induced asymmetric 
transformation was achieved by performing a crystallization under weak basic conditions'". 
HjC4 
»-WÄ1:^ HjC-S СИ, О 
DJ О 
—r> ^ - ^ — η — — i l ' ^ —О 
71 (-)-galanlhamme 
Scheme 2-17. Crystallization-induced asymmetric transformation of covalent diastereomers 
A unique epimerization at two stereocenters in one step was observed during the 
crystallization-induced asymmetric transformation of (-)-narwedine (-)-71, a compound with 
cardiac, analgesic and hypotensive activity (Scheme 2-17). The in situ epimerization mechanism 
involves a retro-Michael reaction via an achiral intermediate. When the epimerization was carried 
out under crystallization conditions in a supersaturated solution and seeded with (-)-71, enantiopure 
(-)-71 was isolated in 84% yield. This product can be converted into (-)-galanthamine, an 
acetylcholine esterase inhibitor which is used in the treatment of Alzheimers disease142. 
d Acid-catalyzed Racemization 
An acid-catalyzed asymmetric transformation was observed for amino acid derivatives 72 and 
73 (Figure 2-9) with camphorsulfonic acid as resolving agent, using high boiling, relatively apolar. 
carboxylic acids such as propanoic, butanoic and hexanoic acid as the solvent. At temperatures 
between 90 and 120°C racemization proceeds at an acceptable rate and the solubility of one of the 
diastereomeric salts is sufficiently low. The yields of these asymmetric transformations vary 
between 75 and 100% with ee's ranging from 85 to 100%'". 
OCT" С OO H 
72a(R,=H,R2=Me) 
72b(R,=H, R,=Et) 
72c(R,=R2=Me) 
73 
Figure 2-9. 
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The two stereocenters of compound 74 are epimenzed in one step via a retro-Mannich 
reaction and reversible enohzation (Scheme 2-18) Combination with selective crystallization using 
(-)-CSA resulted in an asymmetric transformation144 
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Scheme 2-18. Acid-catalyzed epimerization at two stereocenters in one step 
Racemization by reversible opening of ring systems in combination with selective 
crystallization is observed for the compounds shown in Figure 2-10 Racemization of Trogers base 
75 is catalyzed by acid and it has been suggested that racemization follows a ring opening 
mechanism via an lminium ion145 By formation of a diastereomenc salt with an enantiopure 
binaphthylphosphate under acidic condition, a crystallization-induced asymmetric transformation 
was achieved and enantiopure 75 was isolated in 93% yield146 A dynamic kinetic resolution of 5-
hydroxy-2(5H)-furanones 76a was obtained conducting a lipase catalyzed acetylation in quantitative 
yield and ee's up to 100%"'47 In the synthesis of 5-menthyloxy-2(5H)-furanone 76b a 
crystallization-induced asymmetric transformation was observed by crystallization under thermal or 
acidic conditions and enantiopure 76b was isolated in 80% yield The optical lability is probably 
caused by reversible acetahzation148 The same mechanism of epimerization was observed in the 
selective glycosidation of fructose with 2-chloro-l-ethanol under acidic conditions Under these 
conditions an asymmetric transformation was achieved and enantiopure 77 was isolated in 90% 
yield In this case only one of four possible diastereomers was isolated'4' 
-CI 
75 
О 
76a (R=H) 
76b (R=menthyl) 
Figure 2-10. 
e Racemization by Nucleophilic Substitution 
Racemization via a reversible nucleophilic substitution mechanism of bromide is probably the 
cause for the crystallization-induced asymmetric transformation of 78, because in hydrogen-
deuterium exchange experiments in CD3OD no deuteration of 78 could be observed Depending on 
the conditions, compound 78 was isolated with 0-100% ее in almost quantitative yields'50 
Cyanohydnns are receptive for racemization because they can be equilibrated with the 
corresponding aldehyde/ketone and HCN In the asymmetric transformation of cyanohydnn 79 this 
equilibrium was combined with brucine complexation and selective crystallization of one 
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diastereomenc complex Depending on the phenyl substituent, brucine-cyanohydnn complexes 
were isolated in 40-100% yield and with ee's of 50-100%151. 
Crystallization-induced asymmetric transformation was also observed in organometalhc 
chemistry They are usually the result of combination of direct crystallization of a single isomeric 
metallic complex and racemization or epimenzation at a metallic center. An example is the 
transformation of boron ate complexes of amino acids 80152 
CN ° - γ Ο
φ
 Ar 
\ / 79 Η Η 
 80 
Figure 2-11. 
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Chapter 
R acemization and Asymmetric Transformation of Mandelic Acid 
3.1 Introduction 
Crystallization-induced asymmetric transformation result mainly from accidental discoveries 
An exception are amino acids, which were investigated systematically Racemization methodology 
of amino acids in combination with known resolution processes resulted in the rational design of 
crystallization-induced asymmetric transformations as described in section 2 1 ' 
In this thesis the focus is on the rational design of crystallization-induced asymmetric 
transformations of substrates other than amino acids and the scope of these transformations For this 
purpose α-hydroxycarboxylic acids (Chapter 3) and α-arylpropionic acids (Chapter 4) were selected 
as the substrates 
H O ^ X O O H HO COOH
 0 H 
HO COOH COOH Н з С COOH 
Figure 3-1. α-Hydroxycarboxylic acids 
Chiral α-hydroxycarboxylic acid derivatives are important and versatile intermediates for the 
construction of chiral organic compounds or chiral catalysts2 Well-known examples are tartaric acid 
1, malic acid 2, lactic acid 3 and mandelic acid 4 These compounds are industrially produced on a 
large scale (10-25 000 tons/year) at relative low prices and are therefore qualified as compounds of 
the chiral pool Mandelic acid 4 was chosen as a model compound for the rational design of 
crystallization-induced asymmetric transformations of chiral α-hydroxycarboxylic acids, for the 
following reasons 
1 Mandelic acid 4 is industrially prepared by classical resolution and therefore a possible 
crystallization-induced asymmetric transformation is of commercial interest 
2 Both enantiomers are readily available 
3 There are several resolving agents known for racemic mandelic acid 4 which can be tested in 
a crystallization-induced asymmetric transformation 
4 Mandelic acid 4 structurally resembles α-amino acids and α-arylpropionic acids which 
offers the possibility of comparing results in racemizations and asymmetric transformations 
5 The phenyl group in 4 will be beneficial for the crystalhnily of diastereomenc salts and can 
be used to study effects of aromatic substituents 
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The first problem in developing a crystallization-induced asymmetric transformation is the 
racemization step. This racemization must occur under resolution conditions without causing 
decomposition. Systematic investigation of the racemization of mandelic acid 4 is therefore in 
place. Based on such an investigation for amino acids (section 2.2), the racemization constant must 
have a value of about 10°-10-1 s"' corresponding with a half-life period of about 0.3-3 h1. 
OR, 
en COOR, 
S)-5 
a 
b 
с 
d 
e 
f 
g 
Ri 
H 
H 
H 
íBu 
COCH3 
H 
H 
R: 
Me 
Et 
íBu 
/Bu 
H 
/Pr 
Hex 
OH 
Î Q T T C 0 N H R 
\ / (S)-6 a (R=H) 
b (R=OH) 
X 
(S)-7 
COOH 
Figure 3-2. Mandelic acid derivatives. 
A few examples of racemization of mandelic acid derivatives are known in the literature and 
are already described in section 2.2'. However, most of these examples are unsuitable for use in 
crystallization-induced asymmetric transformation because they are performed under rather extreme 
conditions and can not be combined with a possible resolution process The conditions and kinetics 
for racemizing mandelic acid 4 and derivatives 5 to 9 were studied in order to find more suitable 
conditions for a possible asymmetric transformation process 
MeO 
13a (+)-Quinidine (X=OMe) 
12 (-)-Qumine 13b (-)-Cinchonine (X=H) 
NH2 
16(R)-2-benz\lamino-l-butanol 17(R)-BM1 18 (SM-)-Amphelamine 19 (R)-(-)-Adrenaline 
Figure 3-3. Resolving bases for mandelic acid. 
Racemizations were studied using bases, acids, metal ions and redox reagents. Also the effect 
of solvent was investigated. In addition, racemization without the use of solvent was considered. 
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Bases were studied in detail as these give the best opportunities for a combination with resolution 
through diastereomenc salts The results are presented and discussed in section 3 2 
Section 3 3 describes the results of applying these racemization conditions in one of the 
known resolution processes for mandelic acid Of the many resolving agents known for mandehc 
acid, viz (+)- and (-)-oc-methylbenzylamine (MBA) 10\ (-)-brucine ll 4, quinine 12", quinidine 13a4, 
(+)-cinchomne 13b5, (-)-ephednne 14\ (-)-2-amino-l-butanol 157, 2-benzylamino-l-butanol 16 j b", 
(R)-2-tert-butyl-3-methyhmidazolidin-4-one (BMI) lTbc\ amphetamine 183c and adrenaline 193e the 
most simple and least expensive one, ι e MBA 10, was chosen for most experiments 
3.2 Racemization Studies 
Racemization of mandelic acid derivatives 4 to 9 was studied by determing either the degree 
of racemization or the racemization constant The degree of racemization was obtained by 
measuring the enantiomeric excess (ее) after a reaction using chiral HPLC The racemization 
constant was derived from the racemization rate which is the rate of irreversible formation of the 
racemate from a pure enantiomer (Scheme 3-1) 
OH OH OH 
0 Г Т С О О Н + Ca, -^ [ f^COOH
 +Cat.H Jas^ Qj^COOH + ^ 
(SH ^ ^ (RS)-4 
Scheme 3-1. Racemization mechanism 
Racemization is described as a rate-determining deprotonation of the α-proton by a catalyst 
(usually a base) followed by fast re-protonation If the pure enantiomer is considered as the 
substrate, this results in second-order kinetics 
-
d ( S u b S t r a t e )
= k R [Substrate] [Cat] 3-1 
dt 
where kRis the true racemization constant The concentration of catalyst is considered to be constant 
because of its regeneration [Cat]=C With this condition equation 3-1 can be transformed to pseudo 
first-order kinetics 
d(Substrate) 
dt 
: k
obs [Substrate] 3-2 
k
obs = kR [Cat] 3-3 
where k
obs is the observed racemization constant The racemization process leads to the loss of 
optical activity, thus equation 3-2 can be transformed to 
Ln = k o b s t 3-4 
.a , 
where a 0 and a, are the optical rotation at time zero and t, respectively The half-life period (Ц) can 
be calculated from equation 3-4 by 
ln2 
t = 3-5 
Kohs 
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3.2.1 Non-basic Racemizations 
3.2.1.1 Acid-catalyzed Racemization 
In a racemization study of mandelic acid 4 by acid and base Campbell10 stated that 
racemization by base is faster than by acid Also, decomposition to benzoic acid was shown to be a 
side reaction under strongly acidic conditions Nevertheless, some efforts were made to racemize 
mandelic acid 4 under acidic conditions Racemization was checked for mandelic acid (S)-4 and O-
acetyl-mandehc acid (S)-5e by following the optical rotation of the reaction mixture The results are 
summarized in Table 3-1 
Table 3-1. Acid-catalyzed Racemization of Mandelic Acid 4 and O-Ac-mandehc Acid 5ea 
Entry 
1 
2 
3 
4 
5 
6 
Substrate 
(S)-4 
(S)-4 
(S)-4 
(S)-4 
(S)-4 
(S)-5e 
Reagents (equiv) 
NaOAc(lO) 
NaOAc(10),Ac 2 O(3) 
NaOAc(l) ,AcOH(3) 
NaOAc (10), AcOH (30), Ac 2 0 (3) 
B(OH)3(10) 
NaOAc (10), AcOH (30), Ac 2 0 (3) 
Solvent 
AcOH 
AcOH 
o-xylene 
DMSO 
DMSO 
DMSO 
T(°C) 
118 
118 
145 
150 
130 
150 
kObs(10^s-')b 
η r 
η r 
η г 
3 79е 
n r 
7 0 1 d 
a) Conditions mandelic acid 4 (250 mg, 1 6 mmole) or O-Ac-mandelic acid (S)-Se (330 mg, 1 7 mmole), base, 
solvent (35 ml) under N, b) N r=no reaction c) Decomposition of 4 to benzoic acid and reduction of DMSO to 
DMS d) Some decomposition of 5e to 4 and acetic acid was observed 
R - ч ^ R 3 
-\Θ/ 
н
ч
 в 
H-N© О 
21 
Racemization of (S)-4 was observed using sodium acetate, acetic acid and acetic anhydride in 
dimethyl sulfoxide (dmso) at 150°C (entry 4), but it was accompanied by decomposition to benzoic 
acid and dimethyl sulfide (DMS) This is the result of using Ac20/DMSO which is a known 
oxidizing reagent for alcohols to aldehydes/ketones accompanied by formation of DMS" This 
oxidation is prevented using Oacetyl-mandelic acid (S)-5e under the same conditions (entry 6) 
Racemization of (S)-5e followed pseudo first-order kinetics accompanied by some decomposition 
to mandelic and acetic acid It was thought that the use of a boron compound, which may give a 
complex like 20, could enhance the racemization It is known that boron compounds react with 
amino acids to form complexes like 21'2 and with mandelic acid 4 to complex 2013 No racemization 
was observed using boric acid (entry 5) These results confirm the conclusion that acid-catalyzed 
racemization is not suitable for asymmetric transformation of mandelic acid and its derivatives 
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3.2.1.2 Racemization by Metal Catalysts 
In a recent study about the catalytic effect of mandelate racemase14 it was suggested that the 
racemase acts by a combination of acidic and basic binding sites. It was also supposed that 
stabilization of the enolate by metal ions which gives a lower energy barrier, plays an important 
role A few experiments were performed to study a possible catalytic effect of metal ions on the 
racemization rate of mandelic acid 4. As a first approach, (S)-4 was racemized in solution by 
sodium hydroxide or l,4-diazobicycl[2.2.2]octane (DABCO), and a possible acceleration of the rate 
was monitored by adding CuCl2, Cu(OAc)2 and A12(S04)3 respectively (Table 3-2). 
Table 3-2. Base-catalyzed Racemization of Mandelic Acid 4 Using Metal Ions as Catalysts3 
Entry 
1 
2 
3 
4d 
5 
6 
7 
Base 
DABCO 
DABCO 
DABCO 
DABCO 
NaOH 
NaOH 
NaOH 
[Base] 
0.49 
0.49 
0.094 
0.093 
4.07 
4.07 
4.07 
Base 
(equiv) 
10 
10 
1 
1 
2.5 
2.5 
2.5 
Catalyst (equiv) 
-
CuCl2(l) 
CuCl2(l) 
Cu(OAc)2(l) 
-
Al2(SO4)3(0.01) 
Al2(SO4)3(0.17) 
Conditions 
DMSO, 130°C 
DMSO, 130°C 
DMSO, 130°C 
DMSO. 130°C 
H20.80°C 
H20, 80°C 
H20,80°C 
Nibs 
(io-V)c 
1.9 
3.11 
n.r. 
4 92; 
1.54 
0.78 
0.73 
0.72 
GO 
1.0 
0.62 
η г. 
0.99; 
1.25 
2.47 
2.64 
2 67 
a) Conditions, mandelic acid 4 (250 mg. 1 6 mmole) b) Reaction mixtures were homogeneous 
c) N r =no reaction, all reactions followed pseudo first-order reaction kinetics according to equation 3-4 
d) Heterogeneous mixture, two reaction constants were observed 
Figure 3-4. Racemization of Mandelic Acid (S)-4 by DABCO in DMSO Catalyzed by CuCl2 
2 3 
lime (h) 
DABCO (10 equiv)/CuCL2(l equiv): 
• α vs. time 
D ln(a) vs. time 
DABCO (10 equiv). 
• α vs. time 
Ο Ιη(α) vs. time 
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The reactions were earned out under nitrogen and followed by change in optical rotation 
From these results, see also Figure 3-4, it can be concluded that CuCl2 accelerates the racemization 
of mandehc acid (S)-4 by DABCO in dimethyl sulfoxide (entry 2) The use of Cu(OAc)2 results in 
two reaction constants (entry 4) The first reaction constant (4 92 ΚΓ4 s ') was observed in the first 
hour and the second (1 54 10^ s ') after one hour, during which also a substance precipitated from 
the solution The formation of this solid probably caused the change of kinetics The formation of 
CuO(s) and acetic anhydride from Cu(OAc)2 possibly accounts for the observed precipitation, but 
could not be confirmed by analysis Thus, Cu(OAc)2 is not a suitable addendum 
The use of A12(S04)3 in aqueous sodium hydroxide solutions results in the formation of 
Al2(OH)63 as the actual reagent However, racemization of (S)-4 was not accelerated (entry 5-7) 
Racemization of mandehc acid (S)-4 in the melt by 1 0 or 0 01 equiv of CuCl2 or of Cu(OAc)2, in 
the presence or absence of DABCO, resulted in decomposition and low yields of isolated 4 As a 
combination of these conditions with a resolution process has little prospect no further attention was 
paid to this approach 
3.2.1.3 Racemization by Oxidation-Reduction Equilibria 
Redox reactions can be used in racemization processes (section 2 3)1 Racemization of chiral 
amines by H2/Pd or H2/Raney-Ni are the best known examples The use of oxidation-reduction 
equilibria can in principle be used to racemize mandehc acid 4 or ethyl mandelate 5b Examples of 
redox reactions under equilibrium conditions are the Meerwein-Ponndorf-Verley reduction15, 
Oppenauer oxidation16 and Raney-Ni oxidation17 A possible use of the Oppenauer oxidation for the 
racemization of mandehc acid 4 or ethyl mandelate 5b is outlined in Scheme 3-2 
ОН О OH 
/ \ ^ \ ° AI(OR')3 / \ A ? H Al(OR')3 ^ч. X ° jgpCOOR
 + J^ _ ¿ 0^COOR +^ ^ _ ^ 0^COOR + J^ (S)-4 (R=H) 22 
(S)-5b (R-Et) 
(S)-5f(R=iPr) OH OH 
H3C COOEt E t O O C ^ ^ X O O E t 
23 24 
Scheme 3-2. Oppenauer oxidation of mandelate 
A Meerwein-Ponndorf-Verley reduction, the opposite reaction of an Oppenauer oxidation, 
was used for the synthesis of the a-hydroxycarboxylates ethyl lactate'" 23 and diethyl a-hydroxy-
glutarate" 24 The oxidation-reduction equilibrium in an Oppenauer oxidation is directed toward the 
side of the product by the use of excess of ketone and in a Meerwein-Ponndorf-Verley reduction by 
distilling off the ketone Racemization of (S)-4 and (S)-5b was attempted by making use of the 
oxidation-reduction equilibrium without excess acetone The results are summarized in Table 3-3 
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Table 3-3. Racemization (S)-4 and (S)-5b by an Oppenauer Oxidation. 
Entry 
1 
2 
3 
Substrate 
(S)-4 
(S)-4 
(S)-4 
Acetone 
(equiv) 
5 
0 
0 
Al(OR')3 R' Conditions 
(equiv) 
2 /Pr toluene, 110°C, 24 h 
2 /Pr toluene, 110°C, 24 h 
2 ;Pr THF, 67°C, 23 h 
Product 
4 
4 
4 
Yield 
(%) 
94 
93 
62 
Racemization 
(%)a 
0.8 
0.7 
0 
(S)-5b 
(S)-5b 
(S)-5b 
(S)-5b 
(S)-5b 
(S)-5b 
2 /Pr toluene, 110°C, 24 h 
0,5 (Pr benzene, 80°C, 23 h 
0,14 /Pr toluene, 80°C, 19 h 
2 /Pr toluene, 110°C, 24 h 
0,14 /Pr toluene, 80°C, 72 h 
1 /Bu toluene, 110°C, 24 h 
5f 
5b/5f 
= 1/3 
n.d. 
5f 
n.d. 
5b 
63 
100 
n.d. 
77 
n.d. 
93 
100 
100 
0b 
99 
0b 
15 
a) Determined by HPLC (Chiralcel ODH) b) N d = not determined, reaction was followed by the optical rotation of 
the reaction mixture 
Figure 3-5. Racemization of Ethyl Mandelate (S)-5b by Al(OiPr)3 in Toluene at 110°C. 
I ,
 r |,2 
0.9 
0.8 
0.7 
0.6 
0.5 
0.4 
0.3 
k
obs=1.5M0-V 
t,.= l 28 h 
R=0.997 
1,0 
0.6 3 
04 
0.2 
0.0 
05 1 1.5 
time (h) 
2.5 
α vs time D ln(ot) vs. time 
Under the reaction conditions used, no racemization was observed for (S)-4 (entry 1-3). On 
the other hand, racemization took place for (S)-5b. Comparing the results of entry 4 and 7, reveals 
that the observed racemization is induced by AI(0/Pr)3 as the base catalyst and does not result from 
an Oppenauer oxidation mechanism. Reaction of (S)-5b with AI(0/Pr)3 in toluene at 110°C results 
in a transesterification to /iopropyl mandelate 5f, accompanied or followed by racemization induced 
by /sopropoxide (Figure 3-5). In the first half hour the optical rotation increases because of the 
transesterification to 5f, and after half an hour a pseudo first-order racemization is observed 
according to equation 3-4. Transesterification can be prevented by using the more sterically 
hindered ferf-butoxide A\(()tQu)} (entry 9). However, the racemization rate is much lower. 
51 
Chapter 3 
The conclusion from the experiments described above is that the combination of Oppenauer 
oxidation and Meerwein-Ponndorf-Verley reduction did not work in the case of mandelic ester. 
However, a racemization of the substrate by base Al(0/'Pr)3 was effective. 
3.2.2 Base-catalyzed Racemization20 
3.2.2.1 Mandelic Acid 
From the literature survey on the racemization of mandelic acid 4 and in general of a-
hydroxycarboxylic acid derivatives, it was evident that base catalysis is the most prominent method 
(section 2.3)'. As a first approach the racemization of (S)-mandelic acid (S)-4 by 
deprotonation/protonation was studied. Several bases in hexanol and water were tried, viz. MBA 10, 
Et3N, brucine 11, (DABCO) 26, dicyclohexylamine (DCA) 27, 7V,7V,jV',^'-tetramethylethylene-
diamine (TMEDA) 28, l,8-6/'j(dimethylamino)-naphthalene (Proton sponge) 29, (5R,1 lR)-2,8-
dimethyl-6H-12H-5,l l-methanodibenzo[b,f][l,5]diazocine (Trögers base) 30, sparteine 31 and 
sodium hydroxide. The observed rate constants (kobs) and half-life periods (t%) of the racemization 
have been collected in Table 3-4 and were calculated using the least squares method from equation 
3-4. In hexanol the best results were obtained using DABCO 26 and brucine 11 as the base. 
Table 3-4. Racemization of Mandelic Acid (S)-4 by Base in Solution3. 
Λ H \ / \ / H 
¿fe σΝΌ ^  éè Д У Q3ö 
26 DABCO 27 DCA 28 TMEDA 29 Proton sponge 30 Trögers base 31 sparteine 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Base 
MBA 10 
Brucine 11 
Et3N 
DABCO 26 
DABCO 26 
DCA 27 
TMEDA 28 
Proton sponge 29 
Trögers Base 30 
sparteine 31 
NaOH 
NaOH 
NaOH 
[Base] (M) 
0.47 
0.47 
0.47 
0.48 
4.14 
0.43 
0.44 
0.41 
0.36 
0.47 
0.18 
0.82 
4.07 
Base (equiv) 
10 
10 
10 
10 
2.5 
10 
10 
9 
10 
10 
1.3 
2.3 
2.5 
Solvent 
hexanol 
hexanol 
hexanol 
hexanol 
H 20 
hexanol 
hexanol 
hexanol 
hexanol 
hexanol 
H 20 
H20 
H20 
T(°C) 
130 
130 
130 
130 
80 
130 
130 
130 
130 
130 
80 
80 
80 
k o b s ( 1 0 V ) b 
0.22 
1.51 
0.16 
0.61 
n.r. 
0.13 
0.21 
n.r. 
n.r. 
>0 (almost n.r.) 
n.r. 
0.1 
0.78 
ty, (h)' 
8.9 
1.3 
12.3 
3.1 
n.r. 
15.4 
9.3 
n.r. 
n.r. 
>0 
n.r. 
19.8 
2.5 
a) Conditions: (S)-4 (1.6 mmole). b) N.r. = no reaction. 
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In Figure 3-6 the racemization of (S)-4 by DABCO 26 is depicted and this reaction follows 
good first-order kinetics (R=0 999) Some resolving bases for mandelic acid 4, e g MBA 10 and 
brucine 11 (entry 1 and 2), are able to racemize (S)-4, which suggests a possible use in a 
crystallization-induced asymmetric transformation With sparteine 31 (entry 10) no clear 
racemization profile was found, although (S)-4 was racemized Performing the reaction in water 
results in optically stable (S)-4 by use of DABCO 26 (entry 5) Sodium hydroxide results in 
racemization of (S)-4 only when used at high concentrations (entry 11-13) 
Figure 3-6. Racemization of Mandelic Acid 4 by DABCO (10 equiv) in Hexanol at 130°C 
-0 80 
a »J 
-2 20 
time (h) 
• α vs time D ln(a) vs time 
In a deuterium-exchange experiment it was demonstrated that racemization of (S)-4 occurs via 
proton abstraction/enohzation/reprotonation (Scheme 3-3) After treatment of (S)-4 with NaOD in 
D20, NMR-expenments showed that the α-hydrogen signal disappeared and deuterium was 
exchanged at the a-position 
OH OD 
NaOD/D,0 / \ Or* 
^ - ^ (S)-4 
COOH 
90°C 20 h 
COOD 
Scheme 3-3. 
3.2.2.2 Solvent Effects 
In order to establish optimum conditions for the racemization of mandelic acid 4 it was 
important to find an optimal solvent for this process Therefore, the observed rate constant (k
obs) and 
half-life period were determined in different solvents for mandelic acid (S)-4 and the simple 
derivatives (S)-5a, 5b, 5d and 5e (Table 3-5) Best results were obtained in aprotic polar solvents 
and preferably in dimethyl sulfoxide (DMSO), which is in agreement with studies of Cram et al2 1 
Due to differences in solvation bases are relatively stronger in aprotic polar solvents compared to 
protic solvents In aprotic polar solvents, bases are less solvated and relatively 'naked' and therefore 
more reactive than in protic solvents 
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Entry 
] 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Table 3-5. 
Substrate 
(S)-4 
(S)-5a 
(S)-5b 
(S)-5d 
(S)-5e 
Solvent Effect on the Racemization of (S)-4, 
Base 
DABCO 
DABCO 
DABCO 
DABCO 
DABCO 
Et3N 
Et,N 
Et3N 
Et3N 
DABCO 
DABCO 
DABCO 
DABCO 
DABCO 
DABCO 
DABCO 
DABCO 
DABCO 
DABCO 
DABCO 
Solvent 
HexOH 
EtOH 
H 2 0 
toluene 
DMSO 
HexOH 
MeOH 
CHCIj 
DME 
DMSO 
DMSO 
HexOH 
DMSO 
DMI 
NMP 
DMF 
HexOH 
DMSO 
HexOH 
DMSO 
T(°C) 
130 
80 
80 
110 
130 
130 
65 
60 
65 
130 
130 
130 
130 
130 
130 
130 
130 
130 
130 
130 
коь5(10" 
0.61 
n.r. 
n.r. 
n.r. 
1.9 
0.16 
n.r. 
n.r. 
n.r. 
8.9; 16.0 
8.8 
6.1 
13.58 
8.86 
8.11 
8.09 
0.06 
0.34 
1.6 
19.3 
(S)-5a, (S)-5d and (S)-5ea. 
)C t
w
 (h)c 
3.1 
n.r. 
n.r. 
n.r. 
1.0 
12.0 
n.r. 
n.r. 
n.r. 
0.22; 16.0 
0.22 
0.32 
0.14 
0.22 
0 24 
0.24 
32.1 
5.7 
1.2 
0 I 
Isolated product 
4 
4 
4 
4 
4 
4 
4 
4 
4 
5g 
5a 
5g 
5b 
5b 
5b 
5b 
5d 
5d 
4 
5e 
a) Conditions Substrate (1 8 mmole), base (18 mmole), solvent (35 ml) b) Abbreviations DMI = l,3-dimethyl-2-
imidazolidine, NMP=/V-methyl-2-pyrrolidone, DMF^./V-dimethylformamide, DMSO=dimethyl sulfoxide. 
DME=1.2-dimethoxyethane c) N r =no reaction 
Figure 3-7. Racemization of Methyl Mandelate (S)-5a in HexOH by DABCO 26 
0 I 
O racemization of 5a 
2 3 4 
time(h) 
D formation and racemization of 5g • α vs. time 
The use of protic polar alcoholic solvents (ROH) caused some side reactions of derivatives 5 
Reaction of esters (S)-5a and (S)-5b in hexanol with DABCO 26 resulted in a transesterification to 
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hexyl mandelate 5g accompanied by racemization Transesterification of 0-acetyl-mandelic acid 
(S)-5e resulted in hexyl acetate and mandehc acid 4 In the case of (S)-5b and (S)-5e, first-order 
reactions were observed Optical rotations reached zero accounting for complete racemization 
Methyl mandelate (S)-5a showed two reaction constants, probably caused by the racemization of 
(S)-5a and the formation and racemization of hexyl mandelate 5g (Figure 3-7) 
3.2.2.3 Mandelic Acid Derivatives (Preparation) 
To study the effects of substituents at the Ca and carboxyhc acid group of mandelic acid 4, 
derivatives 5 to 9 were prepared (Figure 3-2) Their racemization rates were determined and 
compared 
Mandelic acid derivatives 5 and 6 were synthesized starting from enantiopure (S)-mandelic 
acid (S)-4 (Scheme 3-4) Starting from (S)-4, methyl (S)-mandelate (S)-5a and ethyl (S)-mandelate 
(S)-5b were prepared following standard literature procedures12 Estenfications were performed 
quantitatively and after recrystallization enantiopure (S)-5a and (S)-5b were isolated in yields of 
55% and 92% respectively 
Treatment of (S)-4 with one equiv of Jiobutene, resulted in the isolation of 13% of (S)-5c and 
8% of (S)-5d Using excess of «obutene yielded 8% of (S)-5c and 35% of (S)-5d after purification 
by column chromatography Preparation of (S)-5c using fer/-butanol under acidic conditions 
according to Wood et al 2 3 , resulted in a slow reaction and a mixture of products No further 
attempts were made to improve these results 
Enantiopure 0-acetyl-(S)-mandelic acid (S)-5e was prepared by acylation of (S)-4 with acetic 
anhydride in pyridine using 4-(NjV-dimethylamino)pyndine (DMAP) as the catalyst in 9 1 % yield 
after recrystallization 
OH OtBu 
r^^r^^COOtBu -r r ^ j Y ^ C O O t B u 
^У (S)-5c , ^У (S)-5d 
Vo 
о 
dioxane 
HÏS0 4 
OH OH 
A C Ï O 
pyridine DMAP ©Or MeOH benzene HiSOj OCT 
EtOH toluene, H2S04 
OH 
r ^ ^ ^ C O N H O H 
^ ч ^ (S)-6b 
OH 
ΝΗ,ΟΗ 
MeOH 
Г ^ ч Г ^ С О О Е і 
^ C ^ (S)-Sb 
NH3(I) 
OH 
CONH2 
(S)-6a 
Scheme 3-4. Synthesis of mandelic acid derivatives 5 and 6 
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(S)-Mandelic amid (S)-6a and hydroxamic acid derivative (S)-6b were synthesized trom 
enantiopure ethyl (S)-mandelate (S)-5b by reaction with ammonia24 and hydroxylamine25 
respectively, following literature procedures. After purification, enantiopure (S)-6a and (S)-6b were 
isolated in 68% and 56% yield respectively. 
X CHO 
or о 
MeO OMe OH 
(S)-7 OCT BF3 OEt2 pTosOH " " (5S)-8 
cisltrans=2l 1 
Scheme 3-5. Synthesis of dioxolan-4-one derivatives 7 and 8 of mandelic acid. 
2,2-Dimethyl-5(S)-phenyl-l,3-dioxolan-4-one (S)-7 and (5S)-2,5-diphenyl-l,3-dioxolan-4-
one (5S)-8 were also prepared from enantiopure mandelic acid (S)-4 (Scheme 3-5). Condensation of 
2,2-dimethoxypropane with a catalytic amount of p-toluenesulfonic acid provided enantiopure (S)-7 
in 77% yield after purification by recrystallization. Following a literature procedure26, (5S)-8 was 
synthesized by condensation of (S)-4 with benzaldehyde and BF3.OEt2 as the catalyst. Two 
diastereomers were obtained in a ratio of cis:trans=2:\ in 50% yield. This is in contrast to the 
literature procedure which resulted in pure c/j-product. The mixture obtained was used as such in 
racemization experiments 
„NH2 
O C O O H 
\( J anisóle 
(R)-9 
r ^ N Y ^ C O O C H P t b <* 
( ) " PPh·,, DIAD 
(R)-36 
OH 
r ^ V ' ^ C O O C H P h j 
^У^ (S)-35 
0-^ /\JI COOH 
(S)-37 
Scheme 3-6. 
Mandelic acid derivative (R)-2-phenyl-2-(phthalimidooxy)acetic acid (R)-9 was prepared 
according to a literature procedure described for the synthesis of (S)-3727 (Scheme 3-6). 
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Diphenyldiazomethane 34 was prepared from benzophenone 32 in 77% overall yield following an 
alternative procedure2' because of unsatisfactory results using the method of Murakami et al :7 
Estenfication of (S)-4 using 34 in diethyl ether resulted in the isolation of (S)-35 in 89% yield 
Conversion of (S)-35 by the Mitsunobu reaction29 provided ct-(phthalimidooxy)acetate (R)-36 with 
inversion of configuration Deprotection of (R)-36 by tnfluoroacetic acid and anisóle, followed by 
purification, gave (R)-9 in an overall yield of 31% from (S)-35 
Enantiomeric excesses (ее) of 4, 5a, 5b, 5e and 5f were determined using HPLC with a chiral 
cellulose fra(3,5-dimethyl-phenylcarbamate) column (Daicel Chiralcel ODH) and hexane/2-
propanol/trifluoroacetic acid (TFA) as eluent The results of the chromatographic resolution of these 
compound are collected in Table 3-6 The Chiralcel ODH column was adopted from the report of 
Okamoto et alD0, in which mandelic acid 4 was resolved However, better results were obtained 
using different eluent compositions and a smaller particle size Resolution of compounds 5a, 5b and 
5e using HPLC with a Chiralcel ODH column, were not described previously The ее of dioxolane 
derivative 7 was determined using a chiral B-DEX 120 capillary GC column (Supelco) For other 
derivatives, ee's were calculated based upon their optical rotation in a suitable solvent 
Table 3-6. Determination of the ЕЕ of Mandelic Acid Derivatives using HPLC (Chiralcel ODH) 
Entry 
1 
2 
3 
4 
5 
Compound 
4 
5a 
5b 
5e 
5f= 
Eluent 
hexane/2-propanol/TFA (v/v) 
872/125/2 5 
8/2/0 
8/2/0 
875/125/2 5 
9/1/0 
f a 
r RS 
3 65 
10 35 
8 99 
1 36 
11 6 
b 
α 
1 48 
2 57 
2 76 
1 18 
381 
remarks 
S-enantiomer elutes first 
S-enantiomer elutes first 
S-enantiomer elutes first 
S-enantiomer elutes first 
S-enantiomer elutes first 
a) The resolution factor (fRS) was calculated by fRS=AtR 1 177/Zw0S , where t„ is the retention time and w o s the 
width at half-height b) The separation factor (a) was calculated using ct=k2'/k| , where k' is the capacity factor 
determined by к , ' ^ , - ^ ) / ^ , where t, is the retention time of enantiomer I and !<, the retention lime of the dead 
volume (toluene) c) /sopropyl mandelate 5Г 
3.2.2.4 Mandelic Acid Derivatives (Racemization) 
The racemization of mandelic acid 4 and derivatives 5 to 9 was achieved under the same 
conditions as described in section 3 2 2 2, viz with 10 equiv DABCO 26 in dimethyl sulfoxide at 
130°C The optical rotations of the substrates 4, 5 to 9 were monitored during the racemization and 
are shown in Figure 3-8 (plot A) When ln(a) is plotted against time a linear relationship is 
observed (pseudo first-order kinetics, Figure 3-8, plot B) The racemization constant (k
obs) and half-
life period (t./,) were calculated from the slopes of these straight lines and are collected in Table 3-7 
From these results it can be concluded that the racemization rate increases with an increase in 
electron-withdrawing ability of the substituents at Ca and carboxylic function of mandelic acid 
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Figure 3-8. Racemization of Mandelic Acid Derivatives 4 to 7 
by DABCO 26 (10 equiv) in DMSO at 130°C 
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Table 3-7. Racemization of Mandelic Acid Derivatives 4 to 9a 
OR, 
r g ^ C O O R , 
S)-5 
a 
b 
с 
d 
e 
f 
g 
Ri 
H 
H 
H 
íBu 
COCH3 
H 
H 
R2 
Me 
Et 
/Bu 
/Bu 
H 
iPr 
Hex 
OH 
[ Q T T C O N H R 
\ / (S)-6 a (R=H) 
b(R=OH) 
X 
(S)-7 
COOH 
Entry Substrate kcbsdO^s") t./, (h) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
l l d 
(S)-4 
(S)-5a 
(S)-5b 
(S)-5c 
(S)-5d 
(S)-5e 
(S)-6a 
(S)-6b 
(S)-7 
(S)-8 
(R)-9 
1 9 
8 8 
13.6 
1.3 
0.34 
19.3 
0.21 
2.6b 
891 
3.5e 
3.9 (heat); 37.3 (base) 
1.0 
0 22 
0.14 
1.5 
5.7 
0.1 
9.2 
0.74 
0 002 
0.55 
1.7; 0.2 
a) Conditions, substrate (I 6 mmole), DABCO 26 (10 equiv), dimethyl sulfoxide (35 ml), I30°C b) 
Racemization also occurred without base under influence of heat (130°C) and after work-up, the 
substrate could not be isolated c) No first-order reaction was observed, and the substrate decomposed 
during the reaction, d) Racemization of (R)-9 occurred with or without base under influence of heat, 
but was also accompanied by decomposition 
OH OH 
COOH 
\ ^ (S)-4b 
Scheme 3-7. Base-catalyzed racemization of mandelic acid 4. 
The equilibria shown in Scheme 3-7 have to be considered for base-catalyzed racemization of 
mandelic acid (S)-4. Semi-empiric calculations (AMI) simulating dilute aprotic polar solutions 
indicate that the racemization of α-substituted α-arylacetic acids follow route A. The racemization 
via route С requires much higher activation energies. The same holds for equilibrium D. The 
racemization via route A experiences a negative effect by equilibrium В because strong bases lower 
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the concentration of free acid (S)-4 via deprotonation of the carboxylic acid group This 
consideration strongly suggests that there will be an optimal base strength, which entirely balances 
the deprotonation at Ca and the carboxylic acid group 
The substrates 4 and 6a are characterized by a negative (electron-withdrawing) resonance 
effect (-M) and field effect (-1) Because of the difference in field effect (NH2 is more 
electronegative than OH), the α-hydrogen is more acidic in acid 4 than in amid 6a and therefore 4 
racemized faster (entry 1 and 7) This effect is enhanced using hydroxamic acid 6b (entry 1, 7 and 
8) Hydroxamic acid 6b also racemized at 130°C without any additional base After work-up of this 
base-catalyzed reaction, the substrate could not be re-isolated and some decomposition products 
were obtained It is not clear whether the decomposition is the result of the racemization conditions 
or from the acidic work-up procedure Methyl ester 5a and ethyl ester 5b racemized faster because 
of the absence of competing equilibrium В in Scheme 3-7 The negative field effect in ferr-butyl 
ester 5c is minimized due to the electron-donating ability of the /er/-butyl group compared to 5a and 
5b (entry 2-4) Stenc hindrance of the ierf-butyl group also may cause a decrease in the 
racemization by making the α-hydrogen less accessible for proton abstraction A strong field effect 
(-1) at Ca is observed when mandehc acid 4 and 0-acetyl-mandelic acid 5e (entry 1 and 6) are 
compared The electron-withdrawing ability of the acetate causes a strong increase of the acidity of 
the α-hydrogen, although the resonance effect of the acetate is opposite (+M) The negative field (-
I) and positive resonance effect (+M) at Ca. are minimized and maximized respectively using a tert-
butyloxy substituent (compound. 5d) This causes a decrease in acidity of the α-hydrogen (entry 1,4 
and 5) 
Table 3-8. Racemization of Ethyl Mandelale (S)-5b by DABCO 26 and/or Al(OiPr)3 
Entry Base (equiv) [Base] Conditions k
obs ( 10"4 s ')a t,/;(h)a 
1 DABCO (10) 0 51 DMSO, 130°C 13 58 0 14 
2 DABCO (1) 0 05 Toluene, 80°C nr η г 
3 А1(ОіРг)з(1) 0 05 Toluene, 80°C 15 128 
4 DABCO (l)/Al(OiPr)3 (0 2) 0 05/008 Toluene. 80°C η г nr 
a) N r = no reaction 
In section 3 2 1 3 it was shown that Al(0;Pr)3 is able to racemize ethyl mandelate (S)-5b in 
apolar solvents This was compared with racemization by DABCO 26 (Table 3-8) (S)-5b 
racemized when treated with DABCO 26 in dimethyl sulfoxide, but no racemization was observed 
in toluene (entry 1 and 2) In contrast. (S)-5b was racemized by AI(0;Pr)3 in toluene (entry 3) 
Combination of DABCO and Al(OiPr)3 resulted in an optically stable system (entry 4), probably 
through complex formation between both bases 
Compound (R)-9 was studied because it resembles a recent example of very facile 
racemization of (S)-37 (Scheme 3-6 ) by 1 5 equiv of Et3N in acetomtnle at 0-50°C in one hour7 
The racemization of 0-phthaloyl-mandehc acid (R)-9 was attempted under several conditions The 
results are listed in Table 3-9 
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Entry 
l b 
2C 
3C 
4 d 
5 e 
Substrate 
(S)-37 
(R)-9 
(R)-9 
(R)-9 
(R)-9 
Table 3-9. Base-catalyzed racemization 
Base (equiv) 
Et3N(1.5) 
Et3N(1.5) 
DABCO(1.5) 
DABCO(15) 
DABCO(IO) 
Solvent 
CH3CN 
CH3CN 
DMSO 
DMSO 
DMSO 
T(°C) 
0-50 
0-50 
50 
80 
130 
of(R)-9. 
k
o b s(10V) a 
100% racemization in 1 h2' 
n.r. 
n.r. 
1 
3.9 (heat/, 37.3 (base/ 
b) N r = no reaction b) Conditions· (S)-37 (93 mmole), CH3CN (600 ml) c) Conditions· (R)-9 (0 33 mmole), 
CH3CN (5 ml) d) Conditions· (R)-9 (0 33 mmole), DMSO (10 ml) e) Conditions (R)-9 (1 7 mmole), 
DMSO (35 ml) f) Decomposition was observed during the reaction 
Under the conditions whereby (S)-37 was completely racemized27, (R)-9 is optically stable 
(entry 1 and 2). Also using the strong base DABCO 26 in dimethyl sulfoxide at 50°C gave no 
racemization (entry 3). Under these conditions, the substrate was recovered unchanged after work­
up. This different racemization behavior of similar compounds 37 and 9 under the same conditions 
cannot be explained. The use of excess of DABCO 26 at higher temperatures (entry 4 and 5) caused 
decomposition of 9. Besides jV-hydroxyphthalimid, some unidentified material was isolated. Heat 
(130°C) already caused racemization of (R)-9, but this is probably also responsible for the 
decomposition of the substrate 
OH free rotation 
ЮН 
\ (jl no free rotation 
\ ^ (S)-7 
AS~0 
X ' 
Racemization 
1
 oX 
U о о ¿н q r ° ρ 
Scheme 3-8. Entropy-effect in the racemization of (S)-4 and (S)-7. 
An exceptionally high racemization rate was observed for 2,2-dimethyl-5(S)-phenyl-l,3-
dioxolan-4-one (S)-7. This can be explained by a combination of entropy effects (Scheme 3-8) and 
the absence of acid-base equilibrium В in Scheme 3-7. When mandelic acid (S)-4 racemizes through 
its enolate, it loses one degree of freedom, resulting in a negative entropy factor (AS<0). This loss of 
degrees of freedom during enolization does not occur for dioxolane (S)-7. As a result, no significant 
change in entropy arises (AS~0), which accounts for a relative smaller amount of free energy and 
thus for faster racemization. Generalization of this observation leads to the conclusion that 
optimization or suppressing of racemization can also be controlled by the entropy of the reaction. 
Racemization will be accelerated if no degrees of freedom are lost. In contrast, racemization is 
suppressed when degrees of freedom are lost (AS is < 0, AG is larger and the reaction slower). In 
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addition to this effect, equilibrium В (Scheme 3-7) is absent for base-catalyzed racemization of 23. 
which makes route A (a-deprotonation) more favorable, and accordingly the racemization should 
proceed faster when compared with mandehc acid 4 
Epimenzation of 5(S)-2.5-diphenyl-l,3-dioxolan-4-one (5S)-8 showed no first-order kinetics, 
due to decomposition of this substrate and probably different epimenzation rates of diastereomers 
It was tried to perform a racemization of mandehc acid (S)-4 by in situ formation and 
racemization of dioxolane (S)-7 under equilibrium conditions (Scheme 3-9) The reaction was 
performed using one equiv of acetone and pyndinium p-toluenesulfonate (PPTS), a weakly acidic 
and basic catalyst, in refluxing toluene without the removal of water Although the optical rotation 
of the reaction mixture decreased and some dioxolane 7 was formed, it was not clear whether or not 
racemization occurred Also using benzaldehyde, sahcylaldehyde and cyclohexanone under acidic 
or basic conditions did not result in a clear racemization of (S)-4 
(S)-7 (R)-7 (R)-4 
Scheme 3-9. 
Dioxolane 7 is not a suitable substrate for a crystallization-induced asymmetric transformation 
because resolution via selective crystallization of diastereomenc salts is impossible Π was therefore 
considered to modify structure 7 in such a way that resolution would be feasible The first 
candidate, viz spiropipendone 38, is a known compound31 However, following the literature 
procedure"', 38 could not be prepared Using an alternative procedure-·2, spiropipendone 38 could be 
synthesized, but there were difficulties with the isolation of the product The preparation of cyclic 
phosphate or phosphoric acid 39, as the second candidate for the purpose indicated above, was 
attempted following a procedure for a similar structure', but in vain In view of these difficulties the 
approach involving 38 and 39 was abandoned 
3.2.2.5 2,2-Dimethyl-5(S)-phenyl-l,3-dioxolane-4-one 
Because optimum racemization results were obtained with mandehc acid derivative dioxolane 
7 in dimethyl sulfoxide using DABCO 26 as the base, this system was used for a more detailed 
study of the kinetics of the racemization These results could probably be useful for the design of 
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more accurate racemization conditions for the asymmetric transformation of mandehc derivatives 
Dioxolane (S)-7 was racemized with DABCO 26 whereby the concentration of base and substrate in 
turn were kept constant or varied The reaction followed pseudo first-order kinetics for the 
concentration range 0 001 to 0 4 mol/1 These kinetics are shown for the racemization at the 
concentration of both substrate and base of 0 040 mol/1 (Figure 3-10) The kinetic data k
obs, kR, and 
t/2 were calculated from these plots using equations 3-3, 3-4 and 3-5 The results are collected in 
Table 3-10 and 3-11 
Figure 3-10. Racemization of (S)-7 by DABCO 26 (0 0399M, 1 equiv) in DMSO at 80°C 
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Table 3-10. Racemization of Dioxolane (S)-7 by DABCO in DMSO at 80°C, [(S)-7]=0 0399 
Entry [DABCO] DABCO (equiv) k
o b s ( 10"4 s ' ) kR (10 2 M ' s ') ν ( 10 7 mol/l/s) t7j (h) 
1 
2 
J 
4 
5 
6 
0 00195 
0 00391 
0 0195 
0 0391 
0 078 
0 39 
0 05 
0 1 
05 
1 
2 
10 
0 57 
1 23 
621 
124 
24 4 
106 
2 92 
3 15 
3 18 
3 17 
3 13 
271 
0 23 
0 49 
2 48 
4 00 
9 74 
42 2 
3 36 
1 57 
031 
0 16 
0 08 
0 02 
Table 3-11. Racemization of Dioxolane (S)-7 by DABCO in DMSO at 80°C, [DABCO]=0 0391 
Entry [(S)-7J (S)-7 (equiv) к
о Ь 5 (10" ) k R ( 1 0 2 M ' s ' ) ν (10 7mol/l/s) t 7 (h) 
1 
2 
3 
4 
5 
0 00798 
0 0199 
0 0399 
0 0599 
0 399 
0 02 
05 
1 
1 5 
10 
12 8 
11 6 
11 7 
102 
11 0 
3 28 
2 97 
30 
2 62 
2 82 
1 02 
231 
4 57 
6 12 
43 9 
0 15 
0 17 
0 16 
021 
0 18 
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The kR values shown in Table 3-10 (1 e kobs/[DABCO]) are within the limits of accuracy the 
same The k
obs values shown in Table 3-11 are the same for the applied concentration range of the 
dioxolane These data confirm that the racemization is a bimolecular process, first-order in substrate 
and first-order in base 
Winther34 studied the racemization of mandehc acid 4 in aqueous sodium hydroxide solutions 
He found that the racemization rate was strongly dependent on the concentration of base, while the 
concentration of mandehc acid played a minor role in the range 0 4-13 N at 99°C This is in 
contrast with the above results which must be attributed to the difference in substrate 
Figure 3-11. Temperature-effect on the Racemization of Dioxolane (S)-7 
by DABCO 26 (0 4 M, 10 equiv) in DMSO 
2 
0 0024 0,0026 0,0028 
1/T(1/K) 
0,003 0,003 
The effect of temperature is expressed by the Arrhemus plot (eq 3-6) using the Arrhemus 
equation35 
InK = InA - E
a
/RT (3-6), 
where К is the reaction constant and A the pre-exponential factor, also called the frequency 
factor Increase of temperature results in an increase of racemization rate An activation energy (E
a
) 
of 15 2 kcal/mol and a frequency factor (A) of 3 4 10 M s were determined from this plot 
This kinetic study reveals that the racemization is a bimolecular reaction which follows the 
corresponding kinetics even at higher concentration For a crystallization-induced asymmetric 
transformation high concentrations are required, therefore racemization without solvent, ι e in the 
melt is worth considering here 
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3.2.2.6 Racemization in the Melt 
As indicated in the previous section racemization in the melt may be of interest. The 
racemization of mandelic acid (S)-4 and 2,2-dimethyl-5(S)-phenyl-l,3-dioxolan-4-one (S)-7 was 
investigated in the melt. The results of racemization by DABCO 26 and racemic MBA 10 are 
collected in Table 3-12 and 3-13. 
Table 3-12. Racemization of Mandelic Acid 4 and Dioxolane 7 by DABCO in the Melta 
Entry 
3 
4 
5 
1 
2 
Substrate 
(S)-7 
(S)-7 
(S)-7 
(S)-4 
(S)-4 
DABCO (equiv) 
0 
0.13 
1.11 
1.1 
1.5 
T(°C) 
70 
70 
70 
135 
135 
Time (min) 
1 
1 
1 
60 
60 
Racemization (%) 
n.r. 
28 
87 
86 
98 
a) Conditions mandelic acid(S)-4 (0 3 mmole) or dioxolane (S)-7 (0 8 mmole), DABCO 26, melt b) 
Determined by optical rotation, η r = no reaction 
When dioxolane (S)-7 was racemized in the melt using 1.1 equiv DABCO at 70°C during one 
minute (Table 3-12), an almost complete racemization took place (entry 3). On the other hand, when 
no base was added (S)-7 is optically stable (entry 1). If mandelic acid (S)-4 was racemized by 
DABCO in the melt at 135CC during one hour, an acceleration is observed compared to the 
racemization by DABCO in dimethyl sulfoxide (Table 3-7, entry 1). Mandelic acid 4 is almost 
completely racemized with one equiv of DABCO in the melt at 135°C within one hour, while 
racemization in dimethyl sulfoxide with 10 equiv of DABCO at 135°C, has a half-life period of 
about one hour. 
Racemization in the melt was also tried with the resolving base MBA 103. Racemization took 
place with a half-life period of almost one hour (Table 3-13). This method thus has good promise 
for a crystallization-induced asymmetric transformation of mandelic acid 4. 
Table 3-13. Racemization of Mandelic Acid (S)-4 by DL-MBA 10 in the Melt3. 
Entry 
1 
2 
3 
4 
5 
Time (min) 
0 
1 
5 
30 
60 
Racemization (%)b 
0 
7 
16 
24 
40 
a) Conditions. (S)-4 (0 3 mmole), DL-MBA 5 (0 33 mmole), 135°C, melt 
b) Determined by optical rotation 
Several other bases were investigated to racemize (S)-4 in the melt, viz. Et3N, MBA 10, 
DABCO 26, DCA 27, TMEDA 28, Proton sponge 29, Trögers base 30, 4-(Af,Ar-dimethylamino)-
pyndine (DMAP) 40, morfoline 41, piperidine 42, pyrrolidine 43, l,8-diazobicyclo[5.4.0]undec-7-
65 
Chapter 3 
ene (DBU) 44, 1.5-diazobicyclo[4.3 0]non-5-ene (DBN) 45, tetramethylguanidine (TMG) 46 and 
1.5.7-tnazabi-cyclo[4.4.0]dec-5-ene (TBD) 47. The results of their ability to racemize (S)-4 are 
summarized in the Tables 3-14 and 3-15. These data reveal that TBD 47 gave the best result, 
followed by DBN 45 and TMEDA 28. Furthermore, DCA 27 did not induce racemization, while 
Et3N, MBA 10. Proton sponge 29 and TMG 46 gave moderate results. Trögers base 30 and DMAP 
40 were unsuitable because they gave a heterogeneous melt. The best racemizing base in solution, 
i.e. DABCO 26, gave a homogeneous melt over 130°C and completely racemized mandelic acid 
(S)-4 at this temperature. The use of DABCO 26 below 130°C resulted in a heterogeneous melt and 
no racemization was observed. Intermediate results were obtained with the other bases tested. 
Table 3-14. Racemization of Mandelic Acid (S)-4 by Two Equivalents of Base in the Melt3. 
Ô Û O u CO cow co 
N 
40 DMAP 41 Morfolme 42 Pipendine 43 Pyrrolidine 44 DBU 45 DBN 46 TMG 47 TBD 
Entry Base Time (h) Τ (°C) Racemization (%)b Yield (%) 
Et3N 
MBA 10 
DABCO 26 
DCHA 27 
TMEDA 28 
Proton Sponge 29 
Trogers base 30 
DMAP 40 
Morfoline 41 
Pipendine 42 
Pyrrolidine 43 
DBU 44 
DBN 45 
TMG 46 
5 
5 
5 
5 
1 
1 
1 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
110 
120 
110° 
120 
110c 
120c 
130 
110 
110 
110 
110 
110c 
110c 
110 
110 
110 
110 
110 
110 
17.3 
26.2 
13 1 
32.9 
n.r. 
nd. 
96 
n.r 
51.4 
49 7 
9.0 
18.5 
nd. 
43.0 
44.6 
35.7 
44.6 
40.4 
60.4 
9.7 
87 
95 
97 
94 
96 
n.d. 
95 
74 
97 
90 
90 
88 
87 
94 
93 
100 
93 
79 
94 
91 
a) Conditions mandelic acid (S)-4 (1 6 mmole), base (3 2 mmole), under nitrogen, melt b) Determined by 
HPLC (Chiralcel ODH, ± 0 5%), η r =no reaction, η d =not determined c) Heterogeneous melt 
66 
Racemization and Asymmetric Transformation o/MandeI¡с Acid 
Table 3-15. Racemization of Mandelic Acid (S)-4 by 1.1 Equivalent of Base in the Melt . 
Entrv 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
Base 
Et3N 
MBA 10 
DABCO 26 
TMEDA 28 
Proton Sponge 29 
Trogers base 30 
Morfoline 41 
Piperidine 42 
Pyrrolidine 43 
DBU44 
DBN45 
TMG46 
TBD47 
pKa" 
11.0 
9.4 
2.8; 8.8 
5.9; 9.1 
9.7, 13 5 
10.8 
8.3 
11.1 
11.3 
13.6 
pKac 
0.214 
0.063 
<0.06 
9.4 
Time 
(h) 
5 
5 
1 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
T=90°C 
Racemization 
(%) 
3.8 
f 
r 
193 
0 
f 
9.1 
0.21 
11.3 
9.4 
23.2 
0 3 
23.3 
Yield6 
(%) 
90 
n.d. 
n d . 
93 
95 
95 
93 
92 
96 
96 
99 
90 
95 
T=110°C 
Racemization 
(%) 
19.9 
4.3 f 
n.r 
47.8 
7.9 
27.2' 
25 4 
0.7е 
32.4 
27 9 
47.6 
5.1 
73.9 
Yield 
(%) 
95 
95 
96 
89 
93 
84 
89 
98 
90 
96 
94 
84 
95 
a) Conditions mandelic acid (S)-4 (1 6 mmole), base ( I 8 mmole), under nitrogen, melt b) Basicity in waterj6 
c) Relative basicity in acetonitrile d) Determined by HPLC (Chiralcel ODH, ± 0 5%), η r = no reaction 
e) N d = not determined f) Heterogeneous melt 
There seems to be no relationship between the pKa values of the bases used and their ability 
to racemize mandelic acid (S)-4 in the melt. Good results were obtained with cyclic amines, 
especially with cyclic guanidines and amidines, and also with diamine TMEDA 28 The difference 
between the open guanidine TMG 46 and cyclic guanidine 47 is very large, but no explanation can 
be given for this observation. Currently, semi-empiric molecular modeling calculations (AMI) are 
carried out to gain more insight. 
In conclusion, a relatively mild and fast racemizing process in the melt has been developed for 
mandelic acid 4, with potential application in a crystallization-induced asymmetric transformation. 
3.3 Crystallization-induced Asymmetric Transformation20 
The relative fast racemization of methyl mandelate 5a, ethyl mandelate 5b and Oacetyl-
mandelic acid 5e, opens perspectives for crystallization-induced asymmetric transformation using 
preferential crystallization of conglomerates. Unfortunately however, these compounds are known 
to be racemic compounds and cannot be resolved in this way38. Also mandelic acid 4 and dioxolane 
derivative 7 were shown to be racemic compounds by constructing the binary phase diagrams of 4 
and 7 using differential scanning calorimetry (Figure 3-12). Efforts to resolve O-acetyl-mandelic 
acid 5e via diastereomeric salt formation with a-methylbenzylamine 10 were unsuccessful 
Therefore, 5e cannot be used in a crystallization-induced asymmetric transformation. 
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Figure 3-12. Binary Phase Diagrams of mandelic acid 4 and 
2,2-dimethyl-5-phenyl-1,3-dioxolan-4-one 7. 
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Because of these results a study toward an asymmetric transformation of mandelic acid 4 
using crystallization of diastereomeric salts as resolution method was undertaken, whereby the 
reactions were performed in the melt because then optimal racemizing conditions were expected 
The combination of selective crystallization and racemization in the melt needs to be performed 
under conditions where a heterogeneous melt is formed. This process has been outlined in a binary 
phase diagram (Figure 3-13). A racemic mixture (x05) was heated to a temperature T 0 5 where the 
mixture starts to melt. The mixture is further heated until Ty where the mixture was completely 
homogeneous. Slowly cooling of this mixture to TA resulted in the crystallization of pure isomer p. 
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The mother liquor (or the homogeneous phase) at this point has the composition xML Racemization 
in the mother liquor changes this composition to the racemic composition (xML -> x0:,) This 
racemization destroys the equilibrium in the mother liquor and the enrichment with isomer ρ 
resulted in crystallization of this isomer to recover the equilibrium of the phases (x0, -> xML) This 
process was repeated and resulted in the asymmetric transformation of the racemate to pure isomer 
ρ An asymmetric transformation is therefore applicable in the temperature range T
e u
-T0, where the 
melt is heterogeneous 
In most reactions an excess of base is applied Therefore, no real melt conditions are 
encountered because the excess of base can be viewed as a solvent Nevertheless, such reactions are 
denoted as performed in the melt 
Figure 3-13. Asymmetric Transformation of a Conglomerate in the Melt 
Π XJU XML x 0 5 
I ? H ι 
48 49 
Figure 3-14. New resolving bases for mandelic acid 
Several resolving bases are known for racemic 4 (Figure 3-3), which also may be applicable 
for an asymmetric transformation, viz (+)- and (-)-MBA 10\ (-)-brucine ll 4, (+)-cinchomne 12b5, 
(-)-ephednne 146 and (-)-2-amino-l-butanol 15' Also three new resolving bases were considered, 
viz jVjV-dimethyl-ct-methylbenzylamine 48, (-)-jV-methylephednne 49 and (+)-(2S,3R)-4-dimethyl-
amino-3-methyl-l,2-diphenyl-2-butanol DMDB) 50 Only the latter two were able to resolve 
racemic 4 Further investigations toward new resolving bases are described in Chapter 6 
Two approaches (I and II) have been used as outlined in Scheme 3-10 Both approaches must 
be performed under heterogeneous conditions at relative high temperatures (50-150°C) because 
resolution by crystallization techniques must be performed under racemization conditions 
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Scheme 3-10. Two approaches to the asymmetric transformation of mandelic acid. 
Approach I was designed in analogy with a method used by Shiraiwa et al. (section 2.3.1c) 
who performed a second-order asymmetric transformation of /V-acetyl-p-hydroxyphenylglycine by 
reaction with an excess (2-5 equiv) of resolving base MBA 10 in hexanol/cumene at 130°C. This 
resulted in the isolation of enantiopure 7V-acetyl-p-hydroxyphenylglycine in 90%40. Also 
transformations of jV-acetyl-p-hydroxyphenylglycine'" and jV-acetyl-phenylglycinej: by an excess of 
2-amino-l-butanol 15 in butanol/toluene and MBA 10 in butanol/xylene respectively were 
performed with high ee's and high yields. Excess of resolving base is required to effect both 
resolution and racemization. To study approach I for mandelic acid 4, the resolving bases MBA 10, 
brucine 11 and N-methylephedrine 49 were used. Reactions were monitored by ее measurements 
using chiral HPLC. When reactions of racemic mandelic acid (RS)-4 were performed with an excess 
(5 equiv) of MBA 10 or brucine 11 in solution (hexanol/cumene, rro-butyl alcohol or water) no 
asymmetric transformation was observed. The use of a solvent has the disadvantage that optimum 
racemization conditions cannot be reached and heterogeneous conditions are difficult to attain. The 
results of transformations of racemic 4 in the melt are collected in the Table 3-16 and 3-17 
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Table 3-16. Crystallization-induced Asymmetric Transformation of Mandelic Acid 4 
in the Melt Using (-)-Brucine 11 (Approach I)a. 
Entry 
I e 
2 
J 
5 
4 
6 
4 (starting % ее) 
0 
0 
100 (R) 
100 (S) 
49.7 (R) 
48.5 (S) 
(-)-•11 (equiv) 
1.3 
1.6 
1 6 
1.6 
2 
2 
T(°C) 
100 
120 
120 
120 
110 
110 
Time (day) 
9 
1 
1 
1 
3 
3 
Yield (%) 
100 
94 
85 
94 
91 
88 
4 (final % ee)b 
4.8 ± 0.5 (S) 
2.3 ± 1 (R) 
39.6 ± 0 2 (R) 
81.1 ± 1 (S) 
1.6 (S) 
27 7 ± 0.5 (S) 
a) Conditions racemic mandelic acid 4 (0 4 or 1 4 mmole), (-)-brucine 11, under nitrogen, heterogeneous melt 
b) Determined by HPLC (Chiralcel ODH) c) DMSO (0 2 ml) was added 
Table 3-17. Crystallization-induced Asymmetric Transformation of Mandelic Acid 4 
in the Melt Using (-)-JV-Methylephedrine 49 (Approach I)a 
Entry 
j C d 
2 d 
3 d 
4C 
5 c d 
6 
7d 
8d 
9d 
10d 
4 (starting % ее) 
0 
0 
0 
100 (R) 
100 (S) 
100 (R) 
100 (S) 
100 (S) 
49.2 (S) 
50.6 (R) 
T(°C) 
80 
90 
110 
80 
80 
90 
90 
110 
110 
110 
Time (h) 
23 
23 
17 
23 
23 
23 
23 
3 
17 
17 
Yield (%) 
89 
100 
92 
94 
94 
96 
83 
85 
100 
100 
4 (final % ee)b 
4 0(R) 
0 
2 5(R) 
100 (R) 
96.2 (S) 
83 0 ± 0 . 5 ( S ) 
75 1 ± 0 . 5 ( S ) 
54.5 (S) 
30.9 (S) 
30 4 (R) 
a) Conditions racemic mandelic acid 4 (0 3 or 0 6 mmole), (-)-N-methylephednne 49 (2 equiv). under nitrogen, 
melt b) Determined by HPLC (Chiralcel ODH) c) Sublimation was observed d) Homogeneous melt 
When (R)-MBA 5 (1.1-1.3 equiv) was used as resolving and racemizing agent, no 
crystallization-induced asymmetric transformation was noticed in the temperature range of 105-
115°C A homogeneous melt resulted at higher temperatures, however also quantitative amide 
formation occurred according to Scheme 3-11 The diastereomenc amides were formed in a 1:1 
ratio, separated by column chromatography and identified by comparison with data from the 
literature41 Formation of amides by reacting a carboxylic acid with a primary or secondary amine in 
a homogeneous melt seems to be a general and simple method giving high yields. This process was 
recently published by Jursic and Zdravkovski44. 
OH | OH H r ^ N l OH H 
I 
ОТ
1 4 0 0 0
"* π 
^ ^ (RS)-4 
melt ΙΛ. 'J о 
( S)-4 ~ (R)-10 \ / w (R,R)-51 ^ ~ (S,R)-51 
Scheme 3-11. 
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A very modest asymmetric transformation was observed for mandehc acid 4 using brucine 11 
in the melt (Table 3-16) Brucine 11 was able to racemize both enantiomers, although at a different 
rate (entries 3 to 6) The difference in racemization rate demonstrates the principal possibility of an 
asymmetric transformation using this system A disadvantage of brucine 11 is the decomposition at 
higher temperatures and its toxic properties Only first-order asymmetric transformations of 4 were 
observed using (-)-7V-methylephednne 49 (Table 3-17, entries 1 to 3), mainly because of the 
homogeneous melts obtained A heterogeneous melt was only attained using pure (R)-4 (entry 4 
and 6) Racemization was observed for both diastereomers at almost the same rate which increased 
with increasing temperature (entries 4 to 10) 
Approach II was derived from a resolution technique, developed by Pope and Peachy45 These 
authors used half an equiv each of an achiral and resolving base for the resolution of a racemic acid 
(Scheme 1-2, section 1 4) The idea was to use this achiral base as racemizing agent and the 
resolving base for a crystallization-induced asymmetric transformation Initially, this method was 
tried using sodium hydroxide as racemizing agent in combination with MBA 10 or brucine 11 in 
solution The results are summarized in Table 3-18 In all cases heterogeneous mixture were 
obtained, except when JV /V-dimethyl formamide was used Best results were found with the 
combination of (S)-MBA 10 and sodium hydroxide in 2-butanoI which gave 6 5% ее and a 
quantitative yield 
Table 3-18 Crystallization-induced Asymmetric Transformation of Mandehc Acid 4 in Solution, 
Using a Resolving Base in Combination with NaOH (Approach II)a 
Entry 
1 
2 
3 
4L 
5 
Resolving base 
(S)-MBA 
(S)-MBA 
(S)-MBA 
(S)-MBA 
(-)-Brucine 
NaOH 
(equiv) 
0 15 
1 0 
0 17 
0 15 
1 0 
Solvent 
2-propanol 
2-propanol 
2-butanol 
DMF 
2-butanol 
T(°C) 
85° 
85° 
100° 
100° 
Time (h) 
21 
21 
21 
17 
Yield (%) 
100 
100 
100 
100 
ее (%)c 
2(S) 6 
4(S) 
6 5 ± 0 5(S) 
1 5 (R)B 
ATd 
yes 
yes 
yes 
yes 
a; mnaiuuns racemic mantiene aciu ч \,o о mmoiej, resolving oase (¡ equivj, гчаип, unaer nitrogen, nererogeneous 
mixture b) Solvent (5 ml) c) Determined by HPLC (Chiralcel ODH) d) An asymmetric transformation (AT) is 
achieved when '/2y('/2ee+50)>50 (eq 1-2, section 1-5) e) Homogeneous mixture 0 Solvent (10 ml) g) Determined by 
measuring the optical rotation 
Next, stronger achiral bases, viz amidines and guanidines, were used and the solvent was 
omitted Thus reactions were performed in the melt using different resolving bases in combination 
with DBN 45, one of the best racemizing agents for mandehc acid As resolving bases were tried 
(S)-MBA (S)-10, (-)-brucine 11, (+)-cinchonine 13b, (-)-ephednne 14, (-)-2-amino-l-butanol 15, 
(-)-/V-methylephednne 49 and (+)-DMDB 50 The results are collected in Table 3-19 Although no 
amide formation was observed, the use of MBA 10 and 2-amino-l-butanol 15 in combination with 
DBN 45 (entries 1,2,9) resulted in homogeneous melts and are therefore unsuitable The use of 
brucine 11 gave problems due to decomposition and completely solid mixtures (entries 3 to 5) 
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Table 3-19. Crystallization-induced Asymmetric Transformation of Mandelic Acid 4 in the Melt, 
Using a Resolving Base in Combination with DBN 45 (Approach II)a. 
Entry 
ld 
2d 
3d 
4e 
5C 
6 
І 
8 
9d 
10d 
11 
12d 
13d 
14 
15 
166 
Resolving base 
(equiv) 
(S)-MBA(l) 
(S)-MBA(l) 
Brucine (1) 
Brucine (1) 
Brucine (1) 
cinchonine (1) 
cinchonine (2) 
ephedrine ( 1 ) 
2-amino-1 -butano 1 (1) 
TV-methylephedrine ( 1 ) 
jV-methylephedrine (1.5) 
jV-methylephedrine (2.5) 
DMDB(l) 
DMDB(l) 
DMDB (1) 
DMDB (2.5) 
DBN (equiv) 
1.3 
0.5 
2 
1 
05 
1 
2 
0.5 
1.3 
0.5 
0.05 
0.05 
1 
0.5 
0.5 
0.05 
T(°C) 
RT-110 
RT-90 
120 
90-120 
90 
120 
120 
70-80 
RT-110 
90 
90 
RT-120 
100 
100 
90 
120 
Time 
(h) 
17 
17 
17 
64 
17 
6 
64 
Yield 
(%) 
86 
100 
93 
100 
93 
72 
b 
ее 
(%) 
0.13 ± 0.02 (R) 
0 15 ± 0.05 (R) 
0.6 ± 0.03 (R) 
3.9 (S) 
3.4 ± 0.3 (S) 
0.7 ±0.1 (S) 
ATC 
no 
yes 
no 
yes 
no 
no 
a) Conditions racemic mandelic acid 4 (3 3 mmole or 6 6 mmole), resolving base (1 equiv). DBN 45, under nitrogen, 
heterogeneous melt b) Determined by HPLC (Chiralcel ODH c) An asymmetric transformation (AT) is achieved when 
'/2y('/2ee+50)>50 (eq 1-2, section 1-5) d) Homogeneous mixture e) Solid mixture f) Dimethylimidazole-2-one (2 ml) 
as added for a more homogeneous melt g) Decomposition 
The combination jV-methylephedrine 49 (1 equiv) and DBN 45 (0.5 equiv) gave a 
heterogeneous melt at 50°C and below, and this combination is therefore also unsuitable (entry 10). 
The use of 0 05 equiv of DBN 45 and 1.5 equiv 49 did give a crystallization-induced asymmetric 
transformation, but only with 3.9 %ee (entry 11). The maximum temperature of 90°C seems to be 
the limiting factor in this example. Also with ephedrine 14 the melt temperature was limiting (80°C) 
and almost no optical enrichment was found (entry 8). With cinchonine 13b as resolving base 
dimethylimidazole-2-one (DMI) was added to increase the solubility of the reaction mixture. No 
enrichment was obtained. A long cooling period of 8 h gave no improvement (entries 6,7) The 
major drawback of the use of cinchonine 13b is the possible decomposition in the melt5. Therefore, 
quinine4 12 was not tried. DMDB 50 (1 equiv) in combination with DBN 40 (0.5 equiv) gave no 
asymmetric transformation (entry 14) 
As large amounts of strong bases like DBN 45 usually gave a homogeneous melt at relatively 
low temperatures the use of catalytic amounts was considered. Also an excess of strong base will 
hamper the efficient formation of a diastereomeric salt with the weaker resolving base. Thus, 
mandelic acid 4 was studied with MBA 10 as resolving base and catalytic amounts of DBN 45. The 
results are collected in Table 3-20. 
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Table 3-20. Crystallization-induced Asymmetric Transformation of Mandelic Acid 4 in the Melt, 
Using MBA 10 in Combination with Several Achiral Bases (Approach II)a. 
Entrv 
1 
2 
3 
4d 
5d 
6C 
7 
8 
9 
MBA 5 
(equiv) 
S(l) 
S(l) 
S(l) 
S(l) 
S(l) 
R(2.5) 
S (5) 
S (2.5) 
R(2.5) 
Achiral base 
(equiv) 
DABCO(l) 
DABCO(l) 
Et3N(l) 
DBN(1.3) 
DBN (0.5) 
DBN (0.5) 
DBN (0.1) 
DBN (0.05) 
TBD (0.05) 
Τ 
(°C) 
110 
130 
95 
RT-110 
RT-90 
70 
90 
120 
120 
Time 
(h) 
5 
5 
2 
90 
20 
64 
64 
Yield 
(%) 
93 
100 
96 
11 
89 
97 
91 
b 
ее 
(%) 
1.4 (S) 
1.4 (S) 
1-9 (S) 
64.0 (R) 
14.8 ±0.9 (S) 
27.3 ± 0.2 (S) 
23.7 (S) 
ATC 
no 
yes 
no 
no 
yes 
yes 
yes 
a) Conditions mandelic acid 4 (6 6 mmole), MBA 10 and achiral base, under nitrogen, heterogeneous 
melt b) Determined by HPLC (Chiralcel ODH) c) An asymmetric transformation (AT) is achieved when 
'/2y('/2ee+50)>50 (eq 1-2, section 1-5) d) Homogeneous melt e) The reaction mixture was filtered at 
70°C after 90 h, mother liquor ее- 11.1% (S) 
As expected a heterogeneous melt can be obtained at higher temperatures by using smaller 
amounts of strong achiral base (entries 4 to 6). Also a higher reaction temperature can be reached 
which enhances the rate of racemization. Thus at 120°C and applying 0.05 equiv of DBN 45 and 2.5 
equiv of MBA 10 a crystallization-induced asymmetric transformation was obtained with 27% ее 
and a quantitative yield (entry 8). Almost the same results were obtained with TBD 47 as the 
racemizing base (entry 9), resulting in 24% ее and 91% yield. The use of DABCO 26 or Et3N gave 
poor results (entries 1 to 3) Initial formation of a melt of mandelic acid 4 and the achiral base 
(DABCO 26 or Et3N) followed by a slow addition of MBA 10 in 1-8 h gave no improvement of 
these poor results A misleading high ее of 64% was obtained by use the of DBN 45 (0 5 equiv) and 
MBA 10 (2.5 equiv) at 70°C. In this case the hot reaction mixture was filtered which resulted in the 
isolation of the diastereomer which crystallizes from the melt (yield 11%, entry 6). Calculating the 
exact amounts of (R)- and (S)-mandelic acid 4, obtained from the isolated crystals and mother 
liquor showed that no true asymmetric transformation was obtained. Again, reaction temperatures 
were too low to affect racemization. Attempts to isolate crystals at higher temperatures were 
unsuccessful. 
3.4 Summary 
The racemization of mandelic acid and derivatives were systematically investigated with the 
intention of developing a crystallization-induced asymmetric transformation process for mandelic 
acid 4 Racemization experiments of mandelic acid in hexanol at 130°C revealed that DABCO 26 is 
the best racemizing base. It was also shown that various resolving bases were able to racemize 
mandelic acid. A study of the solvent-effect on the racemization rate of mandelic acid 4 and ethyl 
mandelate 5b resulted in optimum conditions for aprotic polar solvents, especially dimethyl 
74 
Racemization and Asymmetric Transformation of Mandehc Acid 
sulfoxide Racemization experiments of mandelic acid derivatives in dimethyl sulfoxide by 
DABCO 26 showed that racemization rates increased with increasing temperature and with 
electron-withdrawing substituents at the Ca or the carboxylic acid group Racemization can be 
accelerated when the change in entropy during racemization is lowered as shown with 2.2-dimethvl-
5-phenyl-l,3-dioxolan-4-one 7 in dimethyl sulfoxide This reaction was first-order in base and 
substrate A very fast and mild racemization process in the melt was developed The best 
racemizing bases in the melt are DBN 45 and TBD 47 
On the basis of the fast and mild racemization process m the melt, it was attempted to design a 
asymmetric transformation for mandelic acid Two approaches were considered In the first one an 
excess of resolving base was used to accomplish both resolution and racemization of the unwanted 
diastereomer Brucine 11 was able to racemize both enantiomers, but at different rates This resulted 
in an asymmetric transformation in quantitative yield, but only with 5% ее Use of N-
melhylephednne 49 resulted in first-order asymmetric transformations with 3-4% ее because of 
homogeneous melts The use of a-methylbenzylamine 10 resulted in quantitative amide formation 
In the second approach, two bases were used a resolving base for the resolution of mandelic 
acid 4 and a achiral base to induce the racemization of the unwanted diastereomer Performing the 
reaction in 2-butanol with a combination of a-methylbenzy lamine 10 and sodium, resulted in a 
transformation with 6 5% ее in quantitative yield For optimum conditions of racemization the 
reaction was performed with strong achiral bases in the melt Several resolving bases were tried in 
combination with strong achiral bases The best result, viz 27% ce and quantitative yield, was 
achieved by using 2 5 equiv of (S)-a-methylbenzylamine 10 and 0 05 equiv of DBN 45 at 120°C 
during 64 hours Use of TBD 47 instead of DBN 45 gave 24% ее in 91% yield 
These results are still far from the goal of 100% yield and 100% ее However, the approach 
using a chiral base and a catalytic amount of a strong, racemization inducing, base under conditions 
of a heterogeneous melt shows great promise The use of no. or a very small amount of solvent is 
attractive from an industrial point of view 
3.5 Experimental Section 
General Remarks 
' H - N M R spectra were recorded on a Bruker AC-100 (100 MHz, FT) spectrometer with 
tetramethylsilane as internal standard IR spectra were run on a Perkin Elmer 298 spectrophotometer 
or Perkin Elmer FTIR 1720-X spectrophotometer Elemental analysis were performed with a Carlo 
Erba Instruments CHNSO 1108 elemental analyzer For mass spectroscopy, a double focusing VG 
7070E was used For the chemical ionization (CI) technique, methane was used as reacting gas 
GC/MS spectra were recorded on a Varían Saturn II using electron impact (EI) as ionization 
method GC-separation was carried out on a fused silica-capillary column (DB-5, 30 m χ 0 25 mm. 
film thickness 0 25 μιη) Melting points were measured on a Reichert Thermopan microscope 
(uncorrected) or on a Perkin Elmer DSC7 instrument Optical rotations were determined on a Perkin 
Elmer 241 Polarimeter at 589 nm, equipped with a quartz cell of 1 00 dm path length The 
Polarimeter was connected with a thermostat for exact temperature control and a recorder for 
continuous optical rotation measurements GC was performed on a Hewlett-Packard 5890 or 5890 
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Senes II instrument, equipped with a capillary HP crosshnked methyl silicone (25 m χ 0 31 mm) 
column, connected to a HP 5890 calculating integrator Chiral GC was performed using a chiral B-
DEX 120 capillary column (Supelco) DSC thermograms were recorded using a Perkin Elmer DSC7 
instrument Calibration was performed with In and Zn, Sn or Pb depending on the temperature 
range Samples were prepared by the method described by Jacques, Collet and Wilen" Samples 
were measured in stainless-steel large volume pans (75 μΐ) or aluminum pans (30 μΐ) at a rate of 
10°C/min HPLC was performed on a Spectra Physics HPLC system equipped with a chiral Daicel 
Chiralcel ODH column (25 χ 0 46 cm, particle size 5 μπι) with filtered hexane/2-
propanol/tnfluoroacetic acid mixtures as mobile phase Detection was at 254 nm and the flow rate 
was 0 5 ml/min at ambient temperature For column chromatography, the 'flash technique47' was 
used with silicagel 60H (Merck) as stationary phase and a pressure of about 1 5 bar Thin Layer 
chromatograms were run on glass supported silicagel 60 plates (0 25-layer, F2 5 4, Merck) 
Compounds were detected using UV and oxidizing reagents, ι e 5% H2S04 in ethanol or a mixture 
of (NH4)6Mo7024 4 H 2 0 (21 g), (NH4)4Ce(S04)4 2 H 20 (1 8 g), water (469 ml) and 97% H2S04 
(31 ml) Dry solvents were obtained as follows dichloromethane was distilled from phosphorous 
pentoxide Diethyl ether was pre-dned on calcium chloride and distilled from calcium hydride 
Hexane, benzene and dimethyl sulfoxide were distilled from calcium hydride Pyridine, 
tnethylamine, a-methylbenzylamine, pyrrolidine, pipendine, dicyclohexylamine, morfoline. 
tetramethylguanidine and yVNjV'.W-tetramethylethylenediamine were distilled from potassium 
hydroxide Tetrahydrofuran was distilled from lithium aluminum hydride, iV/V-dimethylformamide 
from calcium sulfate, ethyl acetate from potassium hydrogen carbonate and 1,2-dimethoxyethane 
from sodium hydride All other solvents and reagents were either ρ a or 'reinst' quality and used as 
obtained from the supplier Sparteine was liberated from its sulfate salt by treatment with sodium 
hydroxide, extraction with di/iopropyl ether and stored in a refrigerator under nitrogen and in the 
absence of daylight 
Determination of enantiomeric excess 
The enantiomeric excess (ее) of 4, 5a, 5b, 5d and 5f was determined using HPLC (Chiralcel ODH 
column, UV-detection at 254 nm, flow-rate 0 5 ml/min) (RS)-4 (eluent hexane/2-
propanol/tnfluoroacetic acid=875/125/2 5, v/v) (S)-4 Rt=13 5 min, (R)-4 Rt=16 6 min, resolution 
factor (RS)=2 71, separation factor (a)=l 01 (RS)-5a (eluent hexane/2-propanol=8/2, v/v) (S)-5a 
Rt=13 2 mm, (R)-5a Rt=20 6 min, RS=10 35, a=2 57 (RS)-5b (eluent hexane/2-propanol=8/2, 
v/v) (S)-5b Rt=9 6 min, (R)-5b Rt=14 3 mm, RS=8 99, a=2 76 (RS)-5e (eluent hexane/2-
propanol/tnfluoroacetic acid=875/125/2 5, v/v) (S)-5e Rt=10 4 min, (R)-5e Rt=113 mm, 
RS=1 36, ct=l 18 (RS)-5f (eluent hexane/2-propanol=9/l, v/v) (S)-5f Rt=10 7 min, (R)-5f 
Rt=17 4 min, RS=11 6, a=3 81 The enantiomeric excess of 23 was determined using GC (chiral B-
DEX 120 capillary column, Supelco) Nitrogen was the earner gas (0 7 ml/min, 0 8 atm) and the 
oven temperature 180°C (R)-7 Rt=37 7 min, (S)-7 Rt=38 4 min All other ee's were determined 
by measuring the optical rotation 
Racemtzation of (S)-mandelic acid (S)-4 by base m solution 
As a typical procedure, (S)-4 (258 mg, 1 7 mmole) was dissolved in dimethyl sulfoxide (35 ml) at 
130°C. followed by the addition of DABCO 26 (1 9 g, 17 mmole) and stirred at 130°C under a 
nitrogen atmosphere A 1-ml aliquot was taken from the solution by a syringe at appropriate time 
intervals and was cooled immediately to 0°C To this 1-ml aliquot, ethanol (1 ml) and 6M 
hydrochloric acid (0 2 ml) were added This mixture was shaken at room temperature (0 5 h) and the 
optical rotation of the filtrate was measured at 589 nm at 25CC 
Deuterium exchange in (S)-mandehc acid (S)-4 
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In a sealed NMR-tube, a solution of (S)-4 (20 mg, 0 13 mmole) in 30% sodium deuteroxide (0 5 ml) 
and deuterium oxide (0 5 ml) was kept at room temperature for 20 h Ή-NMR (ppm) δ 4 99 (s, 1 H, 
С Щ 7 4 (m, 5Н, АгН) The same mixture was kept at 90°C for 20 h Ή-NMR (ppm) δ 7 4 (m, 5H, 
АгЫ) 
Methyl (S)-mandelate (S)-5a 
(S)-Mandelic acid (S)-4 (5 0 g, 33 mmole) was refluxed in a mixture of benzene (25 ml), methanol 
(3 ml) and concentrated sulfuric acid (0 05 ml) while removing water using a Dean-Stark trap After 
completion of the reaction the mixture was cooled to room temperature and washed with a saturated 
aqueous solution of NaHC0 3 (three times) and the combined water layers with diethyl ether (three 
times) The combined organic layers were washed with brine, dried over MgS0 4 and concentrated 
in vacuo to yield a yellow oil (5 1 g, 92%) Distillation (90°C, 0 1 mm Hg) provided a white solid 
which was recrystalhzed from hexane giving pure (S)-5a as white needles (55%) HPLC (Chiralcel 
ODH, hexane/2-propanol=8/2, v/v) 100% ее (S) Mp 55-56°C, [ct]D 2 5 +137° (methanol, c=l 5) 
Calculated for C 9 H, 0 O 3 65 05 %C, 6 07 %H, found 64 86 %C, 5 96 %H IR (KBr, cm ') ν 3615, 
3515 (OH), 2820-3060 (CH), 1735 (C=0) Ή-NMR (CDC13, ppm) δ 3 46 (d, IH, ОЫ, J=5 1 Hz), 
3 76 (s, 3H, ОСЫз), 5 18 (d, IH, CH, J=5 1 Hz), 7 2-7 4 (m, 5H, ArH) MS (CI+) m/e (%) 167 
(M++l, 31), 166 (M\ 10), 150 (-OH, 10), 149 (-H20, 100), 121 (23) 
Ethyl (S)-mandelate (S)-Sb 
(S)-Mandehc acid (10 0 g, 66 mmole) (S)-4 was refluxed for 4 h in a mixture of toluene (50 ml), 
ethanol (16 ml) and concentrated sulfuric acid (0 1 ml) under azeotropic removal of water using a 
Dean-Stark trap The mixture was cooled to room temperature and washed with saturated aqueous 
solution of NaHCOj (three times) and the combined water layers with diethyl ether (three times) 
The combined organic layers were washed with brine, dried over MgS0 4 and concentrated in vacuo 
to give an oil (11 6 g, 97%) Recrystalhzation from hexane provided pure (S)-5b as a white solid 
(92%) HPLC (Chiralcel ODH, hexane/2-propanol=8/2, v/v) 100% ее (S) Mp 33-34°C, [ a ] D b 
+ 132 9° (chloroform, c=l 0) Calculated for C l 0 H 1 2 O 3 66 65 %C, 6 71 %H, found 65 86 %C, 6 54 
%H IR (KBr, c m 1 ) ν 3520 (OH), 2900-3080 (CH), 1730 (C=0) Ή-NMR (CDCl3/DMSO-d6, 
ppm) δ 1 12 (t, 3H, СЫз, J=6 Hz), 4 06 (dq, 2H, CH2, J=6 Hz, 1 3 Hz), 5 11 (d, IH, CH, J=5 Hz), 
6 05 (d, IH, OH, J=5 Hz), 7 2-7 5 (m, 5H, ArH) MS (Cf ) m/e (%) 181 (M + +l, 8), 180 (M+, 7), 
163 (-H20, 35), 107 (-COOEt, 100) 
Tert-butyl (S)-mandelate (S)-5c 
In a closed flask (S)-4 (3 0 g, 20 mmole) was dissolved in dioxane (50 ml) and concentrated sulfuric 
acid (3 ml) and then cooled to 0°C Aobutene (30 ml, 315 mmole) was added and the mixture was 
stirred for two days while warming to room temperature The resulting mixture was cooled to 0°C 
and poured into a solution of diethyl ether (200 ml) and IN aqueous NaOH (125 ml) at 0°C The 
layers were separated and the water layer was extracted with diethyl ether (three times) The 
combined organic layers were dried over MgS0 4 and concentrated to give a yellow oil (3 3 g, 80%) 
The product was purified by column chromatography (sihcagel 60H, ethyl acetate/hexane=l/3, v/v) 
and provided (S)-5c (1 8 g, 35%) and (S)-5d (350 mg, 8%) (S)-5c Mp 69-70°C, [ a ] D 2 5 +97 4° 
(methanol, c=l 0), literature48 (R)-5c [ a ] D 2 5 -119 I o (CC14, c=l 05) Calculated for C 1 2 H 1 6 0 3 
69 21 %C, 7 74 %H, found 68 56 %C, 7 82 %H IR (KBr, cm ') ν 3610, 3500 (OH), 2800-3100 
(CH), 1730 (C=0) Ή-NMR (CDCI3, ppm) δ 1 41 (s, 9H, C(CH3)3), 3 53 (d, IH, OH, J=6 Hz), 
5 03 (d, IH, CH, J=6 Hz), 7 2-7 5 (m, 5H, ArH) MS (CI+) m/e (%) 209 (M + +l, 2), 153 (-C4H9, 
12). 135 (153-H20, 56), 107 (135-CO, 66), 57 (C 4H 9 +, 100) (S)-5d Mp 34°C, [ a ] D 2 5 +51 0° 
(methanol. c=l 3) Calculated for С 1 6 Н 2 4 0 3 72 70 %C, 9 15 %H, found 72 72 %C, 9 25 %H IR 
(KBr, c m 1 ) ν 2850-3100 (CH), 1750, 1715 (C=0) Ή-NMR (CDC13, ppm) δ 126 (s, 9H, 
77 
Chapter 3 
С02С(СНз)3), 1 4 (s, 9H, СОС(СЫз)з), 4 92 (s, IH. CH), 7 2-7 5 (m, 5H, ArH) MS (СГ) m/e (%) 
265 (M*+l, 2), 209 (-С4Н9. 33), 163 (209-СН2О2, 82), 135 (163-Н20, 60), 107 (PhCHOH+, 100) 
0-Acetyl-(S)-mandelic acid (S)-Se 
(S)-4 (2 0 g, 13 2 mmole) was added to a cooled mixture (0°C) of pyridine (5 ml), acetic anhydride 
(1 3 ml. 14 3 mmole), 4-dimethylaminopyndine (10 mg), and dry diethyl ether (20 ml) The mixture 
was stirred overnight while warming to room temperature The mixture was acidified with 2M 
aqueous hydrochloride and washed with diethyl ether (four times) The combined organic layers 
were extracted with water and brine, and concentrated in vacuo to give crude (S)-5e (2 4 g) 
Recrystallization from water gave pure (S)-5e as white needles in 91% HPLC (Chiralcel ODH, 
hexane/2-propanol/trifluoroacetic acid=875/125/2 5, v/v) 100% ее (S) Mp 79-80°C, [a]D 2 5 +107 8° 
(chloroform, c=l 25) Calculated for C10H10O4 61 85 %C, 5 19 %H, found 61 75 %C, 5 07 %H IR 
(KBr. cm ') ν 2500-3300 (OH, CH), 1755, 1725 (C=0) ' H - N M R (CDC13, ppm) 5 2 16 (s, 3H, 
СЫз), 3 76 (s, ЗН, ОСЫз), 5 81 (s, IH, CH). 7 2-7 6 (m, 5H, АгН), 11 6 (s, IH, OH) MS (CI+) m/e 
(%) 195 (M++l, 6), 194 (M\ 2), 177 (-H20, 4), 152 (-COCH3, 17), 149 (177-CO, 36), 135 (-
CH3COOH. 100), 107 (PhCHOH\ 93) 
(S)-Mandelamide (S)-6a 
Ethyl (S)-mandelate (S)-5b (6 0 g, 33 mmole) was added to a cooled solution (0°C) of 25% 
ammonia (60 ml) and stirred for 2 5 h while warming to room temperature The mixture was 
concentrated and the remaining solid was recrystallized from ethanol to give pure (S)-6a as white 
crystals (2 5 g, 52%) From the mother liquor, another fraction (S)-6a crystallized (0 8 g, 16%) Mp 
118-120°C, [a]D 2 S +94 7° (water, c=2 4), literature24' (R)-6a [ct]D25 -95 5° (water, c=l 8) 
Calculated for C8H9N02 63 57 %C, 9 27 %N, 6 00 %H, found 63 42 %C, 8 98 %N, 5 87 %H IR 
(KBr. cm ') ν 3100-3500 (OH, NH), 1650 (C=0) 'H-NMR (DMSO-d6, ppm) δ 4 87 (d, IH, CH, 
J=4 5 Hz), 6 05 (d, IH, OH, J=4 5 Hz), 6 86 (s. IH. NH), 7 06 (s, IH. NH), 7 2-7 7 (m, 5H, ArH) 
MS (СГ) m/e (%) 152 (M++l, 31), 134 (-H20, 75), 107 (-CONH2, 100), 77 (С6Н5\ 19) 
(S)-2-hydroxy-2-phenylacetohydroxamic acid (S)-6b 
To a stirred solution of NH2OH HCl (4 0 g, 57 mmole) in methanol (20 ml), kept under nitrogen at 
room temperature, was added a solution of potassium hydroxide (4 8 g, 85 mmole) in methanol (15 
ml) The resulting mixture was cooled to 0°C and filtered under a nitrogen atmosphere To the 
stirred filtrate under nitrogen ethyl (S)-mandelate (S)-5b (5 0 g, 28 mmole) was added and the 
solution was immediately filtered under a nitrogen atmosphere The remaining filtrate was kept at 
room temperature for one hour with nitrogen flushing The solution was acidified with 2M aqueous 
acetic acid to pH 5-6 and stirred for one hour The resulting mixture was extracted with ethyl acetate 
(nine times) The combined organic layers were washed with brine, dried over MgS04 and 
concentrated in vacuo to give a white solid Recrystallization from ethyl acetate provided pure (S)-
6b as a white crystalline solid (2 6 g, 56%) Mp 114-116°C, [a]D 2 5 +63 4° (water, c=2 4), literature 
(S)-6b [ct]D25 +164° (water, c=2 5)49, (R)-6b [a]D 2 5 -46° (methanol, c=0 6)25 Calculated for 
C8H9N03 57 48 %C, 8 38 %N, 5 43 %H, found 57 31 %C, 8 13 %N, 5 31 %H FTIR (KBr, cm ') 
ν 2500-3500 (OH, NH), 1676 (C=0) Ή-NMR (DMSO-d6, ppm) δ 4 93 (d, IH, CH, J=5 Hz), 6 00 
(d, IH, CHOH, J=5 Hz), 7 2-7 5 (m, 5H, ArH). 8 81 (s, IH, NHOH), 10 77 (s, IH, NH) MS (CI+) 
m/e (%) 168 (M++l, 5), 150 (-H20, 21), 132 (-2Н20, 21),107 (-CONHOH, 100), 77 (С6Н,\ 27) 
2 2-Dimethyl-5(S)-phenyl-l,3-dwxolan-4-one (S)-7 
A mixture of (S)-mandelic acid (S)-4 (10 0 g, 66 mmole) in 2,2-dimethoxypropane (150 ml) and p-
toluenesulfonic acid (20 mg) was stirred for two days at room temperature The mixture was 
concentrated to 50 ml and diethyl ether (50 ml) was added The resulting solution was extracted 
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with IM aqueous NaHC03, water (two times) and brine, dned over MgS04 and concentrated in 
vacuo to gi\e crude (S)-7 (13 8 g) Recrystallization from hexane gave pure (S)-7 as white needles 
(9 8 g, 77%) GC (B-DEX 120, T=80°C) 100% ее (S) Mp 72-73°C, [a]D 2 5 +84 0° (chloroform, 
c=l 0) Calculated for C, |H| 2 0 3 68 74 %C, 6 29 %H, found 68 09 %C, 6 33 %H FTIR (KBr, cm 
') ν 2870-3070 (CH), 1800 (C=0), 1130 (C-O) ' H - N M R (CDC13, ppm) δ 1 68 (s, ЗН, trans-СЫз), 
1 73 (s. ЗН, cis-СЫз), 5 40 (s, IH, СЫ), 7 3-7 5 (m, 5Н, АгЫ) MS (СГ) m/e (%) 193 (М++1, 2), 
163 (-СН20, 8), 148 (-СООН, 52), 135 (-acetone, 100), 107 (PhCHOH+, 17) By the same 
procedure, pure (RS)-7 and (R)-7 were prepared 
Binary phase diagrams ofmandelic acid 4 and 2 2-Dimethyl-5(S)-phenyl-l 3-dwxolan-4-one 7 
The binary phase diagrams of mandehc acid 4 and dioxolane 7 (Figure ) were determined using a 
Perkin Elmer DSC7 instrument, calibrated with In, Zn or Sn Samples were prepared according to a 
method described by Jacques, Collet and Wilen46 Mixtures of enantiomers of 4 or 7 were prepared 
by dissolving exactly weighed amounts of enantiopure 4 or 7 in diethyl ether or ethyl acetate The 
obtained solution was concentrated and dried in vacuo The composition of obtained mixtures was 
checked by GC (B-DEX 120, T=80°C) for 7 and by HPLC (Daicel Chiralcel ODH, eluent 
hexane/2-propanol/trifluoroacetic acid=875/125/2 5, v/v) for 4 Samples of the mixtures (2-10 mg) 
were weighed with a precision of 0 01 mg and encapsulated in aluminum pans (30 μΐ) 
Thermograms were recorded at a scanning rate of 10 °C/min, a data rate of 0 4-0 8 sec/point, and 
with an empty pan as reference Melting points are given as the top of the peaks 
(5S)-2 5-Diphenyl-l i-dioxolane-4-one (5S)-8 
To a mixture of (S)-mandelic acid (S)-4 (1 5 g, 10 mmole) and benzaldehyde (1 ml, 10 mmole) in 
diethyl ether (20 ml) was added BF3 OEt2 (2 ml, 15 mmole) and stirred at room temperature for two 
hours The resulting mixture was extracted with a saturated aqueous solution of NaHC03 until pH 
7-8, and water The organic layer was dried over MgS04 and concentrated in vacuo to provide a 
white solid which was washed with hexane (three times) to give pure (5S)-8 (1 2 g, 50%) which 
contained half an equiv crystal water GC (170°C) 2 diastereomers (2 1) Mp 96-98°C, [a] D 2 i 
+52 9° (chloroform. c=l 0) Calculated for C,<H1203 0 5 H 2 0 72 28 %C, 5 26 %H, found 71 77 
%C, 6 33 %H IR (KBr, cm ') ν 3000-3100 (CH), 1800 (C=0), 1540 (C=C) 'H-NMR (CDCI3, 
ppm) δ 1 58 (s, IH, 0 5 H20), 5 43 (s, 0 67Н, cis-5H), 5 52 (s, 0 33H, trans-5H), 7 4-7 8 (m, 10H, 
АгЫ) MS (Cf) m/e (%) 241 (M++l, 6), 223 (-H20, 2), 196 (-СООН, 100), 107 (PhCHOH+, 33), 
99 (PhCH\ 30), 77 (C6H5\ 26) 
Diphenyldiazomethane 34 
To a solution of benzophenone 32 (14 2 g, 78 mmole) in n-butanol (80 ml), was added a 85% 
aqueous solution of hydrazine monohydrate (10 ml, 170 mmole) The mixture was stirred under 
reflux for 4 h and subsequently poured into methanol (200 ml) and cooled to 0°C inducing 
crystallization of hydrazone 33 After filtration another fraction of 33 crystallized from the mother 
liquor The fractions of 33 were combined and dried over Р20> in vacuo providing pure 33 (11 8 g, 
77%) IR(CCl4,cm') ν 3420, 3280 (NH), 3020-3080 (CH)" 1530-1610 (C=N) l o a solution of 33 
(6 0 g, 30 mmole) in dry diethyl ether (100 ml) in a closed flask, dry Na2S04 (7 5 g, 53 mmole) and 
a saturated solution of potassium hydroxide in ethanol (2 5 ml) were added The mixture was stirred 
and yellow HgO (20 0 g, 92 mmole) was added while the flask was cooled with a wet towel After 
two hours, the mixture was filtered and washed with petroleum ether (40-60°C) The filtrate was 
concentrated in vacuo, dissolved in petroleum ether (40-60°C), filtered and evaporated to dryness to 
give 34 as a red oil, which solidified on cooling (5 8 g, 100%) IR (CCI.,, cm ') ν 3000-3100 (CH), 
2020 (C=N=N), 1530-1610 (C=N), 1490 The mixture was kept in the refrigerator as a IM solution 
in diethyl ether m the exclusion of light 
79 
Diphenylmethyl (S)-mandelate (S)-35 
To a stirred solution of (S)-mandelic acid (S)-4 (4 3 g, 28 3 mmole) in dry diethyl ether (150 ml) 
was added a IM solution of diphenyldiazomethane 34 in diethyl ether (29 ml, 29 mmole) and stirred 
overnight at room temperature The mixture was evaporated to dryness and washed with hexane 
(three times) providing a white solid Recrystalhzation from a mixture of hexane and a few vol% 
ethyl acetate gave pure (S)-35 as white needles (8 0 g, 89%) Mp 88-89°C, [ct]D25 +40 6° (acetone, 
c=l 0) Calculated for C 2 1H 1 80 3 79 23 %C, 5 70 %H, found 78 52 %C, 5 65 %H IR (CCI«, cm ') 
ν 3510 (OH), 3010-3100 (CU), 1730 ( C O ) ' H-NMR (CDC13, ppm) δ 3 7 (s, IH, OH), 5 28 (s, 
IH, СНОН), 6 87 (s, Ш, СООСЦ), 6 9-7 5 (m. 15H, АгН) MS (Cf ) m/e (%) 317 (M+-l, 0 02), 
241 (-C6HS, 0 5), 223 (-H20, 0 1), 196 (241-C02, 3), 167 (Ph2C\ 100), 107 (PhCHOH\ 76) 
(R)-2-Phenyl-2-(phthalimidooxy)acetic acid (R)-9 
A solution of di/íopropyl diazodicarboxylate (DIAD) (4 5 g, 22 3 mmole) in dry tetrahydrofuran (20 
ml) was added dropwise to a solution of (S)-35 (6 0 g, 18 8 mmole), tnphenylphosphine (7 1 g, 27 
mmole) and N-hydroxyphthahmide (3 7 g, 22 7 mmole) in dry tetrahydrofuran (80 mi) After 
stirring for two days at room temperature the mixture was concentrated The remaining yellow oil 
was dissolved in water and extracted with diethyl ether (four times) The combined organic layers 
were evaporated to dryness and purified by column chromatography (silicagel 60H, hexane/ethyl 
acetate=l/l v/v) providing (R)-36 (7 0 g, -80%) The product was contaminated with DIAD-H2 
and therefore deprotected as such Crude (R)-36 (7 0 g, -15 mmole) was dissolved in 
dichloromethane (50 ml) and cooled to 0°C Tnfluoroacetic acid (19 ml, 240 mmole) and anisóle (7 
ml, 62 mmole) were added and the mixture was stirred for two hours at 0°C and subsequently 
concentrated in vacuo The remaining oil was dissolved in diethyl ether and poured into ice-cold 
water by which the product solidified The mixture was filtered and the residue was recrystalhzed 
from dichloromethane providing pure (R)-9 as white crystals (1 6 g, 29% overall yield) The 
product crystallized as the monohydrate Mp 108-110°C, [ct]D25 -218 0° (acetone, c=l 0) Calculated 
for C2lH1803 H20 60 95 %C, 4 44 %N, 4 16 %H,, found 60 53 %C, 4 45 %N, 4 11 %H IR (KBr, 
cm ') ν 3510 (OH), 2500-3500 (OH, CH), 1785, 1730 (C=0) 'H-NMR (DMSO-d6, ppm) δ 3 36 
(s, 2H, H20), 5 78 (s, IH, CH), 7 3-7 6 (m, 5H, АгН), 7 8-7 95 (s, 4Н, АгН) MS (СГ) m/e (%) 298 
(M++l, 12), 252 (-Н20, -СО, 20), 163 (Phth-0\ 4), 135 (-Phth-OH, 100). 105 (PhCO\ 55), 77 
(С6Н5+, 26) 
Attempted racemization of(R)-2-Phenyl-2-(phthalimidooxy)acetic acid (R)-9 by DABCO 26 
DABCO 26 was added to a solution of (R)-9 (150 mg, 0 32 mmole) in dimethyl sulfoxide (5 ml), 
(55 mg, 0 49 mmole) and the mixture was stirred under nitrogen at 50°C for one hour The mixture 
was cooled to room temperature and concentrated in vacuo Addition of 0 33M aqueous citric acid 
(10 ml) induced an immediate precipitation of 9 as a white solid, which was dried in vacuo (145 
mg, 97%) The 'H-NMR was in agreement with 9 [a]D 2 5 -231 5° (acetone, c=l 4), no racemization 
Racemization of ethyl (S)-mandelate (S)-5b by DABCO 26 in hexanol 
After dissolving (S)-5b (325 mg, 1 8 mmole) in hexanol (30 ml) at 130°C, followed by the addition 
of DABCO 26 (2 0 g, 18 mmole), the solution was stirred at 130°C A 1-ml aliquot was taken from 
the solution by a syringe at appropriate time intervals and was cooled immediately to 0°C To this 
1-ml aliquot ethanol (1 ml) and 6M hydrochloric acid (0 2 ml) were added This mixture was shaken 
at room temperature (0 5 h) and the optical rotation of the filtrate was measured at 589 nm at 25°C 
After stirring for 5 h at 130°C the mixture was cooled to room temperature and water (10 ml), 
ethanol (10 ml) and 6M aqueous hydrochloric acid (7 ml) were added The resulting solution was 
washed with dichloromethane (two times) and diethyl ether (two times) The combined organic 
layers were extracted with brine, dried over MgS04 and concentrated in vacuo to give pure 5g as an 
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oil. IR (KBr, cm"1): ν 3520 (OH), 2840-2980 (CH), 1725 (C=0). ' H - N M R (CDC13, ppm): δ 0.83 (t, 
3H, СЫз, J=6 3 Hz), 1.0-1.4 (m, 6H, 3CH2). 155 (m, 2H, OCH2CH2), 4.00 (s, IH, OH,), 4.12 (t, 
2H, CH 2 0, J=6 5 Hz), 5.16 (s, IH, CH), 7.2-7.5 (m, 5H, АгЩ (see Table 3-5) 
Reaction kinetics of the racemization of 2,2-dimethyl-5(S)-phenyl-1 ,i-dioxolan-4-one (S)-7 
Kinetic data for the racemization of (S)-7 were obtained using stock solutions of (S)-7 and DABCO 
26 in dry dimethyl sulfoxide. Stock solutions used: [(S)-7]=0.0789M, 0.797M and [DABCO 
26]=0.00781M, 0.0781M, 0.156M. Proper aliquots of the stock solutions were put together in a 
quartz cell of 1.00 dm path length, equipped with a surrounding mantle, which was kept at a fixed 
temperature by a connecting heating bath. The optical rotation was measured immediately at the 
desired temperature, and measurements were recorded continuously. Rate constants and half-life 
periods were calculated according to equations 3-3 - 3-5. For the results, see Tables 3-10 and 3-11. 
Racemization of (S)-mandehc acid (S)-4 in the melt 
As a typical example a sealed tube, charged with (S)-4 (250 mg, 1.6 mmole) and DBN 45 (223 μΐ, 
1.8 mmole) under nitrogen, was heated at 90°C with stirring for 5 hours. The mixture was cooled to 
0°C. Water (5 ml) and 2N aqueous hydrochloric acid (2.4 ml) were added to hydrolyse the salt and 
stirred for half an hour at room temperature. The resulting mixture was extracted with ethyl acetate 
(three times) and the combined organic layers were dried over MgS0 4 and concentrated in vacuo to 
give pure 4 in 94% yield. HPLC (Chiralcel ODH, eluent: hexane/2-propanol/trifluoroacetic 
acid=875/125/2.5, v/v): 52 5% ее (S). For other results, see Tables 3-12 to 3-15. 
Work-up procedure for racemization of (S)-4 by Proton Sponge 29, Trogers base 30 or TMG 46: 
After cooling the reaction mixture to room temperature water (5 ml) and 2N aqueous sodium 
hydroxide (2 ml) were added and the mixture was stirred for half an hour. The resulting solution 
was extracted with dichloromethane (three times) and acidified to pH 2 with 2N aqueous 
hydrochloric acid. The water layer was extracted with ethyl acetate (three times) and the combined 
organic layers were dried over MgS0 4 and concentrated in vacuo to give pure 4. 
Acid-catalyzed racemization of 0-acetyl-(S)-mandelic acid (S)-5e 
(S)-5e (338 mg, 1.7 mmole) was dissolved in dimethyl sulfoxide (35 ml). Glacial acetic acid (2.8 
ml, 49 mmole) and acetic anhydride (0.5 ml, 5 mmole) were added and the solution was stirred at 
150°C, followed by the addition of sodium acetate (1.4 g, 17 mmole). A 1-ml aliquot was taken 
from the solution by a syringe at appropriate time intervals and was cooled immediately to 0°C. To 
this 1-ml aliquot water (1 5 ml) was added and shaken for half an hour at room temperature. The 
optical rotation of this solution was measured at 589 nm. For results, see Table 3-1. 
Oppenauer oxidation of ethyl (S)-mandelate (S)-5b 
Al(0/Pr)3 (550 mg, 2.69 mmole) was added to a solution of (S)-5b (240 mg, 1.33 mmole) in dry 
toluene (20 ml) under nitrogen and the mixture was refluxed for 24 h. The resulting mixture was 
cooled to room temperature and extracted with a 30% aqueous sulfuric acid solution and water until 
neutral. The organic layer was dried over MgS0 4 and concentrated in vacuo providing pure 5f as an 
oil in 77% yield. HPLC (Chiralcel ODH, eluent: hexane/2-propanol=9/l, v/v): 0% ее. IR (CC14, 
cm"
1): ν 3520 (OH), 2870-3100 (CH), 1725 (C=0). Ή-NMR (CDC13, ppm): δ 1.05 (d, 3H, CH3, 
J=6.1 Hz), 1.22 (d, 3H, CH3, J=6.4 Hz), 3.52 (d, IH, OH, J=5.4 Hz), 5.01 (dq, IH, CH(CH3)2, 
J=6 1, 6.4 Hz), 5.07 (d, IH, CHOH, J=5 4 Hz), 7.2-7.6 (m, 5H, АгЩ 
N-l-(R)-phenylethyl-mandelamide (R,R)-5l and (S,R)-51 
A mixture of racemic mandelic acid (RS)-4 (140 mg, 0.9 mmole) and (R)-a-methylbenzylamine 
(R)-5 (149 μΐ, 1.2 mmole) was stirred under nitrogen at 125°C in a sealed tube for one hour. The 
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resulting oil was cooled to room temperature GC two diastereomers (11) The crude mixture was 
purified by column chromatography (silicagel 60H, hexane/ethyl acetate=l/l, v/v) and provided 
(R R)-51 and (S.R)-Sl both as an oil (R,R)-51 [a] D 2 ' -18 7° (chloroform, c=l 0) IR (CC14> cm ') 
ν 3500-3100 (NH, OH), 2970-3090 (CH). 1650-1680, 1495 (C=0) ' H - N M R (CDC13, ppm) δ 1 38 
(d, 3H, СЫз, J=6 9 Hz), 4 10 (s, IH, OH), 4 82 (s, IH, CHOH), 5 02 (q, IH. CHNH, d=6 9 Hz), 
6 73 (d, IH, NH, J=6 0 Hz), 7 0-7 5 (m, 10H, ArH) (S,R)-51 [a]D 2 5 +75 9° (chloroform, c=l 0) IR 
(CCI,, cm1) ν 3600, 3400 (NH, OH), 2920-3100 (CH), 1670, 1495 (C=0) 'H-NMR (CDC13, 
ppm) δ 1 39 (d, 3H, CH3, J=6 9 Hz), 3 82 (s, IH, OH), 4 92 (s, IH, CHOH), 5 08 (q, IH, CHNH, 
d=6 9 Hz), 6 53 (d, IH. NH, J=6 0 Hz), 7 0-7 5 (m, 10H, ArH) 
The diastereomers (R,R)-51 and (S R)-51 were identified by comparison with reported data 
(S,R)-51 [a]D 2 5 +1114° (chloroform, c=l 2)43b 'H-NMR (CDC13, ppm) δ 1 3 (d, 3H, CH3, J=7 
Hz), 4 76-4 9 (m, 3H, CHNH, CHOH), 7 13 (m, 1 IH, NH, ArH)o b 
(R,S)-51 [a] D 2 ' -160 3° (ethanol, c=l 34)43a 'H-NMR (CDC13, ppm) δ 1 42 (d, 6H, CH3), 3 50 (s, 
IH, OH), 4 95 (s, IH, CHOH), 5 07 (m, IH, CHNH), 6 65 (d, IH, NH), 7 3 (m, 10H, ArH)"' 
(S,S)-51 [α] 0 2 ' +11 Io (chloroform, c=0 64)43b [a]D 2 5 -53 2° (ethanol, c=l 34)4". 'H-NMR (CDC13, 
ppm) δ 1 42 (d, 6H, CHj), 3 50 (s, IH, OH), 4 88 (s, IH, CHOH), 5 07 (m, IH, CHNH), 6 65 (d, 
IH, NH), 7 3 (m 10H, ArH)"a 'H-NMR (CDC13, ppm) δ 1 33 (d, 6H, CH3, J=7 Hz), 3 9 (s, IH, 
OH). 4 76 (s, IH, CHOH), 4 93 (q, IH, CHNH, J=7 Hz), 6 67 (s, IH, NH), 7 2 (m, ЮН, АгЩ"ь 
A fraction of (S,R)-51 was hydrolyzed to mandehc acid 4 by treatment with aqueous hydrochloric 
acid (pH 2) The mixture was extracted with ethyl acetate (three times), dried over MgS04 and 
concentrated in vacuo providing (S)-4 [a] D ' 3 +74 5° (methanol, c~0 37) 
Crystallization-mduced asymmetric transformation of mandehc acid 4 in the melt (Approach I) 
As a typical example a mixture of (RS)-4 (90 mg, 0 6 mmole) and (-)-N-methylephednne 49 (215 
mg, 1 2 mmole) was stirred under nitrogen at 110°C for 17 h The homogeneous mixture was 
cooled to room temperature, hydrolyzed with 0 5N aqueous hydrochloric acid (10 ml) and extracted 
with ethyl acetate (three times) The combined organic layers were extracted with brine, dried over 
MgS04 and concentrated in vacuo to give pure 4 as a white solid in 92% HPLC (Chiralcei ODH, 
eluent hexane/2-propanol/trifluoroacetic acid=875/125/2 5, v/v) 2 5% ее (R) For other results see 
Tables 3-16 and 3-17 
Crystallization-mduced asymmetric transformation of mandehc acid 4 in solution by (S)-\dBA (S)-
10 and NaOH in sec-butanol (Approach II) 
Grinded sodium hydroxide (30 mg, 0 75 mmole) was added to a stirred solution of (RS)-4 (650 mg, 
4 3 mmole) and (S)-MBA (S)-10 (0 55 ml, 4 3 mmole) in sec-butanol (5 ml) at 100°C under 
nitrogen The resulting heterogeneous mixture was stirred at 100°C for 21 h and subsequently 
cooled to room temperature The mixture was diluted with water (20 ml), hydrolized with 2N 
aqueous hydrochloride (4 ml) and extracted with ethyl acetate (three times) The combined organic 
layers were extracted with brine, dried over MgS04 and concentrated in vacuo to give pure 4 as a 
white solid in 100% The ' H-NMR was in agreement with pure 4 HPLC (Chiralcei ODH, eluent 
hexane/2-propanol/tnfluoroacetic acid=875/125/2 5, v/v) 6 5 ± 0 5% ее (S) 
Crystallization-induced asymmetric transformation of mandehc acid 4 in the melt by (+)-(2S 3R)-
DUDB 50 and DBN 40 (Approach II) 
A mixture of (RS)-4 (250 mg, 1 6 mmole) and (+)-(2S,3R)-DMDB 50 (465 mg, 1 6 mmole) was 
stirred at 100°C under nitrogen DBN 45 (100 μΐ, 0 8 mmole) was added dropwise and the 
heterogeneous mixture was stirred for 17 h at 100°C The resulting heterogeneous mixture was 
cooled to room temperature and dissolved in water (10 ml) 2N Aqueous sodium hydroxide (0 8 ml) 
was added and the solution was stirred (0 5 h) at room temperature and subsequently extracted with 
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dichloromethane (three times). The water layer was acidified to pH 2 with 2N aqueous hydrochloric 
acid and extracted with ethyl acetate (three times). The combined organic layers were extracted with 
brine, dried over MgS04 and concentrated in vacuo to give pure 4 as a white solid in 93%. The H-
NMR was in agreement with pure 4. HPLC (Chiralcel ODH, eluent: hexane/2-
propanol/tnfluoroacetic acid=875/125/2.5, v/v): 3.4 ± 0.3% ее (S). 
Crystallization-induced asymmetric transformation of mandelic acid 4 in the melt by (S)-MBA (S)-
10 and DBN 45 (Approach II) 
A mixture of (RS)-4 (1.0 g, 6.6 mmole), (S)-MBA (S)-10 (2.2 ml, 17.1 mmole) and DBN 45 (41 μΐ, 
0 33 mmole) was stirred under nitrogen and heated to 140°C. The homogeneous mixture was cooled 
to 130°C and seeded with a few crystals of pure (S)-4.(S)-10 salt. The heterogeneous mixture was 
stirred at 120°C for 64 h and gradually cooled to room temperature in 5 h. The resulting mixture 
was filtered, washed with hexane and dried in vacuo providing pure mandelic acid.(S)-MBA salt 
(1.74 g, 97%). 'H-NMR (CDCIJ, ppm): δ 1.40 (d, 3H, CH3, J=6.8 Hz), 4.25 (q, IH, CHNH, d=6.8 
Hz), 4.52 (s, IH, CHOH), 6-7 (4H, NH3\ ОЫ), 7.1-7.6 (m, 10H, ArH). A fraction of the salt 
obtained was hydrolyzed with 2N aqueous HCl at pH 2, stirred for half an hour at room temperature 
and extracted with ethyl acetate (three times). The combined organic layers were dried over MgS04 
and evaporated to give pure 4 as a white solid. The 'H-NMR was in agreement with pure 4. HPLC 
(Chiralcel ODH, hexane/2-propanol/trifIuoroacetic acid=875/l25/2.5, v/v): 27.3 ± 0.2% ее (S). 
Crystallization-induced asymmetric transformation of mandelic acid 4 in the melt by (S)-MBA (S)-
10 and TBD 47 (Approach II). 
A mixture of (RS)-4 (2.0 g, 13.2 mmole), (S)-MBA (S)-10 (4.0 ml, 31 mmole) and DBN 45 (100 
mg, 0.7 mmole) was stirred under nitrogen and heated to 140°C The homogeneous mixture was 
cooled to 120°C with a rate of 20°C/h. The resulting heterogeneous mixture was stirred at 120°C for 
64 h and cooled to 25°C with a rate of 12°C/h The resulting mixture was filtered, washed with 
hexane and dried in vacuo providing pure mandelic acid.(S)-MBA salt (3.24 g, 91%). The H-NMR 
was in agreement with the pure salt. A fraction of the salt obtained was hydrolyzed with 2N aqueous 
hydrochloric acid at pH 2, stirred for half an hour at room temperature and extracted with diethyl 
ether (three times). The combined organic layers were dried over MgS04 and concentrated in vacuo 
to give pure 4 as a white solid. The H-NMR was in agreement with pure 4. HPLC (Chiralcel ODH, 
eluent: hexane/2-propanol/trifluoroacetic acid=875/l25/2.5, v/v). 23.7% ее (S). 
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R acemization and Asymmetrie Transformation of a-Arylpropionic Acids 
4.1 Introduction 
The interest in the past three decades for non-steroidal antiinflammatory drugs (NSAIDs) is 
expressed in the increasing number of publications and patents in this area Among several others, 
well-known examples are indomethacin l1 2, salicylic acids 213 and α-arylpropionic acids (APAs) 
3 M 3 6 In particular ct-arylpropionic acids 3 (the 'profens*) have emerged as an important class of 
NSAIDs They act by inhibiting the cyclooxygenase system and are able to reduce inflammation 
and also show general analgesic activity3 4 
COOH 
/ \ ,COOH 
OH V COOH 
ρ - - - «-
C l " ^ " ^ 1 2 3 
Figure 4-1. Non-steroidal antiinflammatory drugs (NSAIDs) 
COOH oc 
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COOH 
COOH 
Ibuprofen 
COOH 
6 
Naproxen 
^-гР^Л D-W; COOH 
Flurbiprofen Flunoxaprofen 
Figure 4-2. α-Arylpropionic acids (APAs, 'Profens') 
COOH 
Ketoprofen 
Ibuprofen 5 and naproxen 6 are the best known examples in this class of compounds 
Ibuprofen 5 is a widely used drug for headache and minor pains lb57 with annual sales of about $100 
million and a volume of about 10 000 tons in 1995 Naproxen 6, with sales of $200 million and 
85 
1400 tons in 1995. is used in the treatment of rheumatoid arthritus"" and is one of the first 
discovered APA with antiinflammatory activity6 
The (S)-enantiomer of profens is known to be the active agent69 (eutomer) Interestingly, the 
inactive (R)-enantiomer (distomer) is metabolically inverted into the eutomer1 0" This unique 
reaction is specific for this kind of drugs It has been suggested that the inversion proceeds via 
stereoselective activation of the (R)-enantiomer to its CoA thioester whereby it is then racemized 
and subsequently hydrolyzed to release the free drug (Scheme 4-1) This interesting aspect shows a 
possibility of administering the drug as a racemate because the distomer is converted in situ into the 
eutomer With the exception of naproxen 6 and flunoxaprofen 8 most of the APAs are indeed 
marketed as racemates Interestingly, Ketoprofen 9, is marketed both as the R- and the S-
enantiomer albeit for different purposes'2 
acyl-Coa synthetase Ι
 г
_ . 
/ « m к л Ί+ ^ \ ^ \ ,-SCoA 
COOH Coa, ATP, Mg2+ ' ^ ' ^ 
(R)-5 hydrolysis O 
racemizatio 
COOH 
(S)-5 hydrolysis 
Scheme 4-1. Proposed mechanism for metabolic inversion of Ibuprofen 5 
However, the described metabolic inversion mechanism of APAs is more complicated The 
intermediate thioester can undergo acyl exchange with natural fatty acids in tnacylglycerols This 
results in accumulation in fatty tissues as was shown for Ibuprofen 5"*' It is still unknown which 
long term effects the incorporation of profen in fatty tissues have, but toxic side effects are possible 
Any possible and harmful consequence from administering these drugs as racemates can simply be 
overcome by marketing profens in their enantiopure (S)-form 
Since 1983, there has been a 'racemate-versus-enantiomer' debate examining the advantage 
and disadvantage of each The US Food and Drug Administration (FDA) stated that the use of 
single isomers may be advantageous Formal guidelines were issued in 1992-1993'4 However there 
is uncertainty whether and when agencies will approve single isomers that are already approved as 
racemates, the so-called racemic switch At least, there has to be a clear therapeutic advantage of the 
single isomer over the racemate For new drugs the situation is quite clear optical purity is required 
unless a racemate or a mixture of isomers shows a clear-cut advantage A proposal for marketing 
(S)-ibuprofen (S)-5 experienced long delay at the FDA and was finally rejected in 1994 Industry 
observers stated that FDA reviewers have not decided on a clear policy for dealing with racemic 
switches" In fact, the FDA seems to be reconsidering its rejection of 1994 So far, Ibuprofen 5 is 
marketed as enantiopure (S)-enantiomer in Austria only and soon will be introduced in Germany 
and other markets Because of the huge potential markets, commercial organizations have devoted 
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much effort to develop an efficient industrial synthesis of (S)-5. This generally expresses the need 
for asymmetric preparation of enantiopure APAs. 
A number of methods for the racemic and asymmetric synthesis of APAs have been 
developed and are well covered by some reviews""6 Following the general trends in organic 
chemistry most efforts to produce enantiopure APAs have been made in the area of asymmetric 
synthesis. The lewis acid promoted rearrangement of acetáis of α-substituted propiophenones via a 
1.2 aryl shift appears to be a general method'6 1 7. Other widely used methods are the asymmetric 
addition of chiral alcohols to ketenes derived from α-arylpropionic acids". Asymmetric 
hydroformylations have also been applied" 
(L)-Strychnine 10 
¿Ы H .OH 
la (-)-Quinine 
N 
(X=OMe) 
lb(-)-Cinchonidine(X=H) 
OH 
©rV 
12 (-)-Ephednne 
^ ι 0' NHi 
13 MBA 
H O -
r— NR 
—OH 
—OH 
—OH 
I—OH 
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14b(R=Et) 
OH OH 
NH2 
„OH NH2 
(+)-Dehydroabiethylam¡ne 15 16 (R)-(-)-2-amino-l-butanol 
Figure 4-3. Resolving bases for profens 4-6 
0,N NH, 
INAP17 
For economic reasons resolution processes to prepare enantiopure APAs remain the most 
important industrial method. Hydratropic acid 4 has been resolved using (L)-strychnine 1020, 
(-)-quinine 11"', (-)-ephedrine 1222 and (+)- and (-)-a-methylbenzylamine (MBA) 1323. Ibuprofen 5 
was resolved using either MBA 132" or lysine25 and its esters enzymatically by lipases26. Naproxen 6 
has been resolved by chemical means using (-)-cinchomdine l ib2 7 , (+)- and (-)-MBA 1328, /V-
methyl-D-glucamine 14a2', iV-ethyl-D-glucamine 14b30, (+)-dehydroabietyl-amine 15", (R)-(-)-2-
amino-1-butanol 1612 and f/jreo-(+)-2-amino-l-p-nitropheny 1-1,3 -propanediol 1713 and by 
enzymatical means34. Also resolutions by preferential crystallization of methyl or ethyl esters of 
naproxen 63! or covalent diastereomeric amides of naproxen 616 have been reported. 
The present study deals with the rational design of crystallization-induced asymmetric 
transformations of profens. The preliminary interest was focused on hydratropic acid 4, Ibuprofen 5 
and naproxen 6. Hydratropic acid 4 was used because of its structural resemblance with mandelic 
acid, which was used as substrate in Chapter 3. It is of general interest to develop a simple and 
cheap process for the synthesis of enantiopure (S)-ibuprofen 5 because it will probably be marketed 
in enantiopure (S)-form in the near future Naproxen 6 was used in racemization experiments and 
only in a few asymmetric transformation experiments 
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Mild and fast racemization of APAs 4, 5 and 6 was performed using strong bases in the melt 
and is presented in section 4.3. In section 4.4 the crystallization-induced asymmetric 
transformations of 4 and 5 is described by a combination of racemization with resolution in the 
melt Several parameters influencing asymmetric transformations were systematically investigated 
and optimized using Ibuprofen 5 as substrate. 
4.2 Synthesis 
Racemic and enantiopure hydratropic acid 4 were synthesized according to Scheme 4-2. (RS)-
hydratropic acid 4 was prepared by oxidation of relatively cheap hydratropaldehyde 18. Several 
oxidation methods are known for the synthesis of Ibuprofen 5, naproxen 6 and ketoprofen 9 starting 
from the corresponding aldehydes (e.g. KMn04/MgS04", KMn04/H2S0439, Ag20", NaC10235 and 
autoxidation40). Profens are obtained in yields of about 75%. The formation of phenylacetones as 
side product is the main problem. The use of KMn04 as oxidizing reagent"'
8
 for hydratropaldehyde 
18 resulted in poor yields (<50% of (RS)-4) and considerable amounts of phenylacetone as side 
product Therefore, the milder oxidizing agent NaC102 in combination with hydrogen peroxide as 
HOC1 scavenger was used41. Excellent results were obtained: (RS)-4 was isolated in high yields (91-
95%) and no side reactions were observed. Several procedures for the oxidation of profen aldehydes 
by NaC102 involving the use of various HOC1 scavengers such as sulfamide, resorcinol or 2-
methyl-2-butene are reported. Yields are generally around 75%39. 
COOH 
NaCICh 
Η-,Ο-, 
ОС.Г 
A 
NaH2P04 
U(RSM ^ Q J (R.SM9 Ρ 
Scheme 4-2. Synthesis of the enantiomers of hydratropic acid 4. 
Resolution of (RS)-4 was performed using MBA 1323a. Both enantiomers of 4 were prepared 
using either (R)- or (S)-13. Toluene/ethanol mixtures were used as the solvent in stead of benzene/ 
ethanol mixtures reported in the literature. Pure diastereomeric salt (R,S)-19 was obtained after four 
crystallizations with a diastereomeric excess (de) of 94% and in 40% yield based on the maximum 
theoretical amount of (R,S)-19. Liberation of the free acid (S)-4 resulted in 63% yield and 99% 
enantiomeric excess (ее) after one recrystallization. By the same procedure, (S,R)-19 was isolated in 
two crops after two crystallizations in a total theoretical yield of 70% and 99% de. Liberation of free 
acid (R)-4 resulted in 76% yield and 99% ее after one recrystallization. 
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Methyl esters of naproxen 20 were prepared according to Scheme 4-3. Commercially 
available (S)-naproxen (S)-6 was racemized in the melt by l,5-diazobicyclo[4.3.0]non-5-ene (DBN) 
29 at 120°C providing pure racemic 6 in 97%. Pure methyl esters (RS)- and (S)-20 were obtained in 
quantitative yield by reaction of (RS)- and (S)-6 respectively with 2,2-dimethoxypropane (DMP) 
under acidic conditions. 
joocr DMP/MeOH 1 H* 
— О 
COOMe 
(S)-20 
120°C DBN 
COOH DMP/MeOH 
H 
COOMe 
_ 0 ' ν ν (RS)-6 " _ 0 ^ \ ^ \ ^ - (RS)-20 
Scheme 4-3. Synthesis of racemic naproxen (RS)-6 and naproxen methyl esters 20. 
Enantiomeric excesses of hydratropic acid 4, Ibuprofen 5, naproxen 6 and naproxen methyl 
ester 20 were determined using HPLC with a chiral Daicel Chiralcel ODH column and hexane/2-
propanol/trifluoroactic acid mixtures as eluent. The results of the optical resolutions using HPLC 
are collected in Table 4-1. The Chiralcel ODH column was adopted from a procedure described by 
Okamoto et al.42 who resolved hydratropic acid 4 and Ibuprofen 5. However, better results were 
obtained using different eluent compositions and a smaller particle size. Optical resolution of 
profens 6 and 20 were not previously described using a Chiralcel ODH column. 
Table 4-1. Optical Resolution of Profens using HPLC (Chiralcel ODH) 
Entry 
1 
2 
3 
4 
5 
6 
Compound 
4 
5 
5 
6 
6 
20 
Eluent' 
hexane/2-propanol/TFA (v/v) 
950/50/2.5 
980/20/2.5 
980/20/1 
950/50/2.5 
900/100/2.5 
95/5/0 
f a 
: RS 
2.12 
1.90 
1.95 
3.00 
2 23 
2.48 
b 
α 
1.26 
1.15 
1.20 
1.22 
1.23 
1.29 
remarks 
R-enantiomer elutes first 
R-enantiomer elutes first 
R-enantiomer elutes first 
R-enantiomer elutes first 
R-enantiomer elutes first 
R-enantiomer elutes first 
a) The resolution factor (fRS) is calculated by fRS=AtR 1 177/Σνν05 , where tR is the retention time and w 0 5 the 
width at half-height b) The separation factor (a) was calculated using ct=k27k|', where k' is the capacity factor 
determined by ki'=(t|-t0)/t0, t, is the retention time of enantiomer 1 and t0 the retention time of the dead volume 
(toluene) 
О 
CO. NH2 + 
13 
CO. Η 
EbO 
MgSO„ 
Scheme 4-4. 
Η 
CO. о 
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The ее of MBA 13 was determined by condensation of the amine with benzaldehyde to mine 
21 (Scheme 4-4) and subsequently measuring the ее of ïmine 21 using HPLC with a chiral Daicel 
Chiralpak AD column and hexane/2-propanol=99/l (v/v) as eluenf13 
4.3 Racemization" 
Systematic investigation of the racemization of mandelic acid (Chapter 3) led to the 
conclusion that optimum results are obtained by performing a base-catalyzed reaction in a 
preferably homogeneous melt45 This resulted in a rapid and mild racemization reaction, applicable 
for crystallization-induced asymmetric transformations This method was also applied to 
hydratropic acid 4, Ibuprofen 5 and naproxen 6 The results of the racemization using 1 1 equiv base 
are collected in the Tables 4-2 and 4-3 
Table 4-2. Racemization of Profens (S)-4 to 6 by 1 1 Equiv Base in the Melt at 110°Ca 
л V V <°> ^ ^ 
L-v-J ι %jAß н н 
22 D A B C O 2 3 T M E D A 24 Proton sponge 25 Morfoline 26 Pipendin 
¿ CO Co yv CO 
27 Pyrrolidine 28 DBLi 29 DBN 30 TM G 31 TBD 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Base 
Et3N 
MBA 13 
DABCO 22 
TMEDA 23 
Proton sponge 24 
Morfoline 25 
Pipendine 26 
Pyrrolidine 27 
DBU28 
DBN 29 
TMG30 
TBD 31 
pKa" 
11 0 
94 
2 8,88 
5 9, 9 1 
9 7, 13 5 
83 
11 1 
11 3 
0 214c 
0 063c 
136 
(<0 06c) 
9 4c 
(S)-4 
Racemization Yield 
(%r 
69 6 
16e 
96 1 
88 8 
88 9 
67 4 
81 6 
94 8 
100 
100 
63 5 
90 5 
(%) 
100 
95 
97 
99 
95 
99 
97 
100 
97 
97 
100 
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(S)-5 
Racemization Yield 
(%r 
66 8 
0 7e 
82 8 
82 4 
73 6 
61 0 
73 3 
93 2 
100 
100 
42 5 
64 3 
(%) 
97 
96 
95 
96 
97 
95 
98 
98 
100 
98 
85 
100 
(S)-6 
Racemization 
(%)d 
76 6 
3 3c 
3 6e 
92 9 
84 8 
2 9e 
2 4e 
77 5 
97 1 
100 
13 3e 
68 4 
Yield 
(%) 
100 
95 
97 
94 
95 
95 
100 
97 
100 
97 
98 
94 
a) Conditions profen 4 5 o r 6 ( l mmole), base (1 1 mmole), under nitrogen, melt, I I0°C,5 h 
b) Basicm in water46 с) Relative basicity in acetonitrileJ7 d) Determined b> HPLC (Chiralcel ODH) 
e) Heterogeneous melt 
90 
Racemizalion und Asymmetric Transformation of a-Arxlpropumic Acidi 
Table 4-3. Racemization of Profens (S)-4 to 6 by 1.1 Equiv Base in the Melt at 90°Ca 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Base 
Et3N 
MBA 13 
DABCO 22 
TMEDA 23 
Proton sponge 24 
Morfohne 25 
Piperidine 26 
Pyrrolidine 27 
DBU28 
DBN29 
TMG30 
TBD31 
(S)-4 
Racemization 
(%)b 
38.9 
С 
64.7 
52.8 
37.7 
28 9 
44 9 
65 7 
88.8 
100 
21.7 
35.8 
Yield 
(%) 
99 
94 
100 
95 
96 
93 
100 
100 
99 
90 
97 
(S)-5 
Racemization 
(%)b 
33.7 
С 
27.6 
26.9 
35.6 
3 01-
20 9 
36 0 
51 5 
81.2 
3 3L 
22.9 
Yield 
(%) 
95 
95 
100 
95 
100 
90 
87 
96 
97 
97 
96 
(S)-6 
Racemization 
(%)" 
25.4 
t 
L 
15.4C 
31 4 
i. 
2.1L 
2 Τ 
32.3 
10.2е 
L 
27 8 
Yield 
(%) 
95 
88 
95 
98 
100 
94 
98 
95 
a) Conditions profen 4, 5 or 6 ( 1 mmole), base ( 1 1 mmole). under nitrogen, melt, 90°C, 5 h 
b) Determined by HPLC (Chiralcel ODH) c) Heterogeneous melt 
Several bases were tried, viz. Et3N, MBA 13, l,4-diazobicyclo[2.2.2]octane DABCO 22, 
A^jV.Af'./V'-tetramethylenediamine (TMEDA) 23, l,8-/w(dimethylamino)-naphthaline (Proton 
sponge) 24. morfohne 25, piperidine 26, pyrrolidine 27, l,8-diazobicyclo[5.4 0]undcc-7-ene (DBU) 
28, l,5-diazobicyclo[4.3.0]non-5-ene (DBN) 29, tetramethylguanidine (TMG) 30 and 1,5,7-triazabi-
cyclo[4.4 0]dec-5-ene (TBD) 31. 
Comparison of the racemizations of profens 4-6 under the same conditions, leads to the 
following order of racemization. hydratropic acid 4 > Ibuprofen 5 > naproxen 6 This order probably 
can be explained by a positive resonance effect (+M, electron-donating) of the /¿obutyl and 
methoxy substituent in Ibuprofen 5 and naproxen 6 respectively Both substituents cause a higher 
electron density at the α-position and therefore a lower acidity of the α-proton when compared with 
4 As a consequence, the positive resonance effect in naproxen 6 must be higher when compared 
with Ibuprofen 5. Racemization of a-alkylcarboxylic acids 4-6 is faster when compared with 
mandelic acid, an ct-hydroxycarboxylic acid (see Chapter 3)44 "". This effect probably is attributable 
to the more positive resonance effect (+M) of the α-hydroxy substituent in mandelic acid compared 
with that of the α-alkyl substituent in profens 4-6. 
More heterogeneous melts are obtained at the same temperature in going from profen 4 to 5 to 
6 No conclusions could be drawn from the racemization results of naproxen 6 at 90°C because 
almost 70% of these reactions were heterogeneous In none of the described cases a homogeneous 
melt was observed using resolving base MBA 13. 
The qualification of bases based on their ability to racemize profens 4-6 is summarized in 
Table 4-4. From these data it can be concluded that DBN 29 is the best racemizing base, closely 
followed by DBU 30 It is known that DBU 28, DBN 29 and TBD 31 are extremely strong and mild 
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non-ionic bases4748. Moderate racemizing bases are DABCO 22, TMEDA 23, Proton sponge 24, 
pyrrolidine 27, TBD 31 and Et3N. Best results were obtained with bases containing a di-nitrogen 
function, especially amidines A simple relation with base strength, pKb, is not apparent. 
Table 4-4. Qualification of Bases on the Basis of their Ability to Induce Racemization. 
Entry 
1 
2 
3 
4 
5 
6 
T(°C) 
110 
110 
110 
90 
90 
90 
Substrate 
4 
5 
6 
4 
5 
6 
DBN/DBU 
DBN/DBU 
DBN 
DBN 
DBN 
DBU 
DBU 
DBU 
DBU 
Qualification of Base 
DABCO 
Pyrrolidine 
TMEDA 
Pyrrolidine 
Pyrrolidine 
Proton sponge TBD 
reasing order 
Pyrrolidine TBD 
DABCO / TMEDA 
Proton sponge Et3N 
DABCO TMEDA 
/ Proton sponge Et3N 
Et3N TMEDA 
Currently, semi-empiric molecular modeling calculations are in progress to gain more insight. 
Preliminary results indicate that racemization results from equilibrium A in which only a mono-
anion 5b is involved (Scheme 4-5). Equilibrium С through the di-anion 5d appears to be of minor 
importance. Racemizations of Ibuprofen 5 by DABCO 22, DBU 28, DBN 29 and TBD 31 were 
calculated according to route A using techniques simulating dilute aprotic polar solutions. This 
resulted in the following order of base strength: TBD 31 > DBU 28 > DBN 29 > DABCO 22. This 
calculated order of bases differs from the experimental one. This is explained by the neglect of 
equilibrium В in the calculations. A stronger base causes a decrease in available free acid (S)-5a for 
racemization through route A. This in turn leads to the conclusion that there is no linear relationship 
between the pKb-value of the base and the racemization rate of profens 4-6. An optimum base 
strength has to be found in another way 
(S)-5a 
J 
COOH 
base 
base 
COO 
base 
D .. 
base 
Scheme 4-5. 
Recently, several studies toward the action of mandelate racemase were reported4'. In these 
investigations it was shown that histidine, lysine and a metal ion are responsible for the 
racemization of the substrate in the active site of the enzyme Therefore, it was tried to racemize 
Ibuprofen 5 with these basic amino acids. The results are summarized in Table 4-5. 
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Table 4-5. Racemization of Ibuprofen 5 by Lysine and Histidine' 
Entry 
1 
2 
3 
4 
Amino acid 
(equiv) 
His(l 1) 
His (10) 
Lys(l 1) 
Lys (10) 
pKi 
7 5 
9 6 
Solvent 
DMSO(l ml) 
-
DMSO (1 ml) 
DMSO(l ml) 
Time 
(h) 
4 
5 
5 
5 
T(°C) 
110 
130 
110 
130 
Racemization 
(%)" 
8 3c 
41 5C 
84 9 
99 Τ 
Yield 
(%) 
100 
100 
100 
100 
a) Conditions (S)-ibuprofen (S)-5 (0 5 mmole) lysine or histidine, under nitrogen b) Determined by HPLC 
(Chiralcel ODH) c) Heterogeneous melt 
Heterogeneous to solid mixtures resulted in the temperature range 25-130°C Therefore, 
dimethyl sulfoxide (DMSO) was added in most cases to obtain more homogeneous reaction 
mixtures Lysine gave better results than histidine Lysine is a known resolving base for Ibuprofen 
5"5 and combination with the above described racemization could possibly result in a crystallization-
induced asymmetric transformation Also, (S)-ibuprofen (S)-5 will be marketed as the S-lysinate 
salt On the other hand, lysine is known to racemize under thermal conditions (120-140°C)S0 
preventing a possible crystallization-induced asymmetric transformation 
Ibuprofen 5 was tested for a possible acid-catalyzed racemization because the base-catalyzed 
reactions above described are followed by an acidic work-up procedure No racemization was 
observed for (S)-5 under influence of aqueous sulfuric acid at room temperature 
4.4 Crystallization-induced Asymmetric Transformation44 
Crystallization-induced asymmetric transformation of profens was investigated using 
resolution via crystallization of diastereomeric salts in combination with base-catalyzed 
racemization The reactions were performed in the melt because optimal racemization under this 
condition was expected However, the melt must be heterogeneous as outlined in section 3 In most 
reactions an excess of base was applied Therefore, no real melt conditions are encountered because 
the base can be viewed as a solvent Nevertheless, such reactions are denoted to be performed in the 
melt 
-^- [ — + 50 i> 50 (4-1) 
100 I, 2 J 
An asymmetric transformation can be achieved when equation 4-1 is valid In other words, 
when one enantiomer is obtained in a total amount larger than 50% This condition is not always 
fulfilled, mainly because mostly the actual yields are below 90% In most cases this is considered as 
the experimental consequence of a work-up procedure Therefore, yields above 80% are considered 
to be quantitative The ее obtained is of major importance and serves as a primary indication for an 
asymmetric transformation when yields are higher than 80% 
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АЛЛ Ibuprofen 
Two resolving bases are known for Ibuprofen 5, viz. MBA 1324 and lysine25 The latter 
racemizes thermally50 and therefore MBA 13 was predominantly used. It was shown that MBA 13 is 
optically stable under thermal conditions (125°C, 64 h) and therefore can be used in heated reaction 
mixtures. 
Two approaches were used to accomplish an asymmetric transformation (Scheme 4-6) 
racemization 
(S)-MBA 13 
iBu 
О 
© 
COOH3N 
32 
(D (S)-MBA 13 
Jj COOH 
И 
(S)-MBA 13 
iBu 
Π 
© 
COOH3N 
32 
О 
(S)-MBA 13 DBN29 
/ ч . J ^ Θ© (f-yf COO DBN-H 
ß u - ^ ^ (R,S)-32 \ ^ : 
(liquid) 
resolution 
J 
iBu 
iBu 
resolution 
»-
iBu 
racemization 
•< 
ÔP c o o v JÎÔ] k ^ (S,S)-32 ^ 
(precipitate) 
1 
work-up 
r ^ T ^ C O O H 
/ 1 W J 100% yield 
i B u - ^ ^ <S)-S 100% ее 
1 
work-up 
en***® 
(precipitate) 
+ 
(liquid) 
ι 
(S)-MBA 13 
/^J^r 
DBN29 
1 
Θ Θ 
^ПП ПИМ-Н 
DBN29 Q 
iBu 
Scheme 4-6. Two approaches to the asymmetric transformation of racemic Ibuprofen 5 
I: (S)-MBA (S)-13 as the resolving and racemizing base 
II: (S)-MBA (S)-13 as the resolving base and DBN 29 as the racemizing base 
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Approach I was derived from a method described by Shiraiwa et al " They applied an excess 
of resolving base (e g MBA 13, 2-amino-l-butanol 16) for both the resolution and racemization of 
racemic amino acid derivatives (see section 2 3 1) Reaction of racemic Ibuprofen 5 with an excess 
(5 equiv) of (R)-MBA (R)-13 at 110°C during 64 h resulted in the isolation of pure Ibuprofen salt 
32 in 97% yield However, a poor ее was obtained (5 8 %) In this case the poor racemizing ability 
of MBA 13 limits a complete asymmetric transformation Use of 5 equiv of lysine in solution 
(dimethyl sulfoxide or hexanol/cumene mixtures) at 100-130°C during 64 h resulted in complex 
reaction mixtures, from which racemic Ibuprofen 5 was isolated This may be explained by thermal 
racemization or decomposition of lysine under these conditions 
Racemization of the unwanted diastereomer can be improved using approach II This method 
was designed in analogy with a resolution4"1 of Ibuprofen 5 using MBA 13 and Et3N by the Pope 
and Peachy procedure" (Scheme 4-7) Using an achiral base with at least one equiv of enantiopure 
resolving base in a one-pot reaction, may lead to a possible crystallization-induced asymmetric 
transformation This method was tried using one equiv of (R)-MBA (R)-13 in combination with the 
achiral bases Et3N, Bu3N, TMEDA 23 and DBN 29 The results are collected in Table 4-6 
2 Et3N octane reflux 
COOH 
(RS)-5 
racemization 
1) 1 EtjN, octane 
2) 0 5 (S)-MBA t3, 
octane, 125°C, 3h 
3) cooling 
/ ^ - ^ ^ (liquid) 
COO NEt.-H 
COO HjN 
(S S)-32 
(precipitate) 
COOH 
(S)-5 
Scheme 4-7. Resolution of Ibuprofen 5 (S)-MBA (S)-13 by the method of Pope and Peachy 
Several parameters affecting the asymmetric transformation can be identified from these 
results, viz base strength, ratio of achiral base/resolving base, reaction temperature, solubility and 
reaction time Base strength plays a role in salt formation with Ibuprofen 5 and in the racemization 
rate of the unwanted diastereomer Using the best racemizing base for Ibuprofen, ι e DBN 29, 
resulted in asymmetric transformations with good yields and ee"s (entries 1-3) However, some 
experimental problems were noticed The use of half an equiv of DBN 29 caused partial salt 
formation with Ibuprofen 5 preventing a complete asymmetric transformation Therefore, strong 
achiral bases like DBN 29 have to be used in catalytic amounts in the presence of weaker, resolving, 
bases like MBA 13 A good result was achieved using 0 1 equiv of DBN 29 at 130°C, which 
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proceeded in an almost solid mixture. Formation of amid 34 occurred as a side reaction at 
temperatures above 130°C. Using weaker achiral bases (viz. Et3N, Bu3N, TMEDA 23) in excess 
prevented unwanted salt formation with these bases, but gave poorer ee's (entries 4,6,7,9). 
Combination of these bases with a catalytic amount of DBN 29 improved transformation results. It 
can be concluded that the bases Et3N, Bu3N and TMEDA 23 are too weak to induce racemization of 
the unwanted isomer. Solubility and reaction temperature are related parameters. Decrease in 
solubility increases the maximum reaction temperature of a heterogeneous mixture. This in turn 
leads to a higher racemization rate and better asymmetric transformation results Using more equiv 
of base lowers the maximum temperature and racemization rate (entries 10,11) On the contrary, 
amines with longer alkyl chains lower the solubility and increase the reaction temperature and 
racemization rate, (entries 4,6). The reaction time is important when the racemization rate is low 
and the asymmetric transformation is incomplete. Therefore, better results were obtained with 
longer reaction times (entries 6,7). 
Table 4-6. Asymmetric Transformation of Ibuprofen 5 by 
Enantiopure MBA 13 (1 equiv) and Achiral Bases in the Melt*1. 
Entry Achiral base (equiv) Time (h) Τ (°C) Yield (%)b Ее (%)c Mother liquor (%ee)L 
1 
2d 
3 
4 
5 
6 
7 
8 
9 
10 
11 
DBN (0 5) 
DBN (0.1) 
DBN (0.1) 
Et 3N(10) 
Et 3N(10), DBN(0 1) 
Bu3N(10) 
Bu 3N(10) 
Bu3N(10), DBN(O.l) 
TMEDA (5) 
TMEDA (5), DBN (0.1) 
TMEDA (10), DBN (0.1) 
64 
17 
-
17 
17 
64 
168 
168 
64 
64 
64 
110 
130 
140 
90 
90 
120 
120 
116 
100 
90 
70 
92е 
91 
f 
98 
95 
83 
78 
92 
98 
69 
83 
32.3 (R) 
43 9 (S) 
3.5 (R) 
11.6 (R) 
17 8 (R) 
24.0 (R) 
31 8 (R) 
14.9 (R) 
32.3 (R) 
7 1(R) 
n d 
n.d 
n.d 
47.7 (S) 
n.d 
n.d 
31.1 (S) 
55 9 (S) 
58.6 (S) 
58.7 (S) 
51.5 (S) 
a) Conditions a mixture of Ibuprofen 5 (1.0 g, 4 9 mmole), (R)-MBA (R)-13 (0 64 ml, 5 0 mmole) and an achiral base 
was stirred at a maximum temperature giving heterogeneous conditions, under nitrogen The mixture was subsequently 
cooled to room temperature in about 5 h b) Based on the crystallized salt 32 c) Determined by chiral HPLC (Chiralcel 
ODH) on liberated Ibuprofen 5, η d = not determined d) (S)-MBA (S)-I3 was used e) Ibuprofen MBA 32 / 
Ibuprofen DBN 33 ~ 2/1 f) The melt became homogeneous during the reaction because of formation of amid 34 
The effect of adding a small amount of solvent is shown in Table 4-7. The ee's decrease by 
the use of any solvent. This is probably due to a combined effect of lowering the maximum 
temperature and lower concentration of base. Both cause a decrease in racemization rate 
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Entry 
1 
2 
3 
4 
5 
6 
7 
Table 4-7. Solvent Effect on the Asymmetric Transformation 
by MBA 13 and Achiral Bases in the Melta. 
MBA 
(equiv) 
S(l) 
SO) 
SO) 
R(l) 
R(l) 
R(l) 
S(l) 
Achiral base Solvent 
(equiv) (ml) 
DBN (0.1) 
DBN (0.1) DMSO(0.5) 
DBN (0.1) DMSO(1.5) 
Bu3N(10),DBN(0.1) 
BujN(lO), DBN(O.l) DMSO(l) 
DBN (0.5) 
DBN (0.5) octane (5) 
Time 
(h) 
17 
20 
64 
168 
20 
64 
17 
Τ 
(°C) 
130 
120 
90 
116 
90 
110 
90 
Yield 
(%)b 
91 
91 
89 
92 
100 
92d 
79 
of Ibuprofer 
Ее 
(%)c 
43.9 (S) 
37.5 (S) 
27.6 (S) 
31.8 (R) 
17.2 (R) 
32.3 (R) 
13 4 (S) 
i 5 
Mother liquor 
(%ee)c 
n.d. 
49.8 (R) 
55.1 (R) 
55 9 (S) 
n.d 
n.d 
nd 
8 R(5) D B N (0.1) - 64 100 100 36.6 (R) n.d 
9 S (5) D B N (0.1) - 20 90 98 37.7 (S) 54 3 (R) 
10 S (5) D B N (0.1) DMSO(l) 64 110 93 24.0 (S) 54.3 (R) 
11 S (5) D B N (0.1) octane (1) 64 120 67 20.6 (S) 50.6 (R) 
12 S (5) D B N (0.1) H 20(2) 64 100 100 15.2 ((S) n.d 
a) Conditions a mixture of Ibuprofen 5(1 0 g, 4 9 mmole), enantiopure MBA 13 and an achiral base was stirred at a 
maximum temperature giving heterogeneous conditions, under nitrogen The mixture was cooled to room temperature 
in about 5 h b) Based on the crystallized salt 32 c) Determined by chiral HPLC (Chiralcel ODH) on liberated 
Ibuprofen 5, η d =not determined d) The isolated salt consisted of Ibuprofen.MBA 32/ibuprofen DBN 33-2/1 
The above results showed that best results are obtained using excess MBA 13 and a catalytic 
amount of DBN 29. Consequently, attempts were made to find an optimum ratio of these bases and 
results are collected in Table 4-8. Best results were obtained employing 2.5 equiv of MBA 13 in 
combination with 0.05-0.1 equiv of DBN 29 at 120-130°C giving 85-95% yield and 60-70% ее. In 
general, higher reaction temperatures increase the racemization rate of the unwanted diastereomeric 
salt and thus positively affects an asymmetric transformation. This can be influenced by equiv of 
MBA 13 and DBN 29. The amount of DBN 29 should be preferably below 0.1 equiv, limiting salt 
formation with Ibuprofen 5 and increasing the reaction temperature. As more of the 
diastereomencally pure Ibuprofen.MBA salt 32 crystallizes the concentration of the strong 
racemizing base DBN 29 in the liquid phase will steadily increase. This may limit the maximal 
yield and ее. 
Use of less than 5 equiv of MBA 13 decreases the solubility and increases the reaction 
temperature Reaction temperatures above 130°C result in considerable formation of amid 34 
(entries 18,19,23). Prolonged reaction times enhance the ее (entries 12-16). 
Optimization of the asymmetric transformation results was investigated by improving of 
either the resolution or racemization process. Progression of the resolution was tried by several 
methods, i e. seeding with an optically pure salt, starting from optically enriched Ibuprofen, hot 
filtration and optimum crystallization by omitting stirring. 
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Table 4-8. Asymmetric Transformation of Ibuprofen 5 by MBA 13 and DBN 29 in the Melt 
Optimization of the MBA/DBN ratio3 
Entrv MBA DBN Time Τ Yield Ее Mother liquor 
(equiv) (equiv) (h) (°C) (%)" (%)c (%ee)c 
1 
2 
3 
R(10) 
R(10) 
R(10) 
0.2 
0.1 
0.01 
40 120-100" 88 23 3 (R) 50 9 (S) 
64 100 92 44.7 (R) 
64 105 89 19 3(R) 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
S (5) 
S (5) 
S (5) 
R(5) 
R(2.5) 
S (2.5) 
S (2.5) 
S (2.5) 
R(2.5) 
R(2.5) 
R(2 5) 
R(2.5) 
R(2.5) 
S (2.5) 
R(2.5) 
R(2.5) 
0.5 
05 
0.1 
0.1 
0.05 
0.05 
0.05 
0.05 
0.05 
0.05 
0 05 
0.05 
0.05 
0.01 
0.01 
0.01 
20 
20 
20 
64 
64 
64 
64 
64 
40 
40 
64 
64 
168 
64 
64 
64 
80 
90 
90 
100 
130 
130 
130 
130 
130-120e 
130-120e 
120 
120 
120 
130 
135 
140 
72 
78 
98 
100 
85 
90 
85 
88 
84 
87 
91 
68 
91 
84 
82 
47 
52.3 (S) 
35 3 (S) 
37.7 (S) 
36 6 (S) 
69.1 (R) 
62.4 (S) 
64.5 (S) 
61.9 (R) 
56.0 (R) 
56.0 (R) 
60.2 (R) 
60 8 (R) 
65.3 (R) 
67 6 (S) 
56.2 (R) 
33 4 (R) 
50.7 (R) 
57.2 (R) 
54.3 (R) 
n.d. 
53.8 (S) 
n.d. 
58.3 (R) 
50.4 (S) 
39.7 (S) 
52.2 (S) 
n.d. 
43.4 (S) 
nd 
n.d 
f 
20 
21 
22 
R(l) 
S(l) 
R(l) 
0.5 
0 1 
0 1 
64 
17 
64 
110 
130 
140 
92B 
91 
t 
32 3 (R) 
43 9 (S) 
n.d. 
n.d 
n.d. 
nd. 
a) Conditions a mixture of Ibuprofen 5 (1 0 g, 4 9 mmole), enantiopure MBA 13 and DBN 29 was 
stirred at a maximum temperature giving heterogeneous conditions, under nitrogen Subsequently, the 
mixture was cooled to room temperature in about 5 h b) Based on the crystallized salt 32 
c) Determined by chiral HPLC (Chiralcel ODH) on liberated Ibuprofen 5, η d = not determined 
d) The mixture was successively stirred at 120 and 100°C for 20 h e) The mixture was successively 
stirred at 130°C for 16 h and at 120°C for 24 h 0 Formation of amid 34 was observed as side 
reaction, g) The isolated salt consisted of Ibuprofen MBA 32 / Ibuprofen DBN 33-2/1 
Seeding a homogeneous supersaturated mixture of diastereomeric salts with optically pure 
isomer is a general method to facilitate a resolution and also reduces problems due to 
polymorphism51. The results obtained with this method are outlined in Table 4-9. However, no 
improvement was observed by seeding with optically pure ibuprofen.MBA salt (S,S)-32 compared 
with spontaneous crystallization. Even seeding with the wrong diastereomer showed no effect (entry 
4) Also worse results were obtained when using seeding (comparing entries 5 and 6), but 
presumably this is mainly due to the difference in reaction time and temperature. 
Experiments starting from optically enriched ibuprofen.MBA salt 32 are comparable with 
seeding an equimolar mixture of diastereomers with one isomer. In these reactions the temperature 
of the mixture was increased such that a few percent of the salt remained undissolved. This fraction 
consists of optically pure ibuprofen.MBA 32 crystals and the crystallization starts from these pure 
crystal nuclei. The results of this method are collected in Table 4-9 No improvement was observed 
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using this process. A remarkable result is shown in entry 8. In this experiment a net inversion took 
place by reacting enantiopure (S)-ibuprofen (S)-5 with the wrong MBA enantiomer. The least stable 
diastereomer (S,R)-32 is thereby inverted to the more stable (R,R)-32. 
Table 4-9. Attempted improvement of Asymmetric Transformation by Optimization of Resolution: 
Effect of Seeding and of the Initial Enantiopurity of Ibuprofen3. 
Entry 
1 
2 
3 
4 
5 
6 
7d 
8d 
Initial ее (%)b 
0 
0 
0 
0 
0 
0 
30 (S) 
100 (S) 
MBA (equiv) 
R(5) 
S (5) 
S (5) 
R(5) 
S (10) 
R(10) 
S (10) 
R(10) 
Time (h) 
64 
20 
20 
20 
20 
64 
20 
64 
T(°C) 
100 
90 
100 
100 
110 
100 
110 
100 
Seeding 
-
-
(S,S)-32 
(S,S)-32 
(S,S)-32 
-
-
-
Yield (%)c 
100 
98 
90 
88 
94 
92 
93 
87 
Final ее (%)b 
36.6 (R) 
37.7 (S) 
39 0(S) 
41.2 (R) 
15.3 (S) 
44.7 (R) 
38 3 (S) 
20 8 (R) 
a) Conditions a mixture of Ibuprofen 5 (1 0 g, 4 9 mmole), enantiopure MBA 13 and 0 I equiv of DBN 29 (64 μΐ, 
0 53 mmole) was heated to a temperature whereby just a homogeneous solution was obtained The temperature was 
lowered by about 10°C and seeded with optically pure (S,S)-32 salt or lowered to a temperature at which 
spontaneous crystallization occurs The heterogeneous mixture was stirred at this temperature and subsequently 
cooled to room temperature in about 5 h с) Based on the crystallized salt 32 b) Determined by chiral HPLC 
(Chiralcel ODH) on liberated Ibuprofen 5 d) Like a), but the mixture was heated to a temperature whereby about 
10% of the volume became heterogeneous 
Table 4-10. Improvement of Asymmetric Transformation by Optimization of Resolution. 
Effect of Hot Filtration3. 
Entry 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
MBA 
(equiv) 
R(10) 
S (5) 
S (5) 
R(2.5) 
S (2.5) 
S (10) 
S (5) 
R(2.5) 
S (2.5) 
S (2.5) 
R(2) 
R(15) 
S (1.5) 
DBN 
(equiv) 
0 1 
05 
05 
0.05 
0 05 
0 1 
05 
0.05 
0.05 
0.1 
0 05 
0.05 
0.05 
Time 
(h) 
64 
20 
20 
64 
64 
64 
64 
64 
64 
20 
112 
112 
336 
Τ 
(°C) 
100 
80 
90 
130 
130 
90 
100 
110 
130 
130 
130 
130 
130 
Filtration 
(°C) 
RT 
RT 
RT 
RT 
RT 
90 
100 
110 
130 
130 
130 
130 
130 
Yield 
(%)b 
92 
72 
78 
85 
85 
88 
49 
88 
72 
60 
71 
73 
55 
Ее 
(%)C 
44.7 (S) 
52 3 (S) 
35.3 (S) 
69 1 (R) 
64.5 (S) 
62.3 (S) 
69.0 (S) 
74.9 (R) 
54.2 (S) 
52.0 (S) 
72 5 (R) 
73.2 (R) 
69.7 (S) 
Mother liquor 
(%ee)c 
nd. 
50 7 (R) 
57 2 (R) 
53.8 (S) 
58.3 (R) 
n.d. 
11.5(R) 
24.1 (S) 
41.9 (R) 
n.d. 
34.4 (S) 
31.8 (S) 
33.1 (S) 
a) Conditions a mixture of Ibuprofen 5 ( 1 0 g, 4 9 mmole), enantiopure MBA 13 and DBN 29 was stirred at 
a maximum temperature giving heterogeneous conditions, under nitrogen The mixture was filtered hot at the 
reaction temperature or cooled to room temperature in about 5 h and filtered b) Based on the crystallized salt 
32 c) Determined by chiral HPLC (Chiralcel ODH) on liberated Ibuprofen 5, η d = not determined 
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The experiments shown in Tables 4-6 to 4-8 reveal that the mother liquors, obtained during 
asymmetric transformations, contained the unwanted diastereomer in ca. 50% de. Cooling a 
heterogeneous reaction mixture of incomplete asymmetric transformation to room temperature 
causes crystallization of the unwanted diastereomer. This in turn leads to a lower ее of the salt 
obtained. Hot filtration at the reaction temperature should prevent crystallization of unwanted 
diastereomeric salt. As a consequence, higher ee's and lower yields of Ibuprofen are predicted. The 
results are collected in Table 4-10. As expected, hot filtration has a positive effect on the 
asymmetric transformation of Ibuprofen 5. Higher ee's and lower yields of crystallized salt were 
obtained compared with results with filtration at room temperature. As a consequence, the de of the 
mother liquor dropped by about 20%. From these results the best crystallization-induced 
asymmetric transformation of Ibuprofen 5 is: reaction with 1.5-2.5 equiv of enantiopure MBA 13 in 
combination with 0.05 equiv of DBN 29 at 110-130°C for 64-112 h results after hot filtration in 70-
90% yield and 73-75% ее. 
The resolution was finally studied by performing crystallization without stirring. These results 
are collected in Table 4-11 and it can be concluded that reaction without stirring gave no 
improvement in ее or yield. Longer reaction times caused a decrease in yield and increase in ее 
Decomposition and formation of amid 34 may be responsible for this observation 
Table 4-11. Attempted Improvement of Asymmetric Transformation by 
Optimization of Resolution, Effect of Stirring3. 
Entry 
1 
2 
3 
4 
5 
6 
7 
MBA (equiv) 
S (2.5) 
R(2) 
R(1.5) 
S (1.5) 
R(1.5) 
R(1.5) 
R(1.5) 
Stirring (rpm) 
100 
100 
100 
100 
0 
0 
0 
Time (h) 
64 
112 
112 
336 
20 
64 
336 
Yield (%)b 
72 
71 
73 
55 
88 
68 
53 
Ее (%)c 
54.2 (S) 
72.5 (R) 
73 2 (R) 
69 7 (S) 
52.0 (R) 
59.1 (R) 
69.4 (R) 
a) Conditions a mixture of Ibuprofen 5 (1 0 g, 4 9 mmole), enantiopure MBA 13 and 0 05 equiv of 
DBN 29 was stirred at 130°C (heterogeneous), under nitrogen The mixture was filtered hot at 130°C 
b) Based on the crystallized salt 32 c) Determined by HPLC (Chiralcel ODH) on liberated Ibuprofen 5 
Mother liquors with de's of 30-50% showed that racemization of the unwanted isomer is 
incomplete and hampering a complete asymmetric transformation. An ideal transformation should 
result in a racemic mother liquor. Optimization of the racemization rate was tried by higher 
concentrations of DBN 29 and the results are collected in Table 4-12. These results reveal that the 
racemization rate increases with an increase of the amount of DBN 29, as can deduced from 
decreased ee's obtained from the mother liquor. An ideal equimolar mixture of diastereomers in the 
mother liquor was obtained in entry 7 However, the yields of crystallized salt 32 dropped 
dramatically by an increase of DBN. Also a lower de of crystallized salt was observed when the 
ratio MBA/DBN dropped below 10/1 This is due to a substantial formation of racemic 
ibuprofen.DBN salt 33. 
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Table 4-12. Effect of the Racemization on the Asymmetric Transformation ' 
Entry MBA(equiv) DBN (equiv) Time (h) Τ (°C) Yield (%) Ее (%)c Mother liquor (%ee) 
1 
2 
3 
4 
5 
6 
7 
S (10) 
R(10) 
R(2.5) 
S (2 5) 
R(2.5) 
R(1.5) 
R(1.5) 
0 1 64 90 88 62 3 (S) n.d. 
1.0 64 80 15 69.7 (S) 3.7 (R) 
0.05 64 130 72 54.2 (S) 41.9 (R) 
0.05 64 110 88 74.9 (R) 24.1 (S) 
0.5 90 100 41 67.0 (R) 14.3 (S) 
0.05 112 130 73 73.2 (R) 31.8 (S) 
05 64 120 25 56.7 (S) 0 
a) Conditions a mixture of Ibuprofen 5 ( 1 0 g, 4 9 mmole), enantiopure MBA 13 and DBN 29 was stirred at a 
maximum temperature giving heterogeneous conditions, under nitrogen The mixture was filtered hot at the reaction 
temperature b) Based on the crystallized salt 32 c) Determined by HPLC (Chiralcel ODH) on Ibuprofen 5, η d = not 
determined 
Table 4-13. Exact Temperature Control in the Asymmetric Transformation of Ibuprofen 5 by MBA 
13 and DBN 29 in the Melt'. 
Entry Reaction Mixture Cooling Filtration Yield Ее Mother liquor 
(°C) (°C) (%)b (%)c (%ee)c 
1 64 h, 130°C 
2d 64 h, 130°C 
3d 64 h, 130°C 
4 64 h, 110°C 
5 „ ι 
•
i
r^fViio°c^rr1*RT 20 h 20 h 
30 h 30 h 
•°C/h. 130 c
 "Ж* '
10 c
 -Щ*
 13
°
 c) І5Г" RT 
5h 
5h 
-
-
ι _ 
RT 
RT 
130 
110 
RT 
110 
RT 
85 
85 
72 
88 
92 
63 
97 
69.1 (R) 
64.5 (S) 
54.2 (S) 
74.9 (R) 
70.5 (R) 
69.7 (R) 
65.8 (R) 
53.8 (S) 
58.3 (R) 
41.9 (R) 
24.1 (S) 
40.1 (S) 
39.9 (S) 
n.d. 
a) Conditions a mixture of Ibuprofen 5 (1 0 g, 4 9 mmole), 2 5 equiv of (R)-MBA (R)-13 and 0 05 equiv ot DBN 
29 was stirred at a maximum temperature giving heterogeneous conditions, under nitrogen b) Based on the 
crystallized salt 32. c) Determined by HPLC (Chiralcel ODH) on Ibuprofen 5, η d = not determined d) (S)-MBA 
(S)-13 was used 
Finally, optimization of the asymmetric transformation of Ibuprofen 5 was tried by exact 
temperature control. Exact control of the rate of heating and cooling could be achieved using a 
programmable heating apparatus with an accuracy of ± 0.1 °C. The results are collected in Table 4-
13 No substantial improvement in ее or yield resulted by applying exact temperature control. 
Nevertheless, experiments can easily and exactly be performed using such equipment 
Several successive asymmetric transformations of Ibuprofen 5, starting from optically 
enriched Ibuprofen (S)-5, were performed under optimum conditions to study the effect on the ее of 
the isolated product (Scheme 4-8). 
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COO' H3N 
(S,S)-32 
de=60 3% (S,S) 
О 
1) I 5 (S)-MBA (S)-13 
0 05 DBN 29 
64 h, 1I0°C 
2) hot filtration, 11 (PC 
(S,S)-32 
de=78.0% (S.S) 
yield=95% 
1) 1 5 (S)-MBA (S)-13 
0 05 DBN 29 
64 h, 110°C 
2) hot filtration, 110°C 
(S,S)-32 
de=80 0% (S.S) 
yield=95% 
Scheme 4-8. Multi-step asymmetric transformation of Ibuprofen 5. 
The final improvement of the ее of Ibuprofen from 60-70% to 100% is very difficult to 
achieve This can be explained in three ways, i) When the asymmetric transformation progresses the 
relative amount of DBN 29 in the liquid phase increases because the concentration of unwanted 
diastereomer decreases. This in tum leads to an increase of Ibuprofen.DBN salt 33 limiting the 
progress of asymmetric transformation, ii) The amount of liquid phase decreases during the progress 
of an asymmetric transformation which makes racemization in this phase more difficult, lii) 
Asymmetric transformation is dependent on the resolution process. Among others, the eulectic point 
and slope of the phase diagram are important factors in this process. Therefore, the binary phase 
diagram of Ibuprofen.(S)-MBA 32 was determined using mixtures of pure (S.S)- and (R,S)-32 
(Figure 4-4). 
Figure 4-4. Binary Phase Diagram of Ibuprofen.(S)-MBA 32a 
0.9 ι 
(R,S)-32 
a) Calculated diagram54 Ιη(χ)=ΔΗ,Έ.(1/Τ,-1/Τ) where χ is the molar fraction, 
ΔΗ, the enthalpy of fusion and T, the melting point of one of the pure 
diastereomers in the mixture. R is the gas constant and Τ the temperature 
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Both the eutectic composition ала slope are relatively unfavorable for a good resolution 
process. Based on the eutectic composition (x
eu
=0.61), the maximum yield of optically pure 32 is 
limited to 18% starting from racemic Ibuprofen (x=0.5). Moreover, the relatively flat slope of the 
diagram implies a difficult resolution process. Four recrystallizations were needed to generate 
(R.R)-32 with 98% de starting from enriched material with 82% de. This is in accordance with a 
literature report24'55, where three recrystallization were needed to generate >98% de material starting 
from 78% de. 
Final optical enrichment of Ibuprofen 5 can be achieved by recrystallization of sodium salt 35. 
This racemic compound has a binary phase diagram with a favorable slope and eutectic composition 
for purification compared to Ibuprofen 5. Only one recrystallization is necessary to generate 
material with >98% ее starting from 76% ее55. By use of this method, (R)-ibuprofen (R)-5 was 
obtained with 96% ее after two recrystallization starting from material with 68% ее. 
'COONa 
π 
35 
Asymmetric transformation of Ibuprofen was also tried by combining DBN 29 with two other 
resolving bases, viz. lysine and l-(R)-phenyl-2-p-tolyl-ethylamine (PTEA) 36. The latter is a new 
resolving base for Ibuprofen 5, which will be described in Chapter 6. The reactions were performed 
under optimum conditions established for the combination of MBA 13 and DBN 29, viz. 1 5-2.5 
equiv of resolving base, 0.05 equiv DBN 29 at 110-130°C during 64 h No transformation was 
observed using lysine. Moreover, the Ibuprofen.lysine salt was difficult to isolate and resulted in 
low yields of isolated Ibuprofen after work-up. The use of PTEA 36 resulted in an asymmetric 
transformation at 125°C with 100% yield and 8% ее (Scheme 4-9). Reaction temperatures above 
125°C resulted in amid formation. The low ее is the result of partial formation of a solid solution as 
will be discussed in Chapter 5. Moreover, the physico-chemical properties of the pure 
diastereomeric salts differ only slightly which makes a resolution rather difficult. 
1)0 05 DBN 29 f 
•^
2
^ xXf'C0°" 
(R)-36 /^S^/ (R)-5 yield=l00% 
ee=8% 
Scheme 4-9. Asymmetric transformation of ibuprofen 5 by (R)-PTEA (R)-36 and DBN 29. 
103 
Chapter 4 
4.4.2 Hydratropic Acid and Naproxen 
Crystallization-induced asymmetric transformation of hydratropic acid 4 and naproxen 6 was 
performed under optimum conditions established for Ibuprofen 5. 
The resolving bases MBA 13 and ephedrine 12 were used for hydratropic acid 4 (Table 4-14). 
The best results were obtained using 1.5 equiv of MBA 13 in combination with 0 05 equiv of DBN 
29 at 125°C. This transformation proceeded with 94% yield and 68% ее. The use of ephedrine 12 as 
resolving base gave 95% yield and a low ее of 10% An inefficient resolution process is probably 
the reason for this low ее. 
Table 4-14. Crystallization-induced Asymmetric Transformation of Hydratropic Acid 4a. 
Entry 
1 
2 
3 
4 
Resolving Base 
(equiv) 
5 (S)-13 
2.5 (R)-13 
1.5(R)-13 
1 5 (-)-12 
DBN 
(eq) 
0.1 
0.1 
0.05 
0.05 
Time 
(h) 
20 
64 
64 
64 
Τ 
(°C) 
90 
100 
125 
110 
Yield 
(%)b 
90d 
72 
94 
95 
Ее 
(%)' 
9.6 (R) 
69.0 (S) 
68.3 (S) 
9.5 (R) 
Mother liquor 
(%ee)c 
43.1 (S) 
20.2 (R) 
22.2 (R) 
56.5 (S) 
a) Conditions a mixture of racemic hydratropic acid 4 (2 0 g, 13 4 mmole), enantiopure resolving base 12 or 13 
and DBN 29 was stirred at a maximum temperature giving heterogeneous conditions, under nitrogen The 
mixture was filtered hot at the reaction temperature b) Based on the crystallized salt c) Determined by chiral 
HPLC (Chiralcel ODH) on liberated hydratropic acid 4 d) The mixture is gradually cooled to room temperature 
and filtered 
The asymmetric transformation of naproxen 6 was attempted using 1.5-2.5 equiv of the 
enantiopure resolving bases MBA 13, N-methyl-glucamine 14a and dehydroabiethylamine 15 in 
combination with 0.05 equiv of DBN 29 at 110-130°C. However, no optical enrichment of 
naproxen 6 was observed. 
Methyl and ethyl esters of naproxen 6 form conglomerates which makes them suitable for 
direct resolution via preferential crystallization. Combination of this separation process with in situ 
racemization by a base (i.e. DBN 29, NaOEt) in an alcoholic solution results in an asymmetric 
transformation as patented by Nissan; enantiopure naproxen esters were isolated in 63-87%35 An 
asymmetric transformation of naproxen methyl ester (RS)-20 was tried by the same procedure but 
performing the reaction in the melt (Scheme 4-10). 
Г Л П 1 0 05 DBN 29, melt COOMe 
60°C,64 h 
MeO' ^ " ^ ' (RS)-20 MeO 
Scheme 4-10. Asymmetric transformation of naproxen methyl ester 20. 
An asymmetric transformation was observed with quantitative yield and 27% ее using 0.05 
equiv of DBN 29 at 60°C. The use of 0.5 equiv DBN 29 at 40°C resulted in the isolation of racemic 
20 A complete transformation is probably limited due to a low racemization rate of the unwanted 
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enantiomer due to the low maximum reaction temperature The range between the melting points of 
racemic and enantiopure 20 is 66-90°C This range indicates that heterogeneous conditions are 
obtained at the eutectic temperature of 66°C starting from racemic 20 Addition of DBN 29 to the 
melt will decrease this temperature 
4.5 Discussion and Conclusions 
The racemization of the profens hydratropic acid 4, Ibuprofen 5 and naproxen 6 was 
performed by base-catalyzed racemization in the melt For this fast and mild process DBN 29 is the 
best racemizing base, closely followed by DBU 28 Comparison of racemizations under the same 
conditions gave the following order in profens based on their racemizing ability hydratropic acid 4 
> Ibuprofen 5 > naproxen 6 Racemization of these a-alkylcarboxylic acids is fast compared with 
mandelic acid, an α-hydroxycarboxylic acid (see Chapter 3)444S 
The crystallization-induced asymmetric transformation of profens was studied mainly with 
Ibuprofen 5 as the substrate and ct-methylbenzylamine 13 as the resolving base The mild 
racemization process in the melt was extended to an asymmetric transformation in the melt by two 
approaches The first approach used a resolving base to accomplish both resolution and 
racemization A transformation of Ibuprofen 5 was achieved by using an excess of MBA 13 which 
resulted in a quantitative yield, but in a low ее (6%) In this approach the asymmetric transformation 
is hampered by the racemization process This transformation can be improved using strong chiral 
resolving bases with basicities comparable to amidines and guanidines As a consequence, such 
bases have to be prepared and tested as possible resolving base A few chiral amidines, guanidines 
and 1,4-diazo[2 2 2]octanes are known in the literature56 Currently research in this direction is 
undertaken 
In the second approach, two bases were used, namely enantiopure MBA 13 for the resolution 
of Ibuprofen 5 and an achiral base for the racemization of the unwanted diastereomer in the mother 
liquor Several achiral base were tested in combination with one equiv of MBA 13 in the melt From 
these experiments, several parameters affecting asymmetric transformation were identified, namely 
base strength, ratio of achiral base / resolving base, reaction temperature, solubility, reaction time 
and solvent Optimization of these factors led to an asymmetric transformation of Ibuprofen 5 as 
follows, reaction with 2 5 equiv of MBA 13 in combination with 0 05-0 1 equiv of DBN 29 at 120-
130°C during 64 h gave 85-95% yield with an ее of 60-70% 
Optimization was studied by improvement of either the resolution or the racemization 
process Improvement of the resolution was attempted by seeding, starting from enriched substrate 
hot filtration and omitting stirring Applying hot filtration resulted in the best transformation of 
Ibuprofen 5 The treatment with 1 5-2 5 equiv of MBA 13 in combination with 0 05 equiv of DBN 
29 at 110-130°C during 64-112 h resulted, after hot filtration, in 70-90% yield and an ее of 73-75% 
A net inversion was observed by reacting (S)-ibuprofen (S)-5 with the wrong resolving base (R)-
MBA and DBN 29 
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Mother liquors which were enriched with unwanted isomer indicated that racemization in the 
liquid phase restricts a complete transformation Optimization of the racemization process was 
achieved using more equiv of DBN 29 This resulted in nearly racemic mother liquors, but yields of 
isolated salt were low and the ее's were not improved 
The final improvement of the ее from 75 to 100% is difficult to achieve with MBA 13 as 
resolving base, as was shown by several successive asymmetric transformations of Ibuprofen 5 and 
by constructing the binary phase diagram of Ibuprofen MBA salt 32 This led to new and better 
resolving bases for Ibuprofen 5, which are described in Chapter 5 An improved resolution process 
for Ibuprofen 5 in an asymmetric transformation according to the second approach is currently 
under investigation 
Crystallization-induced asymmetric transformation of hydratropic acid 4 was achieved using 
the optimum conditions established for Ibuprofen 5 Reaction of racemic hydratropic acid 4 with 1 5 
equiv of MBA 13 and 0 05 equiv of DBN 29 resulted, after hot filtration, in 94% yield and an ее of 
68% Improvement should be possible by optimization the combination MBA 13/DBN 29 or by 
applying resolving bases with a more favorable phase diagram The phase diagram of hydratropic 
acid MBA salt is known to be relatively unfavorable because of an unsuitable eutectic point 
(x
eu
=0 33) and a small slope23b 
Workable conditions for the asymmetric transformation of naproxen 6 have not been achieved 
vet However, an asymmetric transformation in the melt of its methyl ester 20 was established using 
0 05 equiv of DBN 29 at 60°C for 64 h This resulted in the isolation of (S)-20 in quantitative yield 
and an ее of 27% ее 
Hence, a relatively mild and fast base-catalyzed racemization process in the melt for profens 
4-6 has been developed The use of this process in combination with resolution procedures resulted 
in crystallization-induced asymmetric transformation in quantitative yields and ee's up to 75% 
Further improvement of the ee's must result from a more detailed study of the resolution processes 
4.6 Experimental Section 
For general remarks, see section 3 4 Racemic and enantiopure (S)-ibuprofen were a gift from DSM 
Andeno, Venlo, The Netherlands The chiral bases N-(p-hydroxybenzyl)-2-(R)-tolyl-ethylamine, 1-
(R)-phenyl-2-jC>-to!yl-ethylamine and N-(p-methoxy-a-hydroxybenzyl)-2-(R)-tolyl-ethylamine were 
gift from Sumitomo Chemical Co Ltd, Japan 
Determination of enantiomeric excess 
The enantiomeric excesses (ee's) of hydratropic acid 4, Ibuprofen 5, naproxen 6 and naproxen 
methyl ester 20 were determined using HPLC (Daicel Chiralcel ODH column, UV-detection at 254 
nm, flow-rate 0 5 ml/mm) (RS)-4 (eluent hexane/2-propanol/trifluoroacetic acid=950/50/2 5, v/v) 
(R)-4 Rt=l 1 8 min, (S)-4 Rt=12 9 min. resolution factor (RS)=2 12, separation factor (a)=l 26 
(RS)-5 (eluent he\ane/2-propanol/tnfluoroacetic acid=980/20/2 5. v/v) (R)-5 Rt=16 3 mm, (S)-5 
Rt=17 8min. RS=1 90, a=l 16 (RS)-6 (eluent hexane/2-propanol/trifluoroacetic acid=950/50/2 5, 
v/v) (R)-6 Rt=19 2 min, (S)-6 Rt=21 9 min, RS=3 00, a=l 22 (RS)-20 (eluent hexane/2-
propanol=95/5. v/v) (R)-20 Rt=l 1 4 min, (S)-20 Rt=12 6 min, RS=2 48. a=l 29 
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The enantiomeric excess of MBA 13 was determined using HPLC (Daicel Chiralpak AD column, 
UV-detection at 254 nm, flow-rate 0 75 ml/min)43 To a solution of 13 (100 μΐ, 0 8 mmole) in dry 
ethyl ether (2 ml) was added MgS0 4 (100 mg) and benzaldehyde (200 μΐ, 2 mmole) and the mixture 
was shaken for 0 5 h The formed îmine 21 was measured on HPLC (RS-21) (eluent hexane/2-
propanol=99/l, v/v) (S)-21 Rt=9 9 mm, (R)-21 Rt=114min 
(RS)-Hydratropic Acid (RS)-4 
A solution of NaC102 ( 179 4 g, 1 6 mole) in water (750 ml) was added dropwise over a period of 3 
h to a stirred mixture of hydratropaldehyde 18 (150 5 g, 1 1 mole) in acetomtnle (750 ml) and 
NaH2P04 H20 (35 9 g, 0 26 mole) in water (300 ml) and 35% hydrogen peroxide (112 ml, 13 
mole) while keeping the temperature at 0-10°C Oxygen evolved from the solution until the end of 
the reaction (3 h) To the stirred solution was added Na2S03 (20 g) to destroy unreacted HOC1 and 
H 2 0 : , followed by the addition of NaHC03 until pH 9-10 The resulting mixture was extracted with 
dichloromethane (three times), acidified with concentrated hydrochloride until pH 1-2 and extracted 
with dichloromethane (four times) The combined organic layers from the acidic extraction were 
dried over MgS04 and concentrated in vacuo to give pure (RS)-4 as an oil (1543 g, 91%) 
Calculated for C9H10O2 71 98 %C, 6 71 %H, found 70 80 %C, 6 80 %H IR (CC14, cm ') ν 2500-
3500 (OH), 1705 (C=0) ' H - N M R (CDCI3. ppm) δ 1 51 (d, 3H, CH3, J=7 2 Hz), 3 73 (q, IH, CH, 
J=7 2 Hz), 7 2-7 4 (m, 5H, ArH) 
(R)-a-methylbenzylamine salt of (S)-hydratropic acid (R,S)-19 
Racemic hydratropic acid (RS)-4 (75 g, 0 5 mole) and (R)-MBA (R)-13 (60 5 g, 0 5 mole) were 
dissolved in a hot mixture of toluene (1 1) and ethanol (250 ml) and allowed to crystallize The 
precipitate was filtered off, washed with cold toluene, dried in vacuo and weighed A fraction of the 
salt obtained was hydrolyzed with IN aqueous sulfuric acid, extracted with dichloromethane, dried 
over MgS0 4 and concentrated in vacuo The ее of liberated 4 was measured using HPLC (Chiralcel 
ODH, eluent hexane/2-propanol/trifluoroacetic acid=950/50/2 5, v/v) The main part of the salt 
obtained was recrystalhzed three times from toluene/ethanol=4/l (v/v) to give pure (R,S)-19 as 
white needles (27 g, 0 1 mole) in 40% theoretical yield and 94% ее Mp 162 6°C, , [cc]D25 -19 0° 
(ethanol, c=l 0) Calculated for C l 7 H 2 l N 0 2 75 25 %C, 7 80 %H, 5 16 %N, found 75 11 %C, 7 87 
%H. 5 20 %N FTIR (KBr, cm'1) ν 2500-3000, 2223 (NH), 1656, 1562 (C=0) Ή-NMR (CDC13, 
ppm) δ 1 37 (d, 3H, CH3CN, J=6 7 Hz), 1 40 (d, 3H, CH3CCO, J=7 1 Hz), 3 55 (q, IH, CHCO. 
J=7 1 Hz), 4 07 (q, IH, CHN, J=6 7 Hz), 5 6 (s, NH 3 + ). 7 1-7 4 (m, 10H. ArH) 
(S)-a-methylbenzylamine salt of (R)-hydratropic acid (S R)-19 
Hydratropic acid 4 (17 8% ее (R), 65 3 g, 0 43 mole) and (S)-MBA (S)-13 (52 7 g, 0 43 mole) were 
dissolved in a hot mixture of toluene/ethanol=4/l (v/v, 1100 ml) and allowed to crystallize The 
precipitate was filtered off, washed with cold toluene, dried in vacuo and weighed A fraction ot the 
salt obtained was hydrolyzed with IN aqueous sulfuric acid, extracted with dichloromethane, dried 
over MgS0 4 and concentrated in vacuo The ее of liberated 4 was measured using HPLC (Chiralcel 
ODH, eluent hexane/2-propanol/trifluoroacetic acid=950/50/2 5, v/v) The principal part of the salt 
obtained was recrystalhzed from toluene/ethanol=4/l (v/v, 600 ml) to give pure (S,R)-19 as white 
needles (31 8 g, 0 12 mole) in 55% theoretical yield and 98% ее Mp 163 5°C Calculated for 
C 1 7 H 2 1 N 0 2 75 25 %C, 7 80 %H, 5 16 %N, found 75 05 %C, 7 80 %H, 5 18 %N FTIR and Ή -
NMR were in full accordance with (R,S)-19 
(S)-Hydratropic acid (S)-4 
The (R)-MBA (S)-hydratropic acid salt (R.S)-19 (20 g, 74 mmole, 94%ee) was hydrolyzed with IN 
aqueous sulfuric acid for one hour at room temperature The resulting mixture was extracted with 
dichloromethane (four times) The combined oiganic layers were extracted with brine dried over 
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MgS0 4 and concentrated in vacuo to give an oil (10 3 g, 93%) which crystallized on standing 
Recrystallization from hexane (10 ml) gave pure (S)-4 (7 0 g, 63%) Mp 30-31°C. [ a ] D 2 5 +79 2° 
(ethanol, c=l 0) HPLC (Chiralcel ODH, eluent hexane/2-propanol/trifluoroacetic acid=950/50/2 5, 
v/v) 99% ее Calculated for C 9 H 1 0 O 2 71 98 %C, 6 71 %H, found 72 22 %C, 6 50 %H FTIR and 
' H - N M R were in full accordance with (RS)-4 
(R)-Hydratropic acid (R)-4 
The (S)-MBA (R)-hydratropic acid salt (S,R)-19 (20 g, 74 mmole, 98%ee) was hydrolyzed with IN 
aqueous sulfuric acid for one hour at room temperature The resulting mixture was extracted with 
dichloromethane (four times) The combined organic layers were extracted with brine, dried over 
MgS0 4 and concentrated in vacuo to give an oil (9 4 g, 85%) which crystallized on standing 
Recrystallization from hexane (20 ml) gave pure (R)-4 in two crops (8 4 g, 76%) Mp 30-31°C, 
[ a ] D 2 S -80 0° (ethanol, c=l 0) HPLC (Chiralcel ODH, eluent hexane/2-propanol/trifluoroacetic 
acid=950/50/2 5, v/v) 99% ее Calculated for C 9 H l 0 O 2 71 98 %C, 6 71 %H, found 72 40 %C, 
6 63 %H FTIR and 'H-NMR were in full accordance with (RS)-4 
(RS)-2-(6-methoxy-2-naphthyl)propiomc acid (naproxen) (RSJ-6 
A mixture of enantiopure (S)-6 (15 0 g, 65 1 mmole) and DBN 29 (8 9 ml, 71 6 mmole) was heated 
to 120°C under a nitrogen atmosphere The homogeneous mixture was stirred for 5 h at 120°C and 
subsequently cooled to room temperature The salt obtained was dissolved in water (500 ml) and 
hydrolyzed with 2N aqueous hydrochloric acid (75 ml) during 0 5 h at room temperature The 
obtained mixture was extracted with dichloromethane (four times) The combined organic layers 
were extracted with water and brine, dried over MgS0 4 and concentrated in vacuo to give pure 
(RS)-6(14 5 g, 97%>) Mp 157°C HPLC (Chiralcel ODH, eluent hexane/2-propanoI/tnfluoroacetic 
acid=950/50/2 5, v/v) 0% ее Calculated for C 1 4 H 1 4 0 3 73 03 %C, 6 13 %H, found 72 88 %C, 5 92 
%H IR (KBr. cm ') ν 2500-3400 (OH), 1700 (C=0) 'H-NMR (CDC13, ppm) δ 1 58 (d. 3H, 
CH3C, J=7 1 Hz), 3 87 (q, IH, CH, J=7 1 Hz), 3 90 (s 3H, CH 3 0), 7 1-78 (m, 6H, ArH) 
Methyl (RS)-2-(6-methoxy-2-naphthyl)propionate (RS)-20 
To a solution of (RS)-6 (2 0 g, 8 7 mmole) in 2,2-dimethoxypropane (30 ml) and methanol (30 ml), 
was added a catalytic amount of p-toluenesulfonic acid The mixture was stirred overnight at room 
temperature, subsequently concentrated and dichloromethane was added The organic solution was 
washed with a saturated solution of NaHC0 3 (three times), 2N aqueous hydrochloric acid (three 
times), water, dried over MgS0 4 and concentrated in vacuo to give pure (RS)-20 (2 2 g, 100%) Mp 
66°C Calculated for C,<H,603 73 75 %C, 6 60 %H, found 73 77 %C, 6 57 %H IR (KBr, c m ' ) ν 
2800-3100 (CH), 1735 (C=0) Ή-NMR (CDC13, ppm) δ 1 57 (d, 3H, CH3C, J=7 1 Hz), 3 66 (s, 
3H, CH3OCO), 3 86 (q, IH, CH, J=7 1 Hz), 3 96 (s, 3H, CH3OAr), 7 1-7 9 (m, 6H, ArH) MS ( C f ) 
m/e (%) 245 (M++l, 23), 244 (M+, 63), 213 (144-OMe), 185 (144-COOMe, 100) 
Methyl (S)-2-(6-methoxy-2-naphthyl)propionate (S)-20 
Preparation of (S)-20 was performed by the same procedure as described for (RS)-20 Starting from 
(S)-6 (2 0 g, 8 7 mmole), pure (S)-20 (2 2 g, 100%) was obtained Mp 89-90°C [ a ] D 2 5 +79 2° 
(chloroform, c=l 0) HPLC (Chiralcel ODH, eluent hexane/2-propanol=95/5, v/v) 97% ее 
Calculated for C , 5 H 1 6 0 3 73 75 %C, 6 60 %H, found 73 95 %C, 6 58 %H IR (KBr, cm ') ν 2800-
3100 (CH), 1735 (C=0) Ή-NMR (CDC13, ppm) δ 1 58 (d, 3H. CH3C, J=7 1 Hz), 3 67 (s, 3H, 
CH3OCO), 3 86 (q, IH, CH, J=7 1 Hz), 3 91 (s, 3H, CH3OAr), 7 1-79 (m, 6H, ArH) MS (Cf ) was 
in accordance with (RS)-20 
Racemization ofprofens (S)-4-6 by DBN 29 in the melt 
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As a typical procedure, a sealed tube, charged with (S)-5 (250 mg, 1.2 mmole) and DBN 29 (164 μΐ, 
1.3 mmole) under nitrogen, was stirred at 90°C for 5 h. The mixture was cooled to 0°C. Water (5 
ml) and IM aqueous sulfuric acid (2 ml) were added to hydrolyse the salt and stirred for 0 5 h at 
room temperature. The resulting mixture was extracted with dichloromethane (three times). The 
combined organic layers were extracted with water and brine, dried over MgS0 4 and concentrated 
in vacuo to give pure 5 as an oil which solidified on standing (243 mg, 97%). H-NMR (CDC13, 
ppm): δ 0.89 (d, 6H, (CH3)2C, J=6.5 Hz), 1.49 (d, 3H, CH3CHCO, J=7.1 Hz), 1.5-2.0 (m, IH, 
CHCH2), 2.44 (d, 2H, CH2, J=7.1 Hz), 3.69 (q, IH, CHN, J=7.1 Hz), 7.0-7.4 (m, 4H, ArH), 10.08 
(broad s, IH, OH)· HPLC (Chiralcel ODH, eluent: hexane/2-propanol/trifluoroacetic 
acid=980/20/2.5, v/v): 18.8% ее (S). 
Racemization of Ibuprofen (S)-5 by lysine in the melt 
A sealed tube, charged with (S)-5 (150 mg, 0.7 mmole) and (S)-lysine (117 mg, 0.8 mmole) in 
dimethyl sulfoxide (1 ml) under nitrogen, was stirred for 5 hours at 110°C. The mixture was cooled 
to 0°C and hydrolized with 2N aqueous hydrochloric acid. The resulting mixture was extracted with 
dichloromethane (three times). The combined organic layers were extracted with brine, dried over 
MgS0 4 and concentrated in vacuo to give pure 5 as an oil which solidified on standing (100%). H-
NMR and HPLC were in full accordance with 5. HPLC (Chiralcel ODH, eluent: hexane/2-
propanol/trifluoroacetic acid=980/20/2.5, v/v): 15.1% ее (S). 
Optical stability of (S)-a-methylbenzylamine (S)-13 
(S)-MBA (S)-13 (5 ml, 39 mmole, 100% ее) was heated at 125°C during 64 h under a nitrogen 
atmosphere. The light yellow mixture was cooled to room temperature. A fraction of obtained 13 
(100 μΐ, 0.8 mmole) was dissolved in diethyl ether. MgS0 4 (100 mg) and benzaldehyde (200 μΐ, 2 
mmole) were added and the mixture was shaken for 0.5 h. The formed imine 21 was analyzed by 
HPLC (Chiralpak AD, eluent: hexane/2-propanol=99/l, v/v): 100% ее (S). 
Hydrolysis ofprofen salts 4-6 (general procedure) 
As a typical procedure, a fraction of Ibuprofen.MB A salt 32 was hydrolyzed with IN aqueous 
sulfuric acid at pH 1-2, stirred for 0.5 h at room temperature and extracted with dichloromethane 
(three times). The combined organic layers were extracted with brine, dried over MgS0 4 and 
concentrated in vacuo to give pure Ibuprofen 5 as a white solid. 
Crystallization-induced asymmetric transformation of Ibuprofen 5 by 5 equiv of (R)-MBA (R)-13 in 
the melt (Approach 1) 
A mixture of racemic Ibuprofen (RS)-5 (1.0 g, 4.9 mmole) and (R)-MBA (R)-13 (3.2 ml, 24.8 
mmole) was heated to 125°C under a nitrogen atmosphere. The nearly homogeneous mixture was 
slowly cooled to 110°C and the resulting heterogeneous mixture was stirred for 64 h. The mixture 
was cooled to room temperature, filtered, washed with hexane and dried to give 1.53 g (97%) of 
pure ibuprofen.(R)-MBA salt 32. 'H-NMR (CDC13, ppm): δ 0.66 (d, 6H, (CH3)2CH, J=6.4 Hz), 1 29 
(d, 6H, 2*CH3CH, J=6.9 Hz), 1.5-2.0 (m, IH, CHCH2), 2.41 (d, 2H, CH2, J=7.0 Hz), 3.32 (q, 
0.55H, CHCO, J=7.0 Hz), 3.35 (q, 0.45H, CHCO, J=7.0 Hz), 3.94 (q, IH, CHN, J=6.8 Hz), 6 8-7 4 
(m, 12H, ArH, NH 3 +). Literature": racemic ibuprofen.(S)-MBA salt (RS,S)-32: 'H-NMR (CDC13, 
ppm)· δ 1.19 and 1.21 (2d, 6H, CH3CHCO and CH3CHN, J=6 9 Hz), 3.23 (q, 0.5 H, CHCO, J=7 0 
Hz), 3 27 (q, 0.5 H, CHCO, J=7.1 Hz). 
A fraction of the salt obtained was hydrolyzed according to the general procedure to give pure 
Ibuprofen 5 as a white solid. The H-NMR was in agreement with 5. HPLC (Chiralcel ODH, eluent: 
hexane/2-propanol/trifluoroacetic acid=980/20/2 5, v/v): 5.8% ее (R). 
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Crystallization-induced asymmetric transformation of Ibuprofen 5 by one equiv of '(R)-MBA (R)-13, 
JO equiv Bu3N and 0 I equiv ofDBN 29 m the melt (approach II) 
A mixture of racemic Ibuprofen (RS)-5 (1 0 g, 4.9 mmole), Bu3N (12 ml, 50.4 mmole) and DBN 29 
(60 μΐ, 0.5 mmole) was heated to 120°C under a nitrogen atmosphere. To the homogeneous mixture 
was added (R)-MBA (R)-13 (0.64 ml, 5.0 mmole) and cooled to 116°C. The heterogeneous mixture 
was stirred for 168 h and subsequently cooled to room temperature in 5 h. The crystallized salt was 
filtered, washed with hexane and dried to give 1.45 g (92%) of pure ibuprofen.(R)-MBA salt 32. 
The ' H - N M R was in full agreement with 32. A fraction of the salt obtained was hydrolyzed 
according to the general procedure to give pure Ibuprofen 5 as a white solid. The H-NMR was in 
full agreement with 5. HPLC (Chiralcel ODH, eluent: hexane/2-propanol/trifluoroacetic 
acid=980/20/2.5, v/v): 31.8% ее (R). By the same procedure, impure Ibuprofen 5 was isolated from 
a fraction of the mother liquor. HPLC (Chiralcel ODH, eluent: hexane/2-propanol/trifluoroacetic 
acid=980/20/2.5, v/v): 55 9% ее (S). 
Crystallization-induced asymmetric transformation of Ibuprofen 5 by one equiv of (S)-MBA (S)-13 
and 0 1 equiv of DBN 29 in DMSO (approach II) 
A mixture of racemic ibuprofen (RS)-5 (1.0 g, 4.9 mmole), (S)-MBA (S)-13 (0.7 ml, 5 5 mmole) 
and DBN 29 (65 μΐ, 0.53 mmole) in dimethyl sulfoxide (0.5 ml) was heated to 140°C under a 
nitrogen atmosphere. The homogeneous mixture was cooled to 120°C and the resulting 
heterogeneous mixture was stirred for 20 h The mixture was cooled to room temperature in 5 h and 
the crystallized salt was filtered, washed with hexane and dried to give 1.44 g (91%) of pure 
ibuprofen.(S)-MBA salt 32. The 'H-NMR was in full agreement with 32 A fraction of the salt 
obtained was hydrolyzed according to the general procedure to give pure Ibuprofen 5 as a white 
solid. The 'H-NMR was in full agreement with 5 HPLC (Chiralcel ODH, eluent: hexane/2-
propanol/trifluoroacetic acid=980/20/2 5, v/v)· 37.5% ее (S). By the same procedure, impure 
ibuprofen 5 was isolated from a fraction of the mother liquor. HPLC (Chiralcel ODH, eluent· 
hexane/2-propanol/trifluoroacetic acid=980/20/2.5, v/v) 49.8% ее (R). 
Crystallization-induced asymmetric transformation of Ibuprofen 5 by 2 5 equiv of (R)-MBA (R)-13 
and 0 05 equiv of DBN 29 in the melt (approach II) 
A mixture of racemic ibuprofen (RS)-5 (1 0 g, 4 9 mmole), (R)-MBA (R)-13 (1 6 ml, 12 5 mmole) 
and DBN 29 (30 μΐ, 0.24 mmole) was heated to 140°C under a nitrogen atmosphere. The almost 
homogeneous mixture was cooled to I30°C and the resulting heterogeneous mixture was stirred for 
64 h. The mixture was cooled to room temperature in 5 h and the crystallized salt was filtered, 
washed with hexane and dried to give 1.35 g (85%) of pure Ibuprofen.(R)-MBA salt 32 The H-
NMR was in full agreement with 32. A fraction of the salt obtained was hydrolyzed according to the 
general procedure to give pure Ibuprofen 5 as a white solid. The H-NMR was in full agreement 
with 5 HPLC (Chiralcel ODH, eluent. hexane/2-propanol/trifluoroacetic acid=980/20/2.5, v/v). 
69 1% ее (R). By the same procedure, impure ibuprofen 5 was isolated from a fraction of the 
mother liquor. HPLC (Chiralcel ODH, eluent: hexane/2-propanol/trifluoroacetic acid=980/20/2.5, 
v/v) 53.8% ее (S). 
Crystallization-induced asymmetric transformation of Ibuprofen 5 by one equiv of (R)-MBA (R)-13 
and 0 01 equiv of DBN 29 in the melt (approach II) 
A mixture of racemic ibuprofen (RS)-5 (2.0 g, 9.7 mmole). (R)-MBA (R)-13 (3 2 ml, 24.8 mmole) 
and DBN 29 (12 μΐ, 0.1 mmole) was heated to 150°C under a nitrogen atmosphere The 
homogeneous mixture was cooled to 135°C and the resulting heterogeneous mixture was stirred for 
64 h. The mixture was cooled to room temperature in 5 h and the crystallized salt was filtered, 
washed with hexane and dried to give 2.58 g (82%) of pure Ibuprofen (R)-MBA salt 32. The 
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' H - N M R was in full agreement with 32 A fraction of the salt obtained was hydrolyzed according to 
the general procedure to give pure Ibuprofen 5 as a white solid The 'H-NMR was in full agreement 
with 5 HPLC (Chiralcel ODH, eluent hexane/2-propanol/trifluoroacetic acid=980/20/2 5 v/v) 
37 5% ее (S) A similar work-up procedure for the mother liquor resulted in the isolation of 0 45 g 
(15%) of pure amid 34 'H-NMR (CDC13, ppm) δ 0 89 (d, 6H, (CHj^CH, J=6 5 Hz), 1 34 (d, 
1 5H, CH3CHCO, J=6 9 Hz), 1 38 (d, 1 5H, CH3CHCO, J=6 9 Hz), 1 50 (d, 3H, CH3CHN, J=7 1 
Hz), 1 6-2 1 (m, IH, СЫСН2), 2 46 (d, 2H, CH2, J=7 1 Hz), 3 52 (q, 0 5H, CHCO, J=7 1 Hz), 3 55 
(q, 0 5H, CHCO, J=7 1 Hz), 5 07 (dq, IH, CHN, J=7 1 Hz, 6 5 Hz), 5 65 (broad d, IH, NH, J=6 5 
Hz) 7 0-7 4 (m, 9H, ArH) Literature" racemic amid (RS,S)-34 ("resonances due to the (S,S)-
diastereomer 34) 'H-NMR (CDCI3, ppm) δ 1 27a (d, 1 5H, CHjCHCO, J=6 9 Hz), 1 31 (d, 1 5H, 
CH3CHCO, > 6 9 Hz), 1 43 a (d, 1 5H, CH3CHN, J=7 1 Hz), 1 44 (d, 1 5H, CH.3CHN, J=7 2 Hz), 
3 45 (q, 0 5H, CHCO. J=7 3 Hz), 3 48a (q, 0 5H, CHCO, J=7 1 Hz) 
Inversion of (S)-ibuprofen (S)-S by 10 equiv of(R)-MBA (R)-13 and 0 ! equiv o/DBN 29 in the melt 
(approach II) 
A mixture of (S)-ibuprofen (S)-5 (1 0 g, 4 9 mmole), (R)-MBA (R)-13 (6 4 ml, 49 6 mmole) and 
DBN 29 (65 μΐ, 0 53 mmole) was heated to 120°C under a nitrogen atmosphere The homogeneous 
mixture was cooled to 100°C and the resulting heterogeneous mixture was stirred for 64 h The 
mixture was cooled to room temperature in 5 h and the crystallized salt was filtered, washed with 
hexane and dried to give 1 37 g (87%) of pure Ibuprofen (R)-MBA salt 32 The H-NMR was in 
full agreement with 32 A fraction of the salt obtained was hydrolyzed according to the general 
procedure to give Ibuprofen 5 as a white solid The 'H-NMR was in full agreement with 5 HPLC 
(Chiralcel ODH, eluent hexane/2-propanol/trifluoroacetic acid=980/20/2 5, v/v) 20 8% ее (R) By 
the same procedure, Ibuprofen 5 was isolated from a fraction of the mother liquor HPLC (Chiralcel 
ODH, eluent hexane/2-propanol/trifluoroacetic acid=980/20/2 5, v/v) 51 l % e e ( S ) 
Crystalhzation-mduced asymmetric transformation of ibuprof en S by 2 5 equiv of (S)-MBA (S)-13 
and 0 05 equiv of DBN 29 in the melt use of hot filtration (approach II) 
A mixture of racemic Ibuprofen (RS)-5 (2 0 g, 9 7 mmole), (S)-MBA (S)-13 (3 2 ml, 24 8 mmole) 
and DBN 29 (65 μΐ, 0 53 mmole) was heated to 110°C under a nitrogen atmosphere The 
heterogeneous mixture was stirred for 64 h The resulting mixture was filtered hot at 110°C, washed 
with octane and dried to give 2 77 g (88%) of pure Ibuprofen (S)-MBA salt 32 The 'H-NMR was 
in full agreement with 32 A fraction of the salt obtained was hydrolyzed according to the general 
procedure to give pure Ibuprofen 5 as a white solid The H-NMR was in full agreement with 5 
HPLC (Chiralcel ODH, eluent hexane/2-propanol/trifluoroacetic acid-980/20/2 5, v/v) 74 9% ее 
(S) By the same procedure, Ibuprofen 5 was isolated from a fraction of the mother liquor HPLC 
(Chiralcel ODH. eluent hexane/2-propanol/tnfluoroacetic acid=980/20/2 5, v/v) 24 1% ее (R) 
Crystallization-induced asymmetric transformation of Ibuprofen 5 by 2 5 equiv of (R)-MBA (R)-13 
and 0 05 equiv of DBN 29 in the melt temperature control (approach II) 
A stirred mixture of racemic Ibuprofen (RS)-5 (2 0 g, 9 7 mmole), (R)-MBA (R)-13 (3 2 ml, 24 8 
mmole) and DBN 29 (65 μΐ, 0 53 mmole) was heated and cooled by the following sequence 
(±0 ГС) step 1 heating to 130CC in 0 5 h, step 2 cooling to 110°C in 20 h with a rate of l°C/h, 
step 3 maintaining the temperature at 110°C for 24 h, step 4 cooling to 30°C in 20 h with a rate of 
4°C/h The resulting mixture was filtered, washed with hexane and dried to give 2 9 g (92%) of pure 
Ibuprofen (S)-MBA salt 32 The H-NMR was in full agreement with 32 A fraction of the salt 
obtained was hydrolyzed according to the general procedure to give pure Ibuprofen 5 as a white 
solid The 'H-NMR was in full agreement with 5 HPLC (Chiralcel ODH, eluent hexane/2-
propanol/tnfluoroacetic acid=980/20/2 5, v/v) 70 5% ее (R) By the same procedure, Ibuprofen 5 
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was isolated from a fraction of the mother liquor HPLC (Chiralcel ODH, eluent hexane/2-
propanol/trifluoroacetic acid=980/20/2 5, v/v) 40 1% ее (S) 
Optical purification of partially enriched (R)-ibuprofen sodium salt (R)-3S 
This method was performed according to a literature procedure" Partially enantiomencally 
enriched R-ibuprofen (R)-5 (8 15 g, 39 5 mmole, 67 8% ее) and sodium hydroxide pellets (1 3 g, 
32 5 mmole) were dissolved in refluxing acetone (100 ml) and allowed to crystallize at room 
temperature The precipitate was filtered off, washed with diethyl ether, dried in vacuo and 
weighed Two fractions of the Ibuprofen sodium salt 35 were obtained which were combined (5 8 g, 
64% total) A fraction of the salt obtained was hydrolyzed with IN aqueous sulfuric acid, extracted 
with dichloromethane, dried over MgS04 and concentrated in vacuo HPLC (Chiralcel ODH, 
eluent hexane/2-propanol/trifluoroacetic acid=980/20/2 5, v/v) 85 5% ее (R) The main part of the 
salt obtained was recrystalhzed from acetone to give pure (R)-35 as a white solid in three fractions 
in 32% yield and 96% ее Mp 229-230°C [a]D 2 5 +4 6° (ethanol, c=0 5) The ' H - N M R (DMSO-
d6/D20=l/l (v/v), ppm) δ 0 71 (d, 6H, (CH3)2CH, J=3 3 Hz), 1 17 (d, 3H, CH3CH, J=7 1 Hz), 1 4-
1 9 (m, IH, CHCH2), 2 28 (d. 2H, CH2, J=6 9 Hz), 3 34 (q, IH, CHCO, J=7 1 Hz), 6 97 (d, 2H, 
ArH, J=8 1 Hz), 7 10 (d, 2H, ArH, J=8 1 Hz) IR (KBr. cm ') ν 3600-2800 (COO"Na+), 1590 
(C=0) 
Optically pure (R)-35 salt was hydrolyzed with IN aqueous sulfuric acid for 1 h at room 
temperature The resulting mixture was extracted with dichloromethane (three times) The 
combined organic layers were extracted with brine, dried over MgS04 and concentrated in vacuo to 
give optically pure (R)-ibuprofen (R)-5 in quantitative yield HPLC (Chiralcel ODH, eluent 
hexane/2-propanol/trifiuoroacetic acid=980/20/2 5, v/v) 96 4% ее (R) Mp 49-50°C [a]D 2 5 -57 5° 
(ethanol, c=l 0) Calculated for C 1 3H I 80 2 75 69 %C, 8 80 %H, found 75 87 %C, 8 82 %H Ή-
NMR (CDCI3, ppm) δ 0 89 (d, 6H, (CH3)2CH, J=6 5 Hz), 1 49 (d, 3H, СЫ3СН, J=7 1 Hz), 1 6-2 0 
(m, IH, CHCH2), 2 44 (d, 2H, CH2, J=7 2 Hz), 3 70 (q, IH, CHCO, J=7 1 Hz), 7 0-7 4 (m, 5H, 
ArH OH) IR (KBr, cm1) ν 3500-2300 (OH), 1720 (C=0) 
Optical purification of partially enriched (R)-Ibuprofen (R)-MBA (R R)-32 
Partly diastereomencally enriched Ibuprofen (R)-MBA salt 32 with an de of 69 1 % (R,R) was 
recrystalhzed from a hot 2-propanol solution A fraction of the salt obtained was hydrolyzed with 
IN aqueous sulfuric acid, extracted with dichloromethane, dried over MgS04 and concentrated in 
vacuo The ее of liberated 5 was measured using HPLC (Chiralcel ODH, eluent hexane/2-
propanol/tnfluoroacetic acid=980/20/2 5, v/v) This procedure was repeated three times to give 
optically pure (R,R)-32 as a white crystalline solid with 98% ее (R) Mp 178°C Calculated for 
C2 1H2 9N02 77 03 %C, 8 93 %H, 4 28 %N, found 77 02 %C, 8 84 %H, 4 35 %N Ή-NMR 
(CDCI3, PPm) δ 0 87 (d, 6H, (CH3)2CH, J=6 3 Hz), 1 32 and 1 35 (2d, 6H, CH.3CHN and 
CH3CHCO, J=6 9 Hz), 16-19 (m, IH, CHCH2), 2 41 (d, 2H, CH2, J=7 0 Hz), 3 47 (q, IH, CHCO, 
J=6 9 Hz), 4 0 (q, 1H, CHN, J=6 9 Hz), 5 8 (s, 3H, NH3+), 7 0-7 4 (m, 9H, ArH) 
Optically pure (R,R)-32 salt was hydrolyzed with IN aqueous sulfuric acid for 1 h at room 
temperature The resulting mixture was extracted with dichloromethane (four times) The combined 
organic layers were extracted with brine, dried over MgS04 and concentrated in vacuo to give 
enantiopure (R)-ibuprofen (R)-5 
Binary phase diagram of Ibuprofen (S)-MBA salt 32 
Optically pure (S,S)- and (R,S)-32 salts were prepared by dissolving equal amounts of enantiopure 
(R)- or (S)-ibuprofen 5 (>98% ее) and (S)-MBA 13 in hot ethanol The salts were allowed to 
crystallize and the precipitate was filtered off, washed with cold ethanol and dried in vacuo 
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(S,S)-32: Mp 178.0°C, [ a ] D 2 5 +0.89° (ethanol, c=1.0). Calculated for C 2 , H 2 9 N 0 2 : 77.03 %C, 8 93 
%H, 4 28 %N; found: 76.77 %C, 8.84 %H, 4.37 %N. ' H - N M R (CDC13, ppm)· δ 0.87 (d, 6H, 
(СЫз)ХН. J=6 5 Hz), 1.32 and 1 35 (2d, 6H, CH3CHN and CH3CHCO, J=6 9 Hz), 1.6-1 9 (m, IH, 
CHCH2). 2 41 (d, 2H, CH2, J=7.1 Hz), 3.48 (q, IH, СЫСО, J=7.0 Hz), 4.00 (q, IH, CHN, J=6 9 
Hz), 5.96 (s, 3H, NH 3 + ), 7 0-7.4 (m, 9H, ArH,) IR (KBr, cm"'), ν 3100-2500, 2220 (NH), 1625, 
1545 (C=0). 
(R,S)-32: Mp 158.6°C, [ a ] D 2 5 -40.0° (ethanol, c=0.1). Calculated for C 2 1 H 2 9 N 0 2 : 77.03 %C, 8.93 
%H, 4.28 %N; found: 77.07 %C, 8.76 %H, 4.39 %N. 'H-NMR (CDCI3, ppm): δ 0.83 (d, 6H, 
(CH3)2CH, J=6 4 Hz), 1.32 and 1.38 (2d, 6H, CH3CHCO and CH3CHN, J=6.9 Hz), 1.6-1.9 (m, IH, 
CHCH2), 2.38 (d, 2H, CH2, J=7.1 Hz), 3.55 (q, IH, CHCO, J=6.9 Hz), 4.02 (q, IH, CHN, J=6 9 
Hz), 5.04 (s, 3H, NH 3 + ), 7.0-7.4 (m, 9H, ArH,). IR (KBr, cm"'): ν 3100-2300, 2200 (NH), 1630, 
1550 (C=0) 
The binary phase diagram of ibuprofen.(S)-MBA salt 32 was determined using a Perkin Elmer 
DSC7 instrument, calibrated with In and Zn or Sn. Samples were prepared according to a method 
described by Jacques. Collet and Wilen58. Mixtures of (R,S)- and (S,S)-32 were prepared by 
dissolving accurately weighed amounts of the salts in ethanol. The obtained solution was 
concentrated and dried in vacuo The composition of obtained mixtures was checked by HPLC on 
liberated Ibuprofen 5 (Chiralcel ODH, eluent: hexane/2-propanol/trifluoroacetic acid=980/20/2.5, 
v/v). Samples of the mixtures (2-10 mg) were weighed with a precision of 0.01 mg and 
encapsulated in stainless steel large volume pans (75 μΐ). Thermograms were recorded at a scanning 
rate of 10 °C/min, a data rate of 0.4-0.8 sec/point and with an empty pan as reference under a 
nitrogen atmosphere. Melting points of the broad peaks are given as the top of the peaks. 
Crystallization-induced asymmetric transformation of Ibuprofen 5 by 2 5 equiv of ' (R)-РТЕ'A (R)-36 
and 0 05 equiv ofDBN29 in the melt (approach II) 
A stirred mixture of racemic Ibuprofen (RS)-5 (1.0 g, 4.9 mmole), (R)-PTEA (R)-36 (2.6 g, 12.1 
mmole) and DBN 29 (35 μΐ, 0.28 mmole) was heated to 150CC in 0 5 h The homogeneous mixture 
was cooled to 125°C in 1 h with a rate of 25°C/h. The resulting heterogeneous solution was 
maintained at this temperature for 64 h and subsequently cooled to room temperature in 8 h with a 
rate of 8°C. The mixture obtained was filtered, washed with hexane and dried to give 1 99 g (100%) 
of pure Ibuprofen.(R)-PTEA salt. 'H-NMR (CDC13, ppm): δ 0.89 (d, 6H, (CH3)2CH, J=6 0 Hz), 
1.47 (d, 3H, CH3CHCO, J=7 1 Hz), 1.6-2.0 (m, IH, (Me)2CH), 2.31 (s, 3H, CH3-Ar), 2.44 (d, 2H, 
CH2CH(Me)2, J=7.0 Hz), 2.8-3 0 (m, 2H, CH2CHN), 3.65 (q, IH, CHCO, J=7.1 Hz), 4.15 (dd, IH, 
CHN, J=7 8 Hz, 8.0 Hz), 5.16 (s, 3H, NH 3 +), 7.0-7.4 (m, 13H, ArH). A fraction of the salt obtained 
was hydrolyzed according to the general procedure to give pure Ibuprofen 5 as a white solid. The 
'H-NMR was in full agreement with 5. HPLC (Chiralcel ODH, eluent. hexane/2-propanol/tri-
fluoroacetic acid=980/20/2.5, v/v)· 7 9% ее (R). 
Crystallization-induced asymmetric transformation of hydratropic acid 4 by I 5 equiv of (R)-MBA 
(R)-I3 and 0 05 equiv of DBN 29 in the melt (approach II). 
A mixture of racemic hydratropic acid (RS)-4 (2.0 g, 13.3 mmole), (R)-MBA (R)-13 (2 5 ml, 19.6 
mmole) and DBN 29 (81 μΐ, 0.66 mmole) was heated to 130°C under a nitrogen atmosphere. The 
almost homogeneous solution was cooled to 125°C and the resulting heterogeneous solution was 
stirred for 64 h. The mixture was filtered hot at 125CC, washed with octane and dried to give 3.4 g 
(94%) of pure hydratropic acid.(R)-MBA salt 19. The Ή-NMR was in agreement with 19. A 
fraction of the salt obtained was hydrolyzed according to the general procedure to give pure 
hydratropic acid 4 The H-NMR was in agreement with 4. HPLC (Chiralcel ODH, eluenf 
hexane/2-propanol/trifluoroacetic acid=950/50/2.5, v/v): 68.3% ее (S) By the same procedure. 
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impure hydratropic acid 4 was isolated from a fraction of the mother liquor HPLC (Chiralcel ODH, 
eluent hexane/2-propanol/trifluoroacetic acid=950/50/2 5, v/v). 22 2% ее (R) 
Cry\talltzatton-induced asymmetric transformation of Methyl (RS)-2-(6-methoxy-2-naphthyl)-
propionate (RS)-20 by 0 05 equiv oj DBN29 m the melt 
A mixture of racemic methyl (RS)-2-(6-methoxy-2-naphthyl)propionate (RS)-20 (1 0 g, 4 2 mmole) 
and DBN 29 (25 μΐ, 0 2 mmole) was heated to 70°C under a nitrogen atmosphere The 
homogeneous solution was cooled to 60°C and seeded with pure (S)-20 The resulting 
heterogeneous mixture was stirred for 64 h and subsequently cooled to room temperature The 
obtained product was dissolved in dichloromethane and extracted with 2 N aqueous hydrochloric 
acid (three times) The organic layer was extracted with brine, dried over MgS04 en concentrated in 
vacuo to give 1 0 g (100%) of pure 20 as a yellow solid The ' H - N M R was in agreement with 20 
HPLC (Chiralcel ODH, eluent hexane/2-propanol =95/5, v/v) 26 8% ее (S) 
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N ew Resolving Bases for Ibuprofen and Mandelic Acid 
5.1 Introduction 
Resolution of a mixture of enantiomers still remains the most important method for the 
industrial synthesis of enantiopure compounds The most frequently applied method is formation 
and selective crystallization of diastereomeric salts The main problem of this process is the search 
for suitable resolving agents Until now, no suitable method is available to predict a resolving agent 
for a given racemate' and 'trial and error' is a quite commonly used method Preferred conditions 
for an efficient resolution are the diastereomeric salts consist of a mechanical mixture of crystals of 
the pure diastereomers (eutectic mixture or conglomerate), both salt pairs crystallize separately and 
there are substantial differences in physico-chemical properties between the diastereomers, 
especially solibihties2 
Optimum conditions (e g concentration, temperature) for a resolution process can be 
determined exactly by construction of the ternary (solubility) phase diagram However, this requires 
a large amount of experimental data Moreover, Kozma et al ' have shown that binary (melting) 
phase diagrams are a good approximation for ternary diagrams especially for the selection and 
qualification of a resolving agent for a given substrate These authors stated that the solubility ratio 
of a pair of diastereomeric salts is nearly constant and temperature independent This is based on the 
observation that the eutectic composition in a ternary and binary phase diagram is nearly identical 
and temperature independent As a consequence, the efficiency of a resolution depends on the 
location of the eutectic and not on the solubility relationship Several important observations were 
made in a study of the melting behavior of diastereomeric salt pairs in relation to resolution 
processes2, viz (1) efficient resolution can be expected if there is at least a 20°C difference between 
the melting points of the pure diastereomers, (n) the salt with the highest melting point will 
crystallize first during a resolution, (in) when one of the salts is crystalline and the other is 
amorphous or forms an oil, the crystalline isomer will precipitate first, (ìv) when one the isomers is 
solvated it will crystallize first during the resolution and usually this will result in a successful 
resolution 
Binary phase diagrams of diastereomeric salt pairs are useful tools in the investigation of 
resolutions (Figure 5-1) The formation or existence of a conglomerate, a primary condition for a 
resolution, can be determined from the corresponding binary phase diagram Moreover, the diagram 
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determines the course of a resolution and the maximum yield (R
max
) and efficiency4 (S) can be 
calculated from the diagram Starting from the racemic composition (x0 5) and going to the isolation 
of a pure diastereomer (p), the following equations can be used to calculate these parameters5 
0 5 - х . 
S = k t = 
1-х.. 
l-2x, 
^ 100% (R
max
=0-50%) 
1-х.. 
(S=0-1) 
(5-1) 
(5-2) 
where χ is the molar fraction of the less soluble diastereomer, к the chemical yield (k=2 for 100%) 
and t the optical purity (t=l for 100% ее) A more successful resolution is expected when the 
diagram has a steeper slope, ι e a larger difference between the melting points of the pure 
diastereomers (T
n
-Tp) and a more eccentric eutectic 
Figure 5-1. Binary phase diagram of an eutectic mixture of diastereomers (conglomerate) 
The use of binary phase diagrams for qualification and selection of resolving agents also has 
some limitations, viz diagrams cannot be constructed when thermal decomposition takes place, the 
role of solvates cannot be observed and both diastereomers are not always available 
The binary phase diagram of a conglomerate can be constructed using the Schroder-van Laar 
ΔΗ, ( \_ Γ 
Л 
equation ln(x) = : (5-3) 
R l x T, 
where χ is the molar fraction, ΔΗ, the enthalpy of fusion and T, the melting point of the pure 
isomers, Τ the melting point of a mixture of molar fraction x, R the gas constant and ι the index for 
the pure isomers This equation may be used under nearly ideal conditions, viz the isomers are 
immiscible in the solid state, the isomers behave ideally in the liquid phase and the heat of fusion is 
independent of the temperature6 
In the design of the crystallization-induced asymmetric transformation of Ibuprofen 1 and 
mandelic acid 2 (see Chapter 3 and 4), optimal resolution conditions are necessary for a successful 
transformation process Therefore, the search for new and better resolving bases applicable in these 
processes is of importance 
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U "COOH COOH 
Figure 5-2. 
Five new resolving bases for Ibuprofen 1 are described in section 5 2, viz (S)-l-(benzyloxy-
methyl)propylamine (BOP) (S)-3, (-)-ephednne (-)-4a, (2S,3R)-(+)-l,2,5,5-tetramethyl-3-phenyl-4-
oxa-1-aza-cyclopentane (TPOAC) (+)-S, (R)-l-phenyl-2-/?-tolylethylamine (PTEA) (R)-6 and (S)-
phenylglycinol (S)-7 In section 5 3 two new resolving bases for mandelic acid 2 are presented, viz 
(-)-jV-methylephednne (-)-4b and (+)-(2S,3R)-4-dimethylamino-3-methyl-l,2-diphenyl-2-butanol 
(DMDB) (+)-8 
OH 
(S)-3 (-)-4a (R=H) 
(-)-4b (R=Me) 
NH, 
(R)-6 OC OH (+)-8 
Figure 5-3. New resolving bases for Ibuprofen 1 and mandelic acid 2 
Binary phase diagrams of these lbuprofenates and mandelates were constructed using 
differential scanning calonmetry (DSC) Experimental data are compared with calculated diagrams 
using the Schroder-van Laar equation (eq 5-3) The diagrams were then used for the qualification of 
resolving bases for the given substrate Also known resolving agents with well-described physico-
chemical data were included 
5.2 Ibuprofen§ 
Ibuprofen 1 can be resolved using either a-methylbenzylamine (MBA)7 9 or lysine* 10 and its 
esters by lipases' The binary phase diagram of Ibuprofen MBA salt 11 was not reported previously 
Therefore, this diagram was constructed as already described in section 4 4 1 (Figure 5-5) This 
diagram reveals the formation of a conglomerate 
NH, 
Η,Ν' CO 
9(S)-MBA 10L-Lysme 
Figure 5-4. 
This study was performed in cooperation with DSM Research, FC-BOC, Geleen, The Netherlands 
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The experimental results were in good agreement with the calculated diagram using the heats 
of fusion and melting points of the pure salts in the Schroder-van Laar equation (5-3) A minor 
deviation (9 kJ/mol) was observed between the experimental and fitted AH ( R S ) .n probably due to a 
minor impurity of (R,S)-11 (98% de) Several of the salt mixtures were analyzed by NMR and 
subjected to elemental analysis There were no indications for the occurrence of solvates 
Figure 5-5. Binary phase diagram of Ibuprofen (S)-MB A 11 
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Both the eutectic position (xeu=0 66) and the flat slope are rather unfavorable for a good 
resolution process The calculated maximum yield of enantiopure (S,S)-11 is limited to 24% starting 
from the racemic composition Resolution according to a patent of Ethyl7" resulted in the isolation of 
(S,S)-U with a de of 81% and in a yield of 78% after three crystallizations Four additional 
recrystalhzations were needed to obtain (R,R)-11 (Cf section 4 4 1) The aforementioned patent 
claims the isolation of optically pure salt 11 in 69% yield after three crystallizations The problems 
expected on the basis of the binary phase diagram are confirmed by this experiment, viz that the 
resolution of 11 is a difficult process 
Lysine 10 is an interesting resolving base because Ibuprofen 1 can be marketed as lysinate salt 
12 The phase diagram of lysinate 12 could not be constructed as no clear melting behavior of these 
salts was observed during the DSC experiments From NMR, DSC and elemental analysis it was 
concluded that a solvate of salt 12 was formed with 0 5 equiv of water 
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The binary phase diagram of ibuprofen.(S)-BOP salt 13 is shown in Figure 5-7. The 
conglomerate has an unfavorable eutectic point (xeu=0.33) which results in a low maximum yield 
and efficiency of 25% and 0.5 respectively. Moreover, the small difference between the melting 
points of the pure diastereomers results in a flat slope and will make a resolution process difficult. 
Some attempted resolution experiments on a small scale of racemic Ibuprofen (RS)-l with (S)-BOP 
(S)-3 confirmed the expected difficulties: ibuprofen was resolved with an efficiency (S) of about 
0.1-0.2. Several other 2-amino-l-butanols were investigated but all formed oily ibuprofenates. 
Figure 5-7. Binary phase diagram of ibuprofen.(S)-BOP 13. 
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With (-)-ephedrine (-)-4a as resolving agent the formation of crystalline salt with ibuprofen 1 
was achieved. However, this ibuprofenate 14 was not suitable for the resolution of ibuprofen 
because it exists as a solid solution (Figure 5-8) as was deduced from thermograms of ibuprofenate 
14 mixtures which showed a single broad peak. The construction of such diagrams is difficult 
because the determination of the beginning and termination of fusion is hard to observe10. The 
diagram was made using the beginning and maximum of the broad peaks for the solidus and 
liquidus curve respectively. The start temperature for melting mixtures of diastereomers was 
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corrected with the width of the peaks of the pure diastereomers (T
max
-T
slarl). A few resolution 
experiments using (-)-ephedrine (-)-4 in several solvents (e.g. toluene, di/jopropyl ether) confirmed 
the formation of a solid solution because only low de's and low yields could be obtained. Several 
substituted ephedrines were studied, however all of them gave ibuprofenates as oils. 
Figure 5-8. Binary phase diagram of ibuprofen.(-)-ephedrine 14. 
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The oxazolidine (+)-5 derived from (-)-ephedrine produced crystalline salts 15 with Ibuprofen 
1. However, some acid-catalyzed decomposition probably caused decomposition of this oxazolidine 
derivative during resolution experiments of ibuprofenate 15. This was demonstrated by formation of 
some Ibuprofen.ephedrine salt 14. The salts 15 were not stable at room. For these reasons 
oxazolidine (+)-5 was not investigated further. 
y 
Θ ^N© О 
COO Η' ' υ ' 
15 
(S)-16 
Figure 5-9. 
ОН 
üTftxaH jomêL· xrro (R)-17 (R)-18 UMe (R)-6 
Figure 5-10. Substituted α-methylbenzylamines (MBAs). 
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Several substituted MBAs" namely 6, 16-18 were studied as possible resolving agents. Only 
(R)-PTEA (R)-6 gave a crystalline ibuprofenate 19. Constructing the phase diagram of ibuprofenate 
19 results in a relatively rare diagram (Figure 5-11). Diastereomeric salt mixtures 19 were analyzed 
by NMR and elemental analysis. It was found that ibuprofen 1 and PTEA (R)-6 form salts in a 1.1 
ratio whitout the inclusion of solvent. Such a diagram is best typified as a solid solution between 
crystalline diastereomeric salts existing as conglomerates".The calculated diagram with the 
Schröder-van Laar equation (5-3) is presented by the solid lines in Figure 5-11. These lines are in 
good agreement with the first observed melting peaks by DSC. The diagram does not represent a 
complete solid solution because no broad single peaks were observed. Most thermograms showed 
two peaks, which were deconvolved12 in some cases. The possibility of the formation of a (1:1) 
double salt was rejected due to the absence of the typical maximum at x=0.5n. The use of PTEA 6 
as resolving agent for ibuprofen 1 was abandoned on the above behavior of this ibuprofenate. 
Figure 5-11. Binary phase diagrams of ibuprofen.(R)-PTEA 19 
170 τ— 
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Finally, (S)-phenylglycinol (S)-7 was studied as possible resolving agent for ibuprofen 1. The 
melting diagram (Figure 5-11) of the ibuprofenate salt 20 indicated the formation of a conglomerate 
with a favorable eutectic composition, moreover the diagram has a steep slope. The calculated 
diagram based on the pure diastereomers is in full agreement with the experimental results. Hence, 
"Enantiopure substituted MBAs (R)-6, (R)-17 and (R)-18 were kind gifts from Sumitomo Chemical Company, Ltd 
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phenylglycinol 7 can be qualified as a potential resolving base for Ibuprofen 1 Based on the 
eutectic point (x
eu
=0 83) a resolution with a maximum yield of 40% and efficiency of 0 8 is 
possible A few resolution experiments of Ibuprofen 1 with (S)-phenylglycinol (S)-7 in acetone or 
toluene/hexane mixtures were in full agreement with the expectations The resolution resulted in the 
isolation of (S,S)-20 as crystalline salt with de's up to 53%, with yields above 50% and efficiencies 
of about 0 5 Some thermograms indicated the existence of more then one crystal form but no clear 
conclusions could be drawn More information is needed to substantiate the existence of 
polymorphism Several other substituted phenylglycinols were synthesized but all of them formed 
oily lbuprofenate salts 
Figure 5-12. Binary phase diagrams of Ibuprofen (S)-phenylglycinol 20 
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The results of the various resolving bases investigated for Ibuprofen 1 are summarized in 
Table 5-1 Based on these results it can be concluded that from this series phenylglycinol 7 is by far 
the most promising resolving base for Ibuprofen 1 A qualification of lysine 10 as resolving base 
based on the binary phase diagram could not be given because it formed a solvate Solvate 
formation of one of the diastereomers usually results m good resolution processes2 The patents on 
the resolution of Ibuprofen 1 by lysine 10 do not give any data of melting points or heats of fusion 
of lbuprofenate 12 However, from the experimental results an efficiency of about 0 5-0 6 could be 
calculated Therefore, phenylglycinol 7 has better prospect as resolving base for Ibuprofen than 
lysine 10 Currently, phenylglycinol 7 is further investigated as resolving base for Ibuprofen 1 
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Salt 
(S,S)-11 
(R,S)-11 
12 
(S,S)-13 
(R,S)-13 
(S,(-))-14 
(R,(-))-i4 
15 
(S,R)-19 
(R,R)-19 
(S,S)-20 
(R,S)-20 
Table 5-1. Resolving Agents for Ibuprofen 1 and Their Resolving Abilities4. 
Type 
conglomerate 
solvate 
conglomerate 
solid solution 
decomposition 
partial solid solution / 
conglomerate 
conglomerate 
AH
c x p 
(kJ/mol) 
59.8 
52.9 
30.0 
37.4 
38.5 
41.5 
53.5 
50.9 
44.4 
20.1 
AH
calc 
(kJ/mol) 
61.8 
58.8 
29.7 
42.6 
44.2 
18.5 
Τ 
1
 cxp (°C) 
178 
159 
80 
93 
94 
121 
167 
160 
152 
104 
' cale 
(°C) 
178 
159 
79 
93 
152 
108 
Τ 
1
 eu CC) 
149 
149 
66 
97 
Xeu 
0.66 
0.33 
0.83 
* пах 
(%) 
24 
25 
40 
^calc 
0.48 
0.5-0.68 
0.51 
0.80 
a) ΔΗ„
ρ
 is the experimental heat of fusion, T„ p the experimental melting point, ДНс1к. and Tca]c are the calculated values 
by the Schroder-van Laar equation (5-3), T
cu
 and x
cu
 were determined using the calculated phase diagram, the 
maximum yield (Я™,,) and efficiency (S) were calculated using equations 5-1, 5-2 and x
eil 
5.3 Mandelic Acid 
Mandelic acid 2 is a widely applied resolving agent for all kind of amines14. Enantiopure 
enantiomers of 2 are commercially available at low prices" Physico-chemically well-studied 
mandelate salts used for resolution purposes are MBA mandelate 21 (Figure 5-13)", 2-
benzylamino-1-butanol mandelate 2 2 " ", (R)-2-fev7-butyl-3-methylimidazolidin-4-one (BMI) 
mandelate 2 3 " " and (+)-cinchonine mandelate 24". Other known resolving agents for mandelic 
acid 2 are brucine20, quinine20, quinidine20, (-)-ephednne2', (-)-2-amino-l-butanol22, amphetamine1" 
and adrenaline161 
Two new resolving bases (-)-Af-methylephednne (-)-4b and (+)-DMDB (+)-8, formed 
crystalline mandelates 25 and 26 respectively. Their resolving ability was studied by their binary 
phase diagrams which showed the formation of conglomerates (Figures 5-13 and 5-14). The 
physico-chemical properties of these conglomerates are summarized in Table 5-2 and were 
compared with known mandelates 21-24 The experimental results of mandelates 25 and 26 are in 
good agreement with the calculated diagrams. However, two deviations were observed when 
comparing the experimental and calculated heats of fusion of (S,(-))-25 and (R,(+))-26. In both 
cases a difference of about 15 kJ/mol was observed. This may imply that the simplified Schröder-
van Laar equation (5-3) is not valid for these sections of the diagrams. This deviation may be 
attributed to several effects, e.g. the specific heat capacities of the pure diastereomers cannot be 
neglected, the mixtures of diastereomers do not show ideal behavior in the solid or liquid phase, 
polymorphism and incongruent melting22. 
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Figure 5-13. Binary phase diagrams of (S)-MBA mandelate 21. 
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Table 5-2. Resolving Agents for Mandelic Acid 2 and Their Resolving Abilities3 
Salt 
(S,S)-21" 
(R,S)-21 
(p)-2223 
(n)-22 
(R,R)-2321 
(S,R)-23 
24" 
(S,(-))-25 
(R,(-))-25 
(S,(+))-26 
(R.(+))-26 
Type 
conglomerate 
conglomerate 
conglomerate 
solvate 
conglomerate 
conglomerate 
Д Н
с х р 
(kJ/mol) 
48.9 
30.3 
32.1 
28.8 
51.5 
30 6 
30.0 
40.9 
59.2 
55.9 
AH
calc 
(kJ/mol) 
13.5 
36.9 
60.0 
40.0 
Τ 
1
 exp (°C) 
177 
109 
108 
84 
118 
79 
91 
132 
169 
158 
τ 
1
 cale (°C) 
106 
90 
129 
168 
158 
Τ 
1
 eu (°C) 
108 
69 
76 
75 
142 
x
eu 
0.09 
0.32 
0 15 
0.18 
0.65 
*Nnax 
(%) 
45 
26 
41 
39 
23 
^calc 
0.9 
0 45 
0 82 
0.3-0.5 
0.78 
0 46 
"^exp 
0.86 
0 32 
0.82 
a) ΔΗ„
ρ
 is the experimental heat of fusion, Т
е ч р
 the experimental melting point and S„p the experimental efficiency, 
ДН
са
,
с
 and T „ k are the calculated values by the Schröder-van Laar equation (5-3), Tcll and xtll were determined by 
using the calculated phase diagram, the maximum yield (R,„„) and efficiency (Scak) were calculated by equations 
5-1, 5-2 and xell. 
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Figures 5-14 and 5-15. Binary phase diagrams of 
(+)-DMDB mandelate 26 and (-)-iV-methyl-ephedrine mandelate 25 
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(S,(-))-25 (R,(-))-25 
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The results in Table 5-2 clearly reveal that MBA 9 is by far the most appropriate resolving 
base for mandelic acid 2 (Figure 5-13). The eutectic composition of the corresponding mandelate 
salt 21 lies toward the end of the diagram resulting in an almost ideal efficiency and yield. 
Moreover, the large difference between the melting points of the pure salts results in a steep slope of 
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the diagram and both enantiomers of MBA 9 are readily available at the same prize. However, the 
use of primary amine MBA 9 as resolving and/or racemizing agent for carboxyhc acids may cause 
some problems in asymmetric transformations, as was shown in Chapter 3. Amid formation may 
occur at higher temperatures and the racemizing ability of the weakly basic amine is negligible and 
therefore not applicable for use in asymmetric transformations. These drawbacks can be 
circumvented through the use of tertiary amine (-)-jV-methylephedrine (-)-4b as resolving agent for 
mandelic acid 2. The resolving ability of this base is good and successful resolution is possible. 
(+)-DMDB 8 seems to be of little use as resolving agent for mandelic acid 2 mainly because 
of the unfavorable eutectic point. A third base tested, (S)-jV,A'-dimethyl-a-methylbenzylamine (S)-
16, formed no crystalline mandelate salts. 
5.4 Summary 
New resolving bases for Ibuprofen 1 and mandelic acid 2 were studied and qualified by their 
binary phase diagrams of the corresponding salts. It was shown that analysis of the binary phase 
diagrams gives a good prediction for a resolution process. The first important feature is that the 
phase diagram must correspond with a conglomerate The next item is that the maximum yield and 
efficiency can be calculated from the eutectic position. Comparing these parameters for several 
resolving agents for a given substrate allows a reliable qualification of these resolving agents 
Five new resolving bases were considered for Ibuprofen 1, viz. (S)-l-(benzyloxymethyl)-
propylamine (BOP) (S)-3, (-)-ephedrine (-)-4a, (2S,3R)-(+)-l,2,5,5-tetramethyl-3-phenyl-4-oxa-l-
aza-cyclopentane (TPOAC) (+)-5, (R)-l-phenyl-2-p-tolylethy lamine (PTEA) (R)-6 and (S)-
phenylglycinol (S)-7, which formed crystalline salts. (-)-Ephedrine ibuprofenate 14 turned out to be 
a solid solution, (+)-TPOAC ibuprofenate 15 underwent decomposition, (R)-PTEA ibuprofenate 19 
was a partial solid solution/conglomerate. Therefore, these three bases are not suitable for resolution 
purposes. (S)-BOP ibuprofenate 13 and (S)-phenylglycinol ibuprofenate 20 were conglomerates as 
required for a resolution. Their resolving ability was calculated from the binary phase diagrams and 
compared with the known resolving agents for Ibuprofen 1, viz. MBA 9 and lysine 10. These results 
clearly reveal that phenylglycinol 7 has the best prospects for the resolution of Ibuprofen 1. 
In a preceding chapter (see section 4.4) MBA 9 was used as the resolving base in combination 
with the strong base DBN in the asymmetric transformation of Ibuprofen 1. This process resulted in 
quantitative yields and ee's of Ibuprofen up to 75% (Chapter 4). It is predicted that employing 
phenylglycinol 7 in the same process will lead to even better results. 
Two new resolving bases for mandelic acid 2 were studied, viz. (-)-yV-methylephedrine (-)-4b 
and (+)-(2S,3R)-4-dimethylamino-3-methyl-l,2-diphenyl-2-butanol (DMDB) (+)-8. Both bases 
formed crystalline mandelates as conglomerates. Their resolving ability was deduced from the 
binary phase diagrams and compared with several known resolving bases for mandelic acid 2, e.g. 
MBA 9. These results revealed that (-)-N-methylephedrine (-)-4b is a good resolving base for 
mandelic acid 2 while (+)-DMDB (+)-8 qualifies poorly. However, it is evident that MBA 9 is by 
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far the best resolving base for mandehc acid 2 Only when primary amine MBA 9 might cause some 
problems, such as amide formation, tertiary amine 7V-methylephednne 4b is a good alternative 
5.5 Experimental Section 
For general remarks see section 3 4 
Racemic and enantiopure (S)-ibuprofen were a kind gift from DSM Andeno, Venlo, The 
Netherlands (R)-ibuprofen was prepared by purification of diastereomencally enriched (R)-
lbuprofen (R)-MBA salt or (R)-ibuprofen sodium salt as described in section 4 6 The chiral bases 
A'-0-hydroxybenzyl)-2-(R)-.P-tolyl-ethylamine, l-(R)-phenyI-2-p-tolyI-ethylamine and N-(p-
methoxy-o-hydroxybenzyl)-2-(R)-^-tolyl-ethylamine were a kind gift from Sumitomo Chemical Co 
Ltd.Japan 
Enantiomeric excesses of Ibuprofen and mandehc acid were determined using chiral HPLC (Daicel 
Chiralcel ODH column, UV-detection at 254 run, flow-rate 0 5 ml/min) as described m section 3 4 
and 4 6 Ibuprofen (eluent hexane/2-propanol/trifluoroacetic acid=980/20/2 5, v/v), mandehc acid 
(eluent hexane/2-propanol/trifluoroacetic acid=875/125/2 5, v/v) 
DSC 
DSC thermograms were determined using a Perkin Elmer DSC7 instrument, calibrated with In and 
Zn or Sn Samples (2-10 mg) were weighed with an accuracy of 0 01 mg and encapsulated in 
stainless steel large volume pans (75 μΐ) Thermograms were recorded at a scanning rate of 10 
°C/min, a data rate of 0 4-0 8 sec/point and with an empty pan as reference under a nitrogen 
atmosphere Melting points are given as the top of the peaks because of broad peaks If necessary, 
deconvolution of peaks was performed using PeakFit™ version 4 for Win32 (Jandel Scientific 
Software) Pearson IV peaks were used as peak description 
Preparation of salts 
Pure diastereomenc salts were prepared by mixing equimolar amounts of enantiopure base and acid 
1 or 2 in ethanol The salts obtained were allowed to crystallize, filtered and dried in vacuo 
Diastereomenc salt mixtures were prepared as described by Jacques, Collet and Wilen24 Accurately 
weighed amounts of the pure salts were dissolved in ethanol and the solution obtained was 
concentrated and dried in vacuo The composition of mixtures obtained were analyzed by chiral 
HPLC on liberated Ibuprofen 1 or mandehc acid 2 
Hydrolysis of Ibuprofen and mande l ¡с acid salts (general procedure) 
Ibuprofenates were hydrolyzed with IN aqueous sulfuric acid at pH 1-2, stirred for 0 5 h at room 
temperature and extracted with dichloromethane (three times) The combined organic layers were 
extracted with brine, dried over MgS04 and concentrated in vacuo to give Ibuprofen 1 
Mandelates were hydrolyzed with 2N aqueous hydrochloric acid at pH 1-2, stirred for 0 5 h at room 
temperature and extracted with ethyl acetate (three times) The combined organic layers were 
extracted with brine, dried over MgS04 and concentrated in vacuo to give mandehc acid 2 
(2S,3R)-1,2 5,5-tetramethyl-3-phenyl-4-oxa-l-aza-cyclopentane (+)-(2S,3R)-5 
A solution of (-)-ephednne 4a (24 g, 140 mmole) and p-toluenesulfonic acid (2 5 g, 14 mmole) in a 
mixture of chloroform (100 ml) and 2.2-dimethoxypropane (90 ml, 700 mmole) was refluxed for 
one week The mixture was then cooled to room temperature, concentrated and dissolved in 
dichloromethane (100 ml) This solution was extracted twice with IN aqueous sodium hydroxide 
and concentrated in vacuo The product was purified by column chromatography (flash, sihcagel 
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60H, dichloromethane/ methanol/Et3N=600/100/2, v/v) to give pure (+)-(2S,3R)-5 (4.4 g, 15%). Mp 
40-42°C, [ a ] D 2 5 +17.7° (ethanol, c=1.0). Literature25: Mp 39-43°C, [ a ] D 2 5 +22.0° (ethanol). 
Calculated for C 1 3 H 1 9 NO: 76.06 %C, 9.33 %H, 6.82 %N; found: 75.76 %C, 9.19 %H, 6 88 %N. H-
NMR (CDCI3, ppm): δ 0.63 (d, 3H, CH3CH, J=6.4 Hz), 1.21 (s. 3H, СЫ3С), 1.52 (s, 3H, СЫ3С), 
2.26 (s, 3H, CH3N), 3.14 (dq, IH, CHN, J=6.4 & 8.0 Hz), 5.03 (d, IH, CHP, J=8.0 Hz), 7.2-7.4 (m, 
5H, ArH). MS (EI): m/e (%) 206 (M + +l, 18), 190 (M+-Me, 33), 148 (206-acetone, 100), 133 (148-
Me, 6). 
N,N-dimethyl-(S)-a-methylbenzylamine (S)-16 
The reductive alkylation of (S)-a-methylbenzylamine (S)-9 was performed following an 
Eschweiler-Clark procedure26. (S)-a-Methylbenzylamine (S)-9 (23.5 ml, 210 mmole) was added 
dropwise to cooled (0°C) formic acid (62 ml, 1 mole) while stirring. To the stirred clear solution 
formaldehyde (45 ml, 600 mmole) was gradually added. This mixture was heated to 100°C and 
stirred until no more gas evolved and then cooled to room temperature. 4N aqueous hydrochloric 
acid (100 ml) was added and the resulting solution was concentrated in vacuo under ice cooling. 
The solid product was dissolved in a mixture of water (60 ml) and 18N aqueous sodium hydroxide 
(50 ml), and then extracted with diethyl ether (four times) The combined organic layers were dried 
over MgS0 4 and concentrated in vacuo to give (S)-16 as an oil (36 g). The product was purified by 
distillation (74.5°C, 13 mm Hg) to give pure (S)-16 as an oil (18.5 g, 62%). [ a ] D 2 5 -63 2° (neat, 
1=1). Literature27: (R)-16: [a]D Ï 5 +61.8° (neat, 1=1), (S)-16: [a]D25 +32 2° (neat, 1=0.5) ' H - N M R 
(CDCI3, ppm): δ 1.36 (d, 3H, СЫ3СН, J=6.8 Hz), 2.16 (s, 6H, N(CH3)2), 3.22 (q, IH, CH, J=6.8 
Hz), 7 1-7.3 (m,5H, ArH). 
(S)-1 -(benzyloxymethyl)propylamine (S)-3 
Amine (S)-3 was prepared using the Williamson reaction28. To a slurry of sodium hydride (6.6 g, 
120 mmole) in dry tetrahydrofuran (50 ml) under a nitrogen atmosphere gradually was added (S)-2-
amino-1-butanol (10.0 g, 110 mmole). The mixture was stirred for 17 h at 80°C and then a solution 
of benzylchlonde (15.6 g, 250 mmole) in dry tetrahydrofuran (100 ml) was added dropwise. The 
resulting solution was stirred for 20 h at 70°C and subsequently cooled to room temperature. Ethyl 
acetate (100 ml), methanol (100 ml) and water (100 ml) were added and the resulting solution was 
concentrated until a volume of about 100 ml. Water (200 ml) was added, the mixture was acidified 
to pH 1-2 and extracted twice with dichloromethane. The water layer was treated with sodium 
hydrogen carbonate until pH 11-12 and extracted with dichloromethane (three times). The 
combined organic layers were dried over MgS0 4 and concentrated in vacuo to give pure (S)-3 as an 
oil (15.2 g, 77%). [ a ] D 2 5 -18.1° (methanol, c=1.0). IR (CC14, cm"1): ν 3400-2800 (NH), 1100 (C-O). 
'H-NMR (CDCI3, ppm): δ 0.85 (t, 3H, CH3CH2, J=7.0 Hz)), 1.0-1 8 (m, 4H, СЫ2СН3, NH2) 2.8-3 0 
(m, IH, CH), 3.1-3.5 (m, 2H, OCH2CH), 4.52 (s, 2H, OCH2Ar), 7.1-7.4 (m, 5H, ArH). Literature29· 
[a] D -15.7 and -18.9° (ethanol, c=1.5), IR and H-NMR were identical with those described above. 
(S)-lysine ibuprofenate 12 
The salts were prepared according to the general procedure using a mixture of water/ethaol=95/5 
(v/v) as the solvent. 
(S,S)-12: Calculated for C 1 9 H 3 2 N 2 O 4 .0 5 H 2 0 : 63.13 %C, 9.20 %H, 7 75 %N; found: 63.20 %C, 
9.06 %H, 7 63 %N. 'H-NMR (D 2 0, ppm): δ 0 84 (d, 6H, (CH3)2CH, J=6 6 Hz), 1.2-2.0 (m, 10H, 
(CH2)3, CH3CH, CH(CH3)2), 2.45 (d, 2H, CH2Ar, J=6 9 Hz), 2.97 (t, 2H, CH2N, J=7.2 Hz), 3.4-3.8 
(m, 2H, CHN, CHAr), 7.0-7.4 (m, 4H, ArH). 
(RS,S)-12. Calculated for C,9H3 2N2O4.0.5 H 2 0 : 63.13 %C, 9.20 %H, 7 75 %N; found: 63 34 %C, 
8.84 %H, 7.73 %N. 'H-NMR (D 2 0, ppm): δ 0.85 (d, 6H, (CH3)2CH. J=6.6 Hz), 1.2-2.0 (m, 10H, 
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(СЩз, СЫзСН, СЫ(СН3)2), 2.45 (d, 2H, CH2Ar, J=7.1 Hz), 2.99 (t, 2H, CH 2N, J=7.6 Hz), 3.4-3.8 
(m, 2H, CHN, CHAr), 7.0-7.4 (m, 4H, ArH). 
(S)-1 -benzyloxymethyDpropylamme ibuprofenate 13 
(S.S)-13. Calculated for C 2 4 H 3 5 N0 3 - 74.77 %C. 9 15 %H, 3 63 %N; found: 74.58 %C, 9.17 %H, 
3.58 %N. IR (KBr, cm"1): ν 3100-2500, 2190 (NH), 1640, 1550, 1520 (C=0), 1100 (C-O). Ή-NMR 
(CDClj, ppm): δ 0.7-1 0 (m, 9H, (СНз)2СН, СЫ3СН2), 1.2-1 6 (m, 5Н, СЫ2СН3, СН3СНСО) 1.6-
2 0 (m, IH, СЫ(СН3)2), 2.40 (d. 2Н, СЫ2СН(СН3)2, J=7.0 Hz) 2.8-3.1 (m, IH, CHN), 3 1-3.7 (m, 
ЗН, СЫСО, ОСЫ2СН), 4.46 (s, 2Н, ОСЫ2Аг), 5.43 (S, ЗН, NH 3 + ), 6.9-7.5 (m, 9Н, АгЫ). 
(RS,S)-13. Calculated for C 2 ,H 3 ,N0 3 . 74.77 %C, 9 15 %H, 3.63 %N; found: 74.55 %C, 9 16 %H, 
3.60 %N IR (KBr, cm"1): ν 3100-2200, 2100 (NH), 1630, 1550, 1530 (C=0). ' H - N M R (CDC13, 
ppm): δ 0.7-1 0 (m, 9H, (СЫз)2СН, СЫ3СН2), 1.2-1.5 (m, 5Н, СЫ2СН3, СН3СНСО) 1 6-1.9 (m, 
IH, СЫ(СН3)2). 2.40 (d, 2Н, СЫ2СН(СН3)2, J=7.0 Hz) 2.8-3.0 (m, IH, CHN), 3.1-3.7 (m, ЗН, 
СНСО, ОСЫ2СН), 4.46 (s, 2Н, ОСН2Аг), 5 84 (S, ЗН, NH 3 + ), 6.9-7.5 (m, 9Н, ArH). 
(-)-Ephedrme ibuprofenate 14 
(S,(-))-14 Calculated for C 2 3 H 3 4 N0 3 - 74.16 %C, 9.20 %H, 3 76 %N; found: 74.56 %C, 9.06 %H, 
3 86 %N. IR (KBr, cm"1): ν 3500-2000 (OH, NH). 1580-1560 (C=0). 'H-NMR (CDC13, ppm): δ 
0.83 (d, 6H, (СЫз)2СН, J=6.4 Hz), 0.86 (d, 3H, CH3CHN, J=6 6 Hz), 1.41 (d, 3H, CH3CHCO, 
J=7.1 Hz), 1 5-1.9 (m, IH, CHCH2), 2.28 (s, 3H, CH3N), 2.37 (d, 2H, CH2, J=7.1 Hz), 2 76 (dq, IH, 
CHN, J=6 6 & 1.7 Hz), 3.55 (q, IH, CHCO, J=7.1 Hz), 5.06 (d, IH, CHOH, J=1.7 Hz)), 6.9-7.4 (m, 
9H, ArH), 7.6 (s, 3H, NH 2 + , OH). 
(RS,(-))-14: Calculated for C 2 3 H 3 4 N 0 3 : 74.16 %C, 9.20 %H, 3 76 %N; found: 74.08 %C, 8 89 %H, 
3 76 %N IR (KBr, cm"1): ν 3500-2100 (OH, NH), 2490 (NH), 1560 (C=0). 'H-NMR (CDC13, 
ppm): δ 0.83 (d, 6H, (CH3)2CH, J=6.4 Hz), 0.86 (d, 3H, CH3CHN, J=6.6 Hz), 1 39 (d, 3H, 
CH3CHCO, J=7.1 Hz), 1.5-1.9 (m, IH, CHCH2), 2.24 (s, 3H, CH3N), 2 35 (d, 2H, CH2, J=7.1 Hz), 
2 76 (dq, IH, CHN, J=6.6 & 1.7 Hz), 3.52 (q, IH, CHCO, J=7 1 Hz), 5.07 (d, IH, CHOH, J=1.7 
Hz)), 6.9-7.4 (m, 9H, ArH), 8.2(s, 3H, N H 2 \ OH). 
(R)-1-phenyl-2-p-tolylethylamme ibuprofenate 19 
(S,R)-19: [a]o +70 9° (ethanol, c=1.0). Calculated for C 2 8 H 3 5 N 0 2 : 80 54 %C, 8.45 %H, 3 35 %N; 
found: 80.30 %C, 8.41 %H, 3.42 %N IR (KBr, cm"'): ν 3200-2300 (NH), 1625 (C=0). Ή-NMR 
(CDC13, ppm): δ 0.89 (d, 6H, (CH3)2CH, J=6.0 Hz), 1 47 (d, 3H, CH3CHCO, J=7.1 Hz), 1.6-2.0 (m, 
IH, CH(CH3)2), 2.31 (s. 3H, CH3Ar), 2.44 (d, 2H, CH 2CH(CH 3) 2, J=7.0 Hz), 2.8-3.0 (m, 2H, 
CH2CHN), 3.65 (q, IH, CHCO, J=7 1 Hz), 4 14 (dd, IH, CHN, J=7.8 & 8.0 Hz), 5.16 (s, 3H, 
NH3
+). 7.0-7.4 (m, 13H,ArH,). 
(R,R)-19: [ a ] D 2 5 +27.3° (ethanol, c=0.3). Calculated for C 2 8 H 3 5 N 0 2 . 80.54 %C, 8.45 %H, 3 35 %N; 
found. 79 83 %C. 8.29 %H, 3.51 %N. IR (KBr, cm"1): ν 3200-2300, 2200-2100 (NH), 1615 (C=0) 
Ή-NMR (CDC13, ppm): δ 0.88 (d, 6H, (CH3)2CH, J=6.5 Hz), 1.43 (d, ЗН, CH3CHCO, J=7.1 Hz), 
1.6-2.0 (m, IH, CH(CH3)2), 2.30 (s, 3H, CH3Ar), 2.42 (d, 2H, CH 2CH(CH 3) 2, J=7.1 Hz), 2.8-3.0 
(m, 2H, CH2CHN), 3.60 (q, IH, CHCO, J=7.2 Hz), 4.12 (dd, IH, CHN, J=7.8 & 7 8 Hz), 5.17 (s, 
3H, NH3
+), 6.9-7.4 (m, 13H, ArH,). 
(RS,R)-19: Calculated for C 2 8 H 3 5 N0 2 - 80.54 %C, 8.45 %H. 3.35 %N; found: 80.61 %C, 8 41 %H, 
3 42 %N IR (KBr, cm"1): ν 3200-2300, 2200-2100 (NH), 1620 (C=0). Ή-NMR was identical to 
(S,R)- and (R,R)-19. 
(S)-Phenylglycinol ibuprofenate 20 
(S.S)-20: Calculated for C 2 l H 2 9 N 0 3 : 73.44 %C, 8.51 %H, 4.08 %N; found: 73.29 %C, 8 50 %H, 
4.25 %N. IR (KBr, cm"1): ν 3500-2200, 2180 (OH, NH), 1640, 1550-1520 (C=0). Ή-NMR 
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(CDCI3, ppm) δ О 88 (d, 6H, (СЫ3)2СН, J=6 7 Hz), 1 45 (d, 3H, CH3CHCO, J=7 1 Hz), 1 6-2 0 (m, 
IH, CHCH2). 2 42 (d, 2H, CH2Ar. J=7 1 Hz), 3 4-3 8 (m, 3H, CH2OH, CHCO), 4 10 (dd, IH, CHN, 
J=8 5 & 4 3 Hz), 4 76 (s, 4H, OH, NH 3 +), 6 9-7 5 (m, 9H, ArH) 
(RS S)-20 Calculated for C 2 1 H 2 9 N 0 3 73 44 %C, 8 51 %H, 4 08 %N, found 72 85 %C, 8 37 %H, 
4 06 %N IR (KBr, c m 1 ) ν 3500-2200, 2160 (OH, NH), 1660, 1550 (C=0) ' H - N M R (CDCI3, 
ppm) δ 0 89 (d, 6H, (СЫз)2СН, J=6 5 Hz), 1 46 (d, 3H, CH3CHCO, J=7 2 Hz), 1 6-2 0 (m, IH 
CHCH2), 2 43 (d, 2H, CH2Ar, J=7 0 Hz), 3 5-3 8 (m, 3H, CH2OH, СЫСО), 4 11 (dd, IH, CHN, 
J=8 5 & 4 2 Hz), 4 76 (s, 4H, OH, NH 3 +), 6 9-7 5 (m, 9H, ArH) 
(-)-N-methylephednne mandelate 25 
(S.(-))-25 [ a ] D 2 5 +24 6° (ethanol, c=l 0) Calculated for C 1 9 H 2 S N 0 4 68 86 %C, 7 60 %H, 4 23 %N, 
found 68 59 %C. 7 55 %H, 4 26 %N IR (KBr, cm ') ν 3500-3000 (OH), 3000-2100 (NH), 1600 
(C=0) 'H-NMR (CDCI3, ppm) δ 1 00 (d, 3H, CH3CH, J=6 9 Hz), 2 67 (s, 6H, N(CH3)2), 3 14 (dq, 
IH, СЫСН3, J=2 1 & 6 9 Hz), 4 97 (s, IH, CHCO), 5 41 (d, IH, CHO, J=2 1 Hz)), 7 0-7 5 (m, 13H, 
ArH, NH+, 20H) 
(R,(-))-25 [ a ] D 2 5 +65 8° (ethanol, c=l 0) Calculated for C 1 9 H 2 5 N 0 4 68 86 %C, 7 60 %H, 4 23 
%N, found 68 67 %C, 7 61 %H, 4 25 %N IR (KBr, cm ') ν 3500 (OH), 3400-2200 (NH), 1600 
(C=0) 'H-NMR (CDCI3, ppm) δ 1 00 (d, 3H, CH3CH, J=7 1 Hz), 2 70 (s, 6H, N(CH3)2), 3 12 (dq, 
IH, CHCH3, J=2 0 & 7 1 Hz), 4 94 (s, IH, CHCO), 5 36 (d, IH, CHO, J=2 1 Hz), 7 0-7 5 (m, 13H, 
ArH, N H \ 20H) 
(RS,(-))-25 Calculated for C 1 9 H 2 5 N 0 4 68 86 %C, 7 60 %H, 4 23 %N, found 68 49 %C, 7 58 %H, 
4 26 %N IR (KBr, c m ' ) ν 3500-3000 (OH), 3000-2100 (NH), 1600 (C=0) 'H-NMR (CDC13, 
ppm) δ 1 00 (d, 3H, CH3CH, J=6 7 Hz), 2 69 (s, 6H, N(CH3)2), 3 13 (dq, IH, CHCH3, J=2 0 & 6 7 
Hz), 4 96 (s, IH, CHCO), 5 39 (d, IH, CHO, J=2 0 Hz), 7 0-7 5 (m, 13H, ArH, NH+, 20H) 
(+)-(2S 3R)-4-dimethylamino-3-methyl-l 2-dtphenyl-2-butanol mandelate 26 
(S,(+))-26 [ a ] D 2 5 +47 8° (ethanol, c=l 0) Calculated for C 2 7 H 3 3 N 0 4 74 76 %C, 7 64 %H, 3 22 
%N, found 74 36 %C, 7 58 %H, 3 23 %N FTIR (KBr, cm ') ν 3500-3000, 3401, 3162 (OH) 
3000-2000, 2640, 2400 (NH), 1617 (C=0) 'H-NMR (CDCI3, ppm) δ 0 96 (d, 3H, CH3CH, J=6 7 
Hz), 1 9-2 8 (m, 3H, CHCH3, CH2Ar), 2 40 (s, 6H, N(CH3)2), 3 0-3 4 (m, 2H, CH2N), 4 96 (s, IH, 
CHO), 7 0-7 6 (m, 15H, ArH), 8 06 (s, 3H, NH+, 20H) 
(R,(+))-26 [ a ] D 2 5 -28 9° (ethanol, c=l 0) Calculated for C^HjjNO, 74 76 %C, 7 64 %H, 3 22 
%N, found 74 36 %C, 7 59 %H, 3 23 %N FTIR (KBr, cm ') ν 3500-3000, 3372, 3244 (OH), 
3000-2000 (NH), 1623 (C=0) 'H-NMR (CDCI3, ppm) δ 0 95 (d, 3H, CH3CH, J=6 5 Hz), 1 9-2 9 
(m, 3H, CHCH3, CH2Ar), 2 40 (s, 6H, N(CH3)2), 3 0-3 4 (m, 2H, CH2N), 4 96 (s, IH, CHO), 6 28 
(s, 3H, N H \ 20H), 7 0-7 6 (m, 15H, ArH) 
(RS,(+))-26 Calculated for C 2 7 H3 3 N0 4 74 76 %C, 7 64 %H, 3 22 %N, found 74 36 %C, 7 58 %H, 
3 23 %N FTIR (KBr, cm ') ν 3500-3000. 3372, 3164 (OH), 3000-2100 (NH), 1617 (C=0) Ή -
NMR (CDCI3, ppm) δ 0 97 (d, 3H, CH3CH, J=6 5 Hz), 1 9-2 9 (m, 3H, CHCH3, CH2Ar), 2 41 (s, 
6H, N(CH3)2), 3 0-3 4 (m, 2H, CH2N), 4 96 (s, IH, CHO), 6 65 (s, 3H, NH+, 20H), 7 1-75 (m, 
15H,ArH) 
Resolution of Ibuprofen I by (S)-MBA (S)-9 
Ibuprofen 1 was resolved following a procedure of Ethyl7' Racemic Ibuprofen (RS)-l (1 03 g, 5 0 
mmole) and tnethylamine (0 7 ml, 5 0 mmole) were dissolved in octane (1 ml) under a nitrogen 
atmosphere The stirred mixture was heated to 125°C and to the clear solution obtained (S)-MBA 
(S)-9 (0 32 ml, 2 5 mmole) was added dropwise The white heterogeneous mixture was stirred for 3 
h at 125°C and slowly cooled to room temperature The precipitate was filtered off, washed with 
octane, dried in vacuo and weighed A fraction of the salt was hydrolyzed and the ее of liberated 
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Ibuprofen 1 was analyzed by chiral HPLC. The principal part of the obtained salt was recrystallized 
twice from 2-propanol to give pure (S)-ibuprofen (S)-MBA (S,S)-11 as white crystals (0 6 g, 1 95 
mmole) in 78% yield and an with a de of 80 6% The ' H - N M R was in full accordance with 11 
Resolution of Ibuprofen I by (S)-phenylglycmol (S)-7 
Racemic Ibuprofen (RS)-l (0 5 g, 2 4 mmole) and (S)-phenylglycinol (S)-7 (0 33 g, 2 4 mmole) 
were dissolved in hot acetone (5 ml) or a hot mixture of toluene/hexane=2/l (v/v) and gradually 
cooled The formed crystalline salt (S,S)-20 was filtered off, washed with cold solvent, dried in 
vacuo and weighed A fraction of the salt was hydrolyzed and the ее of liberated Ibuprofen 1 was 
analyzed by chiral HPLC Results acetone as solvent 0 52 g (1 5 mmole, 63%), 39 4% de, S=0 50, 
toluene/hexane=2/l (v/v) as solvent 0 60 g (1 8 mmole, 73%), 37% de, S=0 54 
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P rediction of the Efficiency of Resolution Based on Arbitrary Conglomerate Samples 
6.1 Introduction 
The rational design of resolution processes is a topic of common interest for the industrial 
synthesis of enantiopure compounds However, no suitable method for selecting suitable resolving 
agents is available yet' Binary phase diagrams are valuable tools for the identification, selection 
and determination of efficiency of resolutions2, as was already described in chapter 5 The formation 
or existence of a conglomerate, a primary condition for a resolution, can be deduced from the 
corresponding binary phase diagram Moreover, the diagram governs the course of a resolution and 
the maximum yield (Rmax) and efficiency2 (S) can be calculated from the diagram Starting from the 
racemic composition (x0 5) and going to the isolation of a pure diastereomer (p), the following 
equations can be used to calculate these parameters' 
R m a x = ° 5 " X e u 100% (Rma4=0-50%, xCÜ<xv) (6-1) 
1 - X e u 
S = k t = k= 1 ~ 2 X e u (S=0-l,xeu<xy) (6-2) 
1 - X=u 
where χ is the molar fraction of the least soluble diastereomer, x
eu
 the eutectic position к the 
chemical yield (k=2 for 100%) and t the optical purity (t=l for 100% ее) In fact, the eutectic 
position represents the most important parameters of a resolution A more successful resolution is 
expected if the diagram has a more eccentric eutectic (a very high or very low x
eu
) However, 
determination of such diagrams for all possible resolution processes requires a substantial amount of 
experimental data and work Moreover, both pure isomers are not always available, which results in 
incomplete diagrams Kozma et al2Ь demonstrated that a binary phase diagram is a good 
approximation of a ternary phase diagram (see section 5 1) and that the binary phase diagram can 
approximately be calculated using a single DSC-measurement of the racemic composition (x0,) 
This method was applied to several known and new resolutions and the results were compared with 
experimentally determined diagrams Moreover, the scope of this method was expanded to arbitrary 
mixtures This may be of importance because racemic mixtures are not always available Often one 
diastereomer of undetermined optical purity is available at the start of a resolution study 
Furthermore, the presented method depends on the separate determination of the area of two peaks 
in a differential scanning calonmetry (DSC) thermogram (see Figure 6-1), viz the eutectic and 
mixture peak Racemic mixtures will not always give such separate peaks, especially when the 
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composition is near to the eutectic Mathematical deconvolution3 was applied to obtain more 
accurate values of the peak area's for those cases were the peaks overlapped. 
η x„ *» Ρ mW 
Figure 6-1. Calculation of a binary phase diagram based upon a single DSC thermogram 
of an eutectic mixture of diastereomers (conglomerate). 
6.2 Results and Discussion 
Calculation of the binary phase diagram using the procedure of Kozma et al.2b led to incorrect 
results in half of the cases studied. The correct composition of the eutectic mixture (x
eu
) and section 
of the diagram to which the mixture belongs, were calculated. However, calculation of the 
remaining section of the diagram gave incorrect results. For example, starting from a mixture xy 
(Figure 6-1) a correct eutectic (x
eu
), melting point (Tp), heat of fusion (ΔΗρ) and section of the 
diagram between x
eu
 and pure isomer (p) were calculated correctly, but the section of the diagram 
between pure isomer (n) and x
eu
 showed major deviations resulting in incorrect values of ΔΗ
η
 and 
T
n
. These results suggest that the described heat balance2b (eq. 6-3, AH
eu
 is the heat of fusion of the 
eutectic, AH
m
,
x
 is assumed to zero) that forms the basis for calculation of the remaining section of 
the diagram, is not applicable to most of the substrates used. The neglect of the enthalpy of mixing 
for the two isomers to the conglomerate in the liquid phase is probably the reason for the deviations 
observed*. 
Д Н
е и
= ( 1 - х
е и
) - Д Н
л + х е „ АН р + ДН т 1 Х (6-3) 
Nevertheless, this incorrect prediction forms no obstruction for this method because the 
eutectic point (x
eu
) is calculated correctly, which is the essential parameter for qualification of 
resolutions. 
From a DSC thermogram of a known mixture of two components (xy) existing as a 
conglomerate and with an observable separation of the eutectic and the mixture peak, the following 
parameters can be determined (see Figure 6-1): melting point of the eutectic (T
eu
) and remaining 
component (Ty), heat of melting (J) of the eutectic (Qeu) and remaining component (Qp). 
Deconvolution software3 can be used when no complete separation of peaks is achieved. 
The following equations can be derived from the Schröder-van Laar equation5 
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(xe u<xy) 
(xe u>xy) 
Xy 
1-
X eu 
Xcu 
Xeu 
" X y 
•ln-
ln 1-х. 
•R 
QP 
= c 
1 - X y r i to t 'K- \ A y 1 ei 
= C 
(6-4a) 
(6-4b) 
where ntot is the total amount of the sample (mol). The only unknown variable xeu can be determined 
numerically by these equations. However, these two equations experience a problem in the 
determination of the eutectic position. Based on one DSC-thermogram two eutectic positions are 
possible, viz. x
eu
>xy or xeu<xy. This is depicted in Figure 6-2 where equations 6-4a and b are 
illustrated for two xy values, viz. xy=0.5 or 0.3. The figure for xy=0.5 shows that equations 6-4a and 
b are mirror images. Therefore, in this case always correct values for x
eu
, S and R
max
 are determined. 
However, for xy*0.5 equations 6-4a and b have no relation to each other and two different values for 
x
eu
 are obtained, which results in two different binary phase diagrams (Figure 6-3). 
Figure 6-2. Numerical determination of x
eu
 using equations 6-4. 
-0,5 
υ -ι 
-1.5 
(xe u<x ) (xe u>Xy) 
xy=0.5 x y=0.3 
Figure 6-3. Two binary phase diagrams based on two calculated eutectics with xy *0 5 
x«J>xy 
; 
г 1 
¡ ^ - " " х . / : x, 
\ / 
i i 
X«U 1 X°5 X„ 
Additional information is therefore necessary when xy *0 5 to determine whether xeu >xv or 
x
eu
<xy. In most cases this information is available because mixtures with xy *0.5 originate from 
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initial resolution experiments from the racemic composition xy=0.5. Such resolution experiments 
usually give two mixtures xy when both isomers (n and p) are crystalline, viz. from the crystallized 
salt and from the mother liquor. Moreover, when there is only one crystalline isomer this 
information is also available (see Figure 6-3). When mixture xy (<x0 5) is obtained from a resolution 
starting from x 0 5 , there is an optical enrichment in isomer η and therefore xcu >0.5 because 
otherwise there would be an optical enrichment in p. As a consequence, the following general 
definitions can be applied when xy results from a resolution experiment starting from x0 5 
<=> x e u >0.5 (6-5a) xy < 0.5 
x y >0.5 <0.5 (6-5b) 
Also when the racemic salt (x0 5) is available besides xy> at least two mixtures are available to 
deduce whether x
e u
>xy or xe u<xy. 
The heat of fusion (ΔΗ
ρ
) and melting point (Tp) of component ρ can be calculated from the 
following set of equations: 
for x.„<x
v 
In 
ln(x>) = 
ΔΗ ρ 
R 
ΔΗρ 
1__ 
1 1 λ 
vTp 
for x,„>x
v 
In 
1 -x
e 
l n ( l - x , ) = 
=
 AH„ 
R 
AH„ 
Τ 
τ 
(6-6a) 
(6-7a) 
(6-6b) 
(6-7b) 
The applicability of the method described above was checked by comparing the results with 
experimental data. For this purpose salts from the following substrates, Ibuprofen 1, hydratropic 
acid 2 and mandelic acid 3, and the resolving agents, ct-methylbenzylamine (MBA) (R)-4, (R)-l-
phenyl-2-p-tolylethy lamine (PTEA) (R)-5, (S)-phenylglycinol (S)-6, (S)-l-(benzyloxy-methyl)-
propylamine (BOP) (S)-7, (-)-ephedrine (-)-8a, (-)-jV-methylephedrine (-)-8b and (+)-(2S,3R)-4-
dimethylamino-3-methyl-l,2-diphenyl-2-butanol (DMDB) (+)-9 were prepared and analyzed 
(-)-8a (R=H) 
(-)-8b (R=Me) 
Figure 6-4. Substrates and resolving agents. 
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Prediction of the Efficiency of Resolution Based on a Single and Arbitrary Conglomerate Sample 
The results of the calculations and the comparison with experimental data are summarized in 
Table 6-1 The results reveal that the calculation of physico-chemical properties of conglomerates 
from arbitrary mixtures provide acceptable results In nearly all cases a correct eutectic point (xeu) 
was calculated (±0 05) Therefore, this method can be applied in the selection and qualification of a 
resolving agent for a given substrate with a minimal amount of experimental work using the 
following protocol 
1 Preparation of the racemic salt 
2 First resolution experiment to give a mixture xy (crystallized salt) 
3 Determination of the yield and the de, which gives an impression of the experimental 
efficiency of the resolution 
4 Analyzing the mixture xy by DSC and calculation of the eutectic composition (xeu) 
5 Calculation of the theoretical efficiency, which is in fact the maximum efficiency possible 
Qualification of the resolving bases 4-8a for Ibuprofen 1 revealed that phenylglycinol 6 is the 
best resolving base6 The same qualification was provided by the calculation method shown in Table 
6-1 The salt formed from Ibuprofen 1 and (-)-ephednne (-)-8a behaves as a solid solution This is 
apparent from the DSC thermogram (only one broad peak) This observation is in line with poor 
resolution processes A relatively rare observation was made for the salt of PTEA (R)-5 and 
Ibuprofen 1, which shows partial formation of a solid solution between conglomerates Such a case 
can only be identified by construction of the whole diagram Calculation of this diagram by the 
present method would have led to wrong conclusions MBA 4 was selected as the best resolving 
base for mandelic acid 3, after evaluation of the bases 4, 8 and 9ia Also in this case the same 
conclusion resulted from the calculations shown in Table 6-1 
The correct values for calculated eutectics indicates that the deconvolution technique used for 
overlapping DSC peaks is reliable Mathematical deconvolution was used in most cases since fully 
separated peaks are an exception 
The calculated melting points of pure components are in acceptable agreement with the 
experimental values However, calculated heats of fusion are unreliable and vary too much These 
values were calculated by means of the simplified Schroder-van Laar equation which is only valid 
under specific conditions5, e g the heat of fusion should not depend on the temperature and the 
isomers should behave ideally in the solid and liquid phase These conditions were apparently not 
valid in all cases causing the observed deviations in the calculations The discrepancies of the 
calculated heats of fusion may also be responsible for the observed deviations in the calculation of 
the other section of the diagram This section was calculated with the aid of a heat balance 
(Equation 6-3) derived from heats of fusion, and also neglects the enthalpy of mixing of the 
isomers Two diagrams which fit reasonably well with the calculated ones are depicted in Figure 6-
5a and b 
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Figure 6-5. Calculated vs. experimental binary phase diagrams 
a 
- calculation based on the pure diastereomers 
experimental 
• calculation based on the mixture x=0 67 
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6.3 Conclusions 
A method for the calculation of efficiencies of resolution starting from arbitrary conglomerate 
mixtures was developed. This method can be used for the selection and qualification of resolution 
processes with minimal amount of experimental work using the described protocol. Deconvolution 
software for separating DSC peaks was on one hand indispensable and on the other hand gives 
reliable results. 
The method is restricted to conglomerates (majority of crystalline diastereomeric salts, 
minority of crystalline enantiomers). Solid solutions can be identified by a single broad peak in the 
142 
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DSC thermogram However, addition compounds or partial formation of solid solutions cannot be 
identified properly and may lead to false conclusions Also, the role of solvates or 
(pseudopolymorphism cannot be established by this method A useful resolution process may be 
overlooked when only one isomer is crystalline 
Despite these limitations this method is useful for a first selection and qualification of 
resolution processes following the protocol described and is an improvement of the traditional 'trial 
and error' method 
6.4 Derivation of the Equations 
Starting point is a mixture of two pure isomers (usually diastereomers) η and ρ which form a 
conglomerate with composition xy (Figure 6-1) The following variables are known from the DSC 
thermogram melting point of the eutectic (T
eu
) and remaining component (Ty) respectively, heat of 
melting of the eutectic (Q
c u
) and remaining component (Qp) The total amount of this mixture (n lo t) 
is described by 
n , o i = n
n y + n p y (n in mole) (6-8) 
When the eutectic mixture is richer in component ρ, ι e x
eu
 < xy, then the molar fractions of 
both components is described by 
Xy = - ^ » П р
У
 =n,„, xy (6-9) 
n,„, 
l - x , = — о л , , = п
І 0 , (1-х«) (6-10) 
Π,о. 
The amount of eutectic (n
eu
) is determined exclusively by the amount of component η present 
in the mixture Formally, the mixture xy consists only of an eutectic and component ρ (component η 
is completely integrated in the eutectic) 
Пей = n
n c u
 + n p e u (6-11) 
n „
e u
 = n„y (6-12) 
Component ρ is remaining 
Пр = Пру -Прс, (6-13) 
The molar fraction of the eutectic is described by 
x
eu
 = — (6-14) 
n
eu 
l - x
c u
= — (6-15) 
n
.u 
Combination of equations 6-14 and 6-15 results in 
n p e u = - — — nn5„ (6-16) 
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Association of equations 6-12, 6-13 and 6-16 gives 
n„ = По у — 
1-х,, 
n n ) 
Substitution of 6-9 and 6-10 in 6-17 furnishes 
Xv Xei 
n„ = 1-х., n,< 
(6-17) 
(6-18) 
The following two relations can be derived from the simplified Schroder-van Laar equation5 
ln(Xy) = ΔΗΡ 
R 
ln(x
eu
) = ΔΗ ρ 
R 
J 1_ 
V ' P ' і У 
J 1_ 
4 'ρ Uu j 
(6-7a) 
(6-19) 
where ΔΗ
ρ
 is the heat of fusion of component p, R is the gas constant, Tp and Teu the melting point 
of pure component ρ and the eutectic respectively Extraction of 6-7a from 6-19 results in 
In 
' χ .
 Λ ΔΗ„ 1 1 
R ν Ту T
e u
 j 
(6-6a) 
The heat of fusion of component ρ in combination with equation 6-17 is determined by 
Г 1 - х . . л QP _ QP Δ Η
Ρ
= ^ = 
Пр Піоі К. у Лу
 —
 Л
с и
 J 
Combination of equations 6-6a and 6-20 gives 
QP Ay Xei 
1 - X
e
u 
In 
f
 \ 1 Л 
η,οι R Τ Τ 
= c 
(6-20) 
(6-4a) 
6.5 Experimental Section 
For general remarks see section 3 4 
Racemic and enantiopure (S)-ibuprofen (RS)- and (S)-l were a kind gift from DSM Andeno, Venlo, 
The Netherlands (R)-ibuprofen (R)-l was prepared by purification of optically enriched (R)-
lbuprofen (R)-MBA salt or (R)-ibuprofen sodium salt as described in section 4 6 The chiral base 1-
(R)-phenyl-2-p-tolyl-ethylamine (PTEA) (R)-5 was a kind gift from Sumitomo Chemical Co Ltd , 
Japan 
Enantiomeric excesses of Ibuprofen 1, hydratropic acid 2 and mandelic acid 3 were determined 
using chiral HPLC (Daicel Chiralcel ODH column, UV-detection at 254 nm, flow-rate 0 5 ml/min) 
as described in section 3 4 and 4 6 Ibuprofen 1 (eluent hexane/2-propanol/trifluoroacetic acid= 
980/20/2 5, v/v), hydratropic acid 2 (eluent hexane/2-propanol/tnfluoroacetic acid=950/50/2 5, 
v/v), mandelic acid 3 (eluent hexane/2-propanol/trifluoroacetic acid=875/125/2 5, v/v) 
Calculations were performed using Microsoft Excel version 5 0 for Windows 
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Prediction of the Efficiency of Resolution Based on a Single and Arbitrary Conglomerate Sample 
DSC 
DSC thermograms were determined using a Perkin Elmer DSC7 instrument, calibrated with In and 
Zn or Sn. Samples (2-10 mg) were weighed with an accuracy of 0.01 mg and encapsulated in 
stainless steel large volume pans (75 μΐ). Thermograms were recorded at a scanning rate of 10 
°C/min, a data rate of 0.4-0.8 sec/point and with an empty pan as reference under a nitrogen 
atmosphere. Melting points are given as the top of the peaks because of broad peaks. If necessary, 
deconvolution of peaks was performed using PeakFit™° version 4 for Win32 (Jandel Scientific 
Software). Pearson IV peaks were used as peak description. 
Preparation of salts. 
Pure diastereomenc salts were prepared by mixing equimolar amounts of the respective enantiopure 
bases 4-9 and respective acids 1-3 in ethanol. The salts obtained were allowed to crystallize, filtered 
and dried in vacuo. 
Diastereomeric salt mixtures were prepared by the method described by Jacques, Collet and Wilen'. 
Accurately weighed amounts of the pure salts were dissolved in ethanol and the solution obtained 
was evaporated. The residue was dried in vacuo. The composition of mixtures obtained was 
analyzed by chiral HPLC on liberated Ibuprofen 1, hydratropic acid 2 or mandelic acid 3 
Hydrolysis of Ibuprofen, hydratropic acid or mandelic acid salts (general procedure) 
Ibuprofenates or hydratropates were hydrolyzed with IN aqueous sulfuric acid at pH 1-2, stirred for 
0 5 h at room temperature and extracted with dichloromethane (three times). The combined organic 
layers were extracted with brine, dried over MgS04 and concentrated in vacuo to give Ibuprofen 1 
or hydratropic acid 2. 
Mandelates were hydrolyzed with 2N aqueous hydrochloric acid at pH 1-2, stirred for 0.5 h at room 
temperature and extracted with ethyl acetate (three times). The combined organic layers were 
extracted with brine, dried over MgS04 and concentrated in vacuo to give mandelic acid 3. 
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6 See Chapter 5 I 
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Models m Chemistry 1995, 132, 441 
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Chapter 
A nhydride-mediated Racemization of α-Substituted Carboxylic Acids; Mild and Fast 
7.1 Introduction 
Analysis of the literature on racemization of the passed three decades learns that of the several 
available methods the base-catalyzed racemization is the most prominent one' Heating an 
enantiopure substrate with an excess or equimolar amount of hydroxide, alkoxide or amine in inert 
solvents is a generally applied racemization method. However, this method is often unsuitable when 
needed in combination with other processes in one-pot reactions In the preceding chapters 3 and 4 a 
general and base-catalyzed racemization of α-substituted carboxylic acids in the melt was 
described This method can be used in combination with a resolution processes resulting in 
crystallization-induced asymmetric transformation Mild and fast racemization of α-amino acids via 
Schiff base intermediates is another well-known procedure which is used in crystallization-induced 
asymmetric transformations (section 2 3) 
A mild method to racemize α-substituted carboxylic acids involves the use of anhydride 
intermediates in the presence of base as has been reported for 2-hydroxy-4-phenylbutync acid 1 ! 
and arylacetic acids 2' 
OH 
[ Q J , Ar^COOH 
Figure 7-1. 
According to this method α-hydroxycarboxylic acid 1 was racemized by heating with 1-3 
equivalent of acetic anhydride and 0 05-2 equivalent of base, e g sodium or potassium formate, 
acetate or benzoate, Et3N or pyridine Racemization of arylacetic acids 2 was performed by 
refluxing with 10 mol% of acetic anhydride and in the presence of sodium acetate in an apolar 
solvent, e g /¿opropyl acetate or toluene This mild racemization method may be combined with a 
kinetic resolution process, as was reported by Gartner et al4 for arylacetic acids 2 It is of interest to 
apply this racemization method for Ibuprofen 3 as the substrate The purpose of this study is to 
develop a mild and fast racemization process for Ibuprofen 3 which can be combined with (kinetic) 
resolution processes 
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7.2 Results and Discussion 
A plausible mechanism for racemization using anhydrides under basic conditions is outlined 
in Scheme 7-1. It involves three possible racemization routes, viz. direct base-catalyzed 
racemization of Ibuprofen 3 (A), racemization of asymmetric anhydride 4 (B) and a symmetric 
anhydride 5 (C). Racemization is hereby considered as the irreversible formation of a racemate from 
a pure enantiomer. It is conceivable that formation of an acylium ion and/or ketene from anhydride 
4 or 5 with an acid as leaving group plays a role. 
Ac20, Et3N ~~ 3, Et3N ^ 
rQr^COOH AcOH,Et3N r Q f ^ T ° Y ^ ÂcOH, Et3N j Q j ^ Y ° 
" ^ ^ ( S ) - 3 / B u ' " ^ ^
 (S)_4 ' B u ' ' ^ ' ( S , R ) - a n d (S,S)-5 ;Bu /Bu 
Ш 
Et3N S) Et3N © Et3N 
Ac20, Et3N 
(Bu 
r j ^ ^ X O O H AcOH, Et3N 
^ ^ ^ ( R S ) - 3 i B u 
О О 
(racemic)-5 "iBu 
Scheme 7-1. Anhydride-mediated racemization of Ibuprofen 3. 
Deprotonation of the anhydride formed is assumed to be rate-determing resulting in pseudo 
first-order kinetics. The racemization was studied by monitoring the decrease of optical activity and 
using equation 7-1 
Γ
α 0 In = k0 (7-1) 
where a 0 is the optical rotation at time zero and a, at time t, kobs is the observed racemization 
constant. The half-life period (Ц) can be calculated by equation 7-2 
In 2 
t * = 7 — С7"2) 
K 0 bs 
The results are collected in Table 7-1. The racemization does not take place when the 
acylating catalyst5 7V,N-dimethyl-4-aminopyridine (DMAP) is absent (entry 1). However, when in 
this experiment a crystal of DMAP was added acylation and racemization commenced immediately. 
This experiment indicates that direct base-catalyzed racemization via route A (Scheme 7-1) does not 
occur with Et3N as the base. This conclusion was confirmed by the experiment where strong base 
(DBN) was used: no racemization was observed (entry 7). In the presence of anhydride, however 
faster racemization can be achieved by employing the same strong base (DBN) or increasing the 
temperature (entry 5,6). An optimum result was obtained using DBN (1 equiv), acetic anhydride 
(0.1 equiv) at 50°C in toluene, under these conditions the half-life period was only 30 seconds! 
Increasing the amount of acetic anhydride does not result in an increased racemization rate 
indicating that the reaction with anhydride is not involved in the rate-determing step of 
racemization. In fact, a small decrease in the rate was observed which can be explained by a 
148 
Anhydride-mediated Racemization of α-Substituted Carboxylic Acids; Mild and Fast 
decrease of the concentration of base. Racemization was not achieved using 10 mol% of both base 
and anhydride (entry 8), thus the base concentration must be at least equimolar. 
Table 7-1. Anhydride-mediated Racemization of Ibuprofen (S)-3 in Toluene3. 
Entry 
I e 
2 
3 
4 
5 
6 
7 
8 
Base (equiv) 
Et3N (1) 
Et3N(l) 
EtjN(l) 
Et3N(l) 
DBN(l) 
DBN(l) 
DBN(l) 
DBN(O.l) 
Ac20 (equiv) 
0.1 
0.1 
1 
0.1 
0.1 
0.1 
-
0.1 
T(°C) 
RT 
RT 
50 
50 
RT 
50 
RT 
RT 
kObs(10V) b 
n.r. 
0.52 
0.32 
1.34 
40.2 
229 
n.r. 
n.r. 
4 (h) 
n.r. 
3.69 
6 
1.44 
0.05 
0.008 
n.r. 
n.r. 
a) Conditions. The optical rotation of a mixture of Ibuprofen (S)-3, Ac20, base and a catalytic 
amount of DMAP in toluene was measured continuously Concentrations were kept constant in all 
experiments b) All reactions followed pseudo first-order reaction kinetics according to equation 
7-1, η г = no reaction, c) No DMAP was added 
As reported in Chapter 3, the optimum base-catalyzed racemization conditions are obtained in 
aprotic polar solvents. Therefore, the racemization was investigated using dimethylsulfoxide 
(DMSO) and ^.jV-dimethylformamide (DMF) as the solvent (Table 7-2). These results confirmed 
that preferably aprotic polar solvents should be used in anhydride-mediated racemization under 
basic conditions. The combination DMSO/Ac20 should be handled with care because it is an 
oxidizing reagent for alcohols to aldehydes/ketones6 (Swem-type oxidation). However, in the 
present study, no problems were encountered. 
Table 7-2. Anhydride-mediated Racemization of Ibuprofen (S)-3 
by Et3N (0 1 equiv) and Ac 2 0 ( 1 equiv); Solvent Effect3. 
Entry 
1 
2 
3 
4 
5 
6C 
Solvent 
toluene 
toluene 
DMSO 
DMSO 
DMF 
DMF 
T(°C) 
RT 
50 
RT 
50 
50 
50 
kobs(10V)b 
0.52 
1.34 
0.93 
45.5 
10.7 
n.r. 
t* (h) 
3.69 
1.44 
2.08 
0.04 
0.18 
n.r. 
a) Conditions' The optical rotation of a mixture of Ibuprofen (S)-3, Ac,0, base and a catalytic 
amount of DMAP in toluene was monitored continuously Concentrations were kept constant 
in all experiments, b) All reactions followed pseudo first-order reaction kinetics according to 
equation 7-1, nr = no reaction c) No Ac20 was added 
It is conceivable that the racemization in Ac20/DMSO/base may be in part the result of 
activation of the carboxylic acid via sulfoxonium species. The Pummerer rearrangement, a possible 
side reaction of dimethylsulfoxide7 involving such sulfoxonium intermediate was not observed. 
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Racemization of Ibuprofen (S)-3 on a preparative scale was earned out using DBN (1 equiv), 
acetic anhydride (0 1 equiv) in toluene or DMF at room temperature for 30 min which gave pure 
Ibuprofen 3 in high yield and with an ее of 13% and 19% respectively (Scheme 7-2) The solvent 
effect as mentioned above was not observed in these experiments This may be due to the absence 
of the acylating catalyst DMAP Under the same conditions no racemization was observed applying 
0 1 equivalent of DBN in a more concentrated DMF solution Therefore, use of at least one 
equivalent of base seems to be a prerequisite 
COOH 
0 1 A c 2 0 , I DBN 
: 1 
RT, 30 mm OJ COOH 
(S)-3 
100% ее Solvent 
toluene 
DMF 
Yield 
98% 
93% 
ее 
13% 
19% 
Scheme 7-2. 
A general method for activation of carboxylic acids involves the use of dicyclohexyl-
carbodnmide (DCC) whereby formation of symmetric anhydrides plays a role (Scheme 7-3)" DCC 
is widely applied in peptide synthesis but is also used for various other reactions' Racemization of 
activated α-amino acids by DCC was observed as a side reaction, which however can be suppressed 
by several reagents such as 1-hydroxybenzotnazole or 3-hydroxy-3,4-dihydro-l,2,3-benzotnazin-4-
one
10 
j®m R R ι ι N N H 
Τ 
(S)-7 
1 
N-Acyl rearangement 
DCC 
m 
iBu'" О 
Η-
Ν
γ
Ν Η 
Me Π 
η U
 6 
ЮГ™ ûTïYH\a 
(S)-3 
ι hydrolysis 
О NR 
(RS)-6 iBu 
О 
COOH 
о о 
(S) 5 
R = C6H,|, DHU = dicyclohexylurea. D and F = racemization 
Scheme 7-3. Racemization of Ibuprofen 3 by DCC 
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Table 7-3. Racemization of Ibuprofen (S)-3 Using DCC a 
Entry Et3N(equiv) DCC (equiv) k o b s (10 s ' ) t./,(h) 
1 
2 
3 
1 
2 
-
0.1 
0.1 
0.1 
0.66° 
0.22c 
0.36 
2.92 
8.65 
5.34 
a) Conditions the optical rotation of a mixture of Ibuprofen (S)-3, DCC and base in dimethyl 
sulfoxide was monitored continuously at room temperature Concentrations were kept constant in all 
experiments using stock solutions of 1 0 M. b) Pseudo first-order reaction kinetics according to 
equation 7-1 c) A first-order relationship was observed after an initiation period. 
The racemization of Ibuprofen 3 was attempted with DCC in the presence of Et3N as the base. 
The results are collected in Table 7-3. The racemization rate constants and half-life periods must be 
treated with care because chiral intermediates are formed. However, the optical rotation of the 
reaction mixture decreased continuously and approached zero indicating a complete racemization. 
First-order kinetics were observed after an initiation period of 0.5 h. The corresponding k
o b s values 
are included in Table 7-3. Also a reaction in which the base was omitted was carried out (entry 3), 
which resulted in good pseudo first-order kinetics. The observation that DCC can cause 
racemization in the absence of base implies that one of the intermediates serves as the base. An 
intramolecular deprotonation of iminoanhydride 8 can conceivably facilitate the racemization 
(Scheme 7-3: E). Also the combination DMSO/DCC was used, which is known as the Pfitzner-
Mofatt reagent for the oxidation of alcohols to aldehydes/ketones". However, oxidation cannot 
occur in the present case and accordingly the typical formation of dimethyl sulfide was not observed 
(smell). 
DCC(l), DMSO 
RT, 4 h 
xJOCr 
100% ее RT, 4 h 
DCC (0 5), DMSO 
0% ее 
30% yield 
28% ее 
COOH 
3 >90% yield 
10% ее 
9 (<5%) 
Scheme 7-4. 
Racemization reactions of Ibuprofen using DMSO/DCC were performed on a preparative 
scale and were monitored by TLC, H-NMR and HPLC for possible side reactions (Scheme 7-4). 
With one equivalent of DCC the formation of N-acylurea derivative 7, a known by-product of the 
activation of carboxylic acids with DCC was observed With 0.5 equivalent of DCC the formation 
of N-acylurea 7 was suppressed (less then 5%) and Ibuprofen 3 was isolated in a yield of more than 
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90% with an ее of 10% Dicyclohexylurea (DHU) was isolated during the acidic work-up 
procedure 
Although racemization of Ibuprofen could be achieved with DCC, in the presence or absence 
of base, the experimental procedure is not very practical Apart from the fact that DCC is an 
expensive and toxic reagent, the formation of dicyclohexylurea and some N-acylurea 7 is 
cumbersome especially in the work-up Combination of this racemization procedure with a 
resolving agent in a set-up for crystallization-induced asymmetric transformation may be very 
difficult, if possible at all 
7.3 Conclusions 
A relatively mild and fast racemization method of α-substituted carboxylic acids via 
anhydride intermediates has been developed A combination of acetic anhydride and DBN in an 
aprotic polar solvent at RT-50°C is preferred Short half-life periods of less than one minute can be 
obtained The mild conditions of racemization are applicable on a preparative scale and result in 
high yields The anhydride methodology described here, in principle can be combined with a 
resolution process provided that the resolving agent does not react with acetic anhydride and thus 
will be restricted to tertiary amines Further research in this direction seems justified 
A mild and fast racemization of Ibuprofen takes place using DCC in DMSO at room 
temperature However, from a practical point of view this method is less attractive 
7.4 Experimental Section 
For general remarks see section 3 4 
Racemic and enantiopure (S)-ibuprofen were a kind gift from DSM Andeno, Venlo, The 
Netherlands Enantiomeric excesses of Ibuprofen were determined using chiral HPLC (Daicel 
Chiralcel ODH column, UV-detection at 254 nm, flow-rate 0 5 ml/min) as described in section 4 6, 
ι e eluent hexane/2-propanol/tnfluoroacetic acid=980/20/2 5, v/v) 
Racemization of (S)-Ibuprofen (SJ-3 determination of racemization rates and half-life periods 
Racemization rates (k
obs) and half-life periods (t/J of the racemization of (S)-ibuprofen (S)-3 were 
determined by monitoring the decrease of optical activity Proper aliquots of stock solutions were 
put together in a quartz cell of 1 00 dm path length, equipped with a surrounding mantle, which was 
kept at a fixed temperature by a connecting heating bath If necessary, also a crystal of DMAP was 
added to the mixture of stock solutions The optical rotation was measured immediately at the 
desired temperature, and measurements were recorded continuously Rate constants and half-life 
periods were calculated according to equations 7-1 and 7-2 Stock solutions used [(S)-3], [Ac20], 
[TFAA], [TMAA], [DCC], [Et3N] and [DBN] in dry toluene, dimethyl sulfoxide and NN-
dimethylformamide 1 0, 2 0 and 10 0M 
Racemization of (S)-Ibuprofen (S)-3 by acetic anhydride (1 equiv) and DBN (0 1 equiv) 
(S)-ibuprofen (S)-3 (1 0 g, 4 9 mmole, 100% ее), DBN (0 6 ml, 4 9 mmole) and acetic anhydride 
(46 μΐ, 0 5 mmole) were dissolved in toluene (10 ml) This mixture was stirred for 30 mm at room 
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temperature and subsequently hydrolyzed with IN aqueous sodium hydroxide. The obtained 
mixture was acidified with 2N aqueous sulfuric acid until pH 1-2 and layers were separated. The 
aqueous layer was extracted with dichloromethane (three times) and the combined organic layers 
were dried over MgS04 and concentrated in vacuo to give pure Ibuprofen 3 (980 mg, 98%). H-
NMR(CDC13, ppm): δ 0.88 (d, 6H, (CH3)2C, J=6.5 Hz), 1.49 (d, 3H, СЫ3СНСО, J=7.1 Hz), 1 6-1 9 
(m, IH, CH(CH3)2), 2.44 (d, 2H, CH2, J=6.9 Hz), 3.70 (q, IH, CHCO, J=7.1 Hz), 7.0-7.3 (m, 4H, 
ArH), 11.59 (broad s, IH, OH). HPLC: 13% ее (S). 
The same reaction was performed in DMF (10 ml) by the same procedure to give pure Ibuprofen 3 
(930 mg, 93%). The Ή-NMR was in full accordance with Ibuprofen 3. HPLC: 19% ее (S). 
Racemization of (S)-Ibuprofen (S)-3 by DCC. 
(S)-ibuprofen (S)-3 (0.5 g, 2.4 mmole, 100% ее) and DCC (0.5 g, 2.4 mmole) were dissolved in 
dimethyl sulfoxide (20 ml) and stirred for 4 h at room temperature. TLC showed the formation of a 
side product. The mixture obtained was acidified with IN aqueous sulfuric acid and a white 
precipitate (DHU) was filtered off and washed with dichloromethane. The filtrate was extracted 
with dichloromethane (three times) and the combined organic layers were dried over MgS04 and 
concentrated in vacuo. The crude product was purified by column chromatography (flash, silicagel 
60H, hexane/ethyl acetate/acetic acid=300/100/l, v/v) to give 3 (300 mg, 54%) and 9 (270 mg, 
30%). 3: The Ή-NMR was in full agreement with pure Ibuprofen 3. HPLC: 0% ее. 9: Calculated 
for C26H40N2O2: 75.68% C, 9.77% H, 6.79% N; found: 75.52% C, 9.78% H, 6.74% N. IR (CC14, 
cm"
1): ν 3380 (NH), 2980-2880 (CH), 1690 (C=0). Ή-NMR (CDC13, ppm): δ 0.87 (d, 6H, 
(CH3)2C, J=6.5 Hz), 1.0-2.0 (m, 21H, 10CH2(cyclohexyl), CH(CH3)2), 1.43 (d, 3H, СЫ3СНСО, 
J=6.8 Hz), 2.44 (d, 2H, CH2Ar, J=6.9 Hz), 3.4-3.8 (m, IH, CHNH), 3.8-4.1 (m, 2H, CHCO, CHN), 
6 9-7 3 (m, 5H, ArH, NH). HPLC: 28% ее. 
By the same procedure (S)-ibuprofen (0.5 g, 2.4 mmole) was treated with DCC (0.25 g, 1.2 mmole) 
in dimethyl sulfoxide (20 ml). Acidic work-up afforded Ibuprofen 3 with 9.8% ее (S) in a yield of 
about 90% with a slight impurity as indicated by Η-NMR and TLC. 
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Since enantiomeric stereoisomers of a chiral compound exhibit differences in physiological 
action, it is of great importance to develop and market chiral pharmaceuticals in their enantiopure 
form This consideration has a great impact on modem synthetic chemistry which is briefly 
described in chapter 1 For economic reasons resolution by selective crystallization techniques is 
still the most important method for the preparation of enantiopure compounds The major drawback 
of this method is the maximum yield of 50% in an ideal case (usually less than 40%) This process 
can be improved when an in situ racemization of the unwanted isomer can be achieved allowing for 
a maximum yield of 100% of the wanted enantiopure isomer Such a process is called a 
crystallization-induced asymmetric transformation An overview of this methodology is given in 
chapter 2 This survey shows that many successful examples are mainly the result of accidental 
discoveries, except for amino acids Therefore, a more rational design of asymmetric 
transformations preferably applicable for a broad range of compounds is desirable This thesis deals 
with the design of asymmetric transformations for a series of α-substituted carboxylic acids The 
attention was focused on some industrially attractive compounds, viz. mandehc acid 1, hydratropic 
acid 2, Ibuprofen 3 and naproxen 4 
OH ( § r t C O O H CO. COOH Ρ COOH MeO COOH 
6 0 ? H ! 
Figure 1. 
Smooth in situ racemization is a basic condition for the development of asymmetric 
transformations However, racemization has drawn little attention A review of available methods, 
focusing on the selected substrates, is presented in chapter 2 
Several racemization methods for mandelic acid 1 were studied (chapter 3) It was found that 
base-catalyzed racemization in aprotic polar solvents is the most promising method Furthermore, it 
was shown that racemization increases with increasing temperature and with electron-withdrawing 
substituents at the α-carbon atom and carboxylic acid unit Racemization is also strongly influenced 
by the change of entropy during racemization, when this entropy change is about zero as is the case 
for dioxolane derivative 5, a relatively fast racemization was observed The kinetics of the 
racemization reactions were first-order in base and substrate A very fast and mild base-catalyzed 
racemization reaction in the melt was developed The best racemizing bases in the melt are DBN 6 
and TBD 7 An important issue was the incorporation of this mild and fast racemization in the 
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design of a crystallization-induced asymmetric transformation in the melt. Two approaches were 
investigated. In the first approach an excess resolving base was used to accomplish both the 
racemization and the resolution. This method gave poor results with enantiomeric excesses (ee's) of 
5% only In the second approach two base were used, viz. a resolving base for the resolution and a 
strong achiral base for the racemization of the unwanted isomer. The best results were obtained with 
a combination of 2.5 equivalent of (S)-MBA 8 and 0.05 equivalent of DBN 6 or TBD 7 which gave 
an almost quantitative yield with an ее of 24-27% ее (Scheme 1). 
OH 2 5(S)-MBA8 O H 
z ^ A C O O H 0.05 DBN 6 or TBD 7 ^ ^ C 0 0 H 
[ О Т 1200C, 64 h 0 ,
С Л | y.eld = 91-97% 
^У (RS)-l Ч ^ (S)-l ее = 24-27% 
Scheme 1. Crystallization-induced asymmetric transformation of mandelic acid. 
Chapter 4 deals with the racemization and asymmetric transformation of the pro fens 2-4 using 
the methodology developed in chapter 3. For the base-catalyzed racemization reaction in the melt 
DBN 6 turned out to be the best base. Again, two approaches for the asymmetric transformation 
were considered, viz (1) excess of resolving base and (2) combination of a resolving base with a 
strong achiral base Only the latter showed good results and was more systematically investigated 
using Ibuprofen 3 as the substrate and MBA 8 as the resolving base. Several important parameters 
affecting the asymmetric transformation were identified, viz base strength, ratio of achiral 
base/resolving base, reaction temperature, solubility, reaction time and solvent Optimization of 
these factors resulted in an asymmetric transformation of Ibuprofen 3 in a yield of 85-95% yield and 
with an ее of 60-70%. Further improvement was achieved by optimization of both the resolution 
and the racemization step, by seeding with the optically pure isomer, starting from an optically 
enriched substrate, hot filtration, control of stirring speed and the use of varying amounts of achiral 
base. Hot filtration as isolation procedure gave the best transformation results for Ibuprofen 3, viz 
reaction of racemic 3 with 1.5-2.5 equivalent of (S)-MBA 8 in combination with 0.05 equivalent of 
DBN 6 and subsequent hot filtration resulted in (S)-3 in a yield of 70-90% yield with an ее of 73-
75% (Scheme 2). 
I 1) 1 5-2 5(S)-MBA8 ; 
I ^ V ^ C O O H 0 0 5 D B N 6 . . r ^ r ^ C O O H 
Ι К )\ 110-130°C,64-112h К ) yield = 70-90% 
y ^ - ^ ^ y (RS)-3 2) hot filtration У^У^У (S)-3 ее = 73-75% 
Scheme 2. Crystallization-induced asymmetric transformation of Ibuprofen. 
An improvement of this asymmetric transformation to produce enantiopure Ibuprofen 3 is 
difficult to accomplish with MBA 8 as it is a moderate resolving base for Ibuprofen 3. This 
observation was confirmed by an analysis of the corresponding phase diagram. 
Crystallization-induced asymmetric transformation of hydratropic acid 2 was attained using 
the optimum conditions established for Ibuprofen 3 and resulted in a yield of 94% with an ее of 
68% Suitable conditions for naproxen 4 were not found. However, an asymmetric transformation in 
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the melt of its methyl ester, a conglomerate, was accomplished using a catalytic amount of DBN 6 
giving a quantitative yield with an ее of 27% 
In chapter 5, the search of new resolving bases for Ibuprofen 3 and mandelic acid 1 is 
described Several resolving bases were considered for these substrates and qualified by their binary 
phase diagrams Conglomerate formation, a primary condition for a good resolving agent, could be 
determined from the phase diagram and the efficiency of resolution could be calculated from the 
eutectic composition Comparing these parameters for several resolving bases for a given substrate 
allowed the qualification of the resolution of choice Two new resolving bases for Ibuprofen 3, viz 
(S)-l-(benzyloxymethyl)-propylamine (S)-9 and (S)-phenylglycinol (S)-10, were identified using 
this method A comparison of the results with that of known resolving bases, viz. MBA 8 and 
lysine, revealed that (S)-phenylglycinol (S)-10 is the best resolving base for Ibuprofen 3 By the 
same procedure, two new resolving bases for mandelic acid 1 were identified, viz (-)-N-
methylephednne (-)-ll and (+)-(2S,3R)-4-dimethylamino-3-methyl-l,2-diphenyl-2-butanol (+)-12 
However, the known resolving base (S)-MBA 8 is still by far the best resolving base for mandelic 
acid 1, with ¿V-methyl-ephednne 11 as a good alternative 
O^C @r*" О^" ^Л 
(S)-9 (S)-10 (-)-H ^z^ (+)-12 
Figure 2. New resolving bases for Ibuprofen and mandelic acid. 
Chapter 6 deals with a method for the calculation of efficiencies of resolution starting from 
arbitrary conglomerate mixtures This method can be used for a fast and reliable selection and 
qualification of resolution processes with a minimum amount of experimental work A usefull 
protocol was described It was found that use of deconvolution software for overlapping peaks in 
differential scanning calonmetry (DSC) thermograms is essential and reliable 
A relatively mild and fast anhydride-mediated method for the racemization of α-substituted 
carboxylic acids is described in chapter 7 Activation with acetic anhydride should preferably be 
employed in combination with DBN 6 in aprotic polar solvents Half-life periods of less then one 
minute are possible An external base is not strictly necessary when dicyclohexylcarbodnmide 
(DCC) is employed as racemizing agent Both methods can be applied at room temperature 
resulting in a good racemization with high yields results 
In conclusion, the research described in this thesis contributes to better insights in the rational 
design of asymmetric transformations 
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Samenvatting 
Aangezien enantiomere stereoisomeren van chirale verbindingen verschillende fysiologische 
werkingen hebben is het van groot belang om chirale farmaceutica op de markt te brengen in 
enantiomeerzuivere vorm. Deze gewaarwording heeft grote invloed op de moderne synthetisch 
organische chemie zoals in het kort is beschreven in hoofdstuk 1. Resolutie via selectieve 
kristallisatie is nog steeds de belangrijkste methode voor de industriële bereiding van 
enantiomeerzuivere verbindingen, vooral omdat het een eenvoudig en goedkoop proces is. Het 
belangrijkste principiële nadeel is de maximale opbrengst van 50% (in de praktijk meestal lager dan 
40%). Een ideaal proces kan worden verkregen als het ongewenste enantiomeer in situ racemiseert 
waardoor in principe een maximale opbrengst van 100% van het gewenste isomeer mogelijk wordt. 
Een dergelijk proces wordt een kristallisatie-geïnduceerde asymmetrische transformatie genoemd. 
Een overzicht van deze methodologie staat beschreven in hoofdstuk 2. Dit literatuuronderzoek laat 
zien dat veel asymmetrische transformaties bij toeval zijn ontdekt, met uitzondering van 
aminozuren. Hierdoor is behoefte aan een meer rationele ontwikkeling van, bij voorkeur, breed 
toepasbare asymmetrische transformaties. In dit proefschrift wordt de ontwikkeling van 
asymmetrische transformaties van een serie van α-gesubstitueerde carbonzuren beschreven, waarbij 
de aandacht vooral is gericht op een aantal industrieel interessante verbindingen, te weten 
amandelzuur 1, hydratroopzuur 2, Ibuprofen 3 en naproxen 4. 
OH 
MeO 
Û?H' 
Figuur 1 
Milde racemisatie is een primaire voorwaarde voor een asymmetrische transformatie. 
Racemisaties zijn echter summier beschreven in de vakliteratuur. Een overzicht van de beschikbare 
racemisatie-methoden, toegespitst op de gekozen substraten, staat beschreven in hoofdstuk 2. 
In hoofdstuk 3 wordt ingegaan op diverse racemisatie-methoden voor amandelzuur 1. Dit 
resulteerde in optimale condities voor de base-gekatalyseerde racemisatie in aprotisch polaire 
oplosmiddelen. Aangetoond werd dat de racemisatie wordt versneld bij hogere temperaturen en 
door electronenzuigende substituenten op het a-koolstofatoom en de carboxyl functie. De 
racemisatie van dioxolaan derivaat 5 toonde aan, dat de racemisatie sterk wordt versneld als de 
entropie gedurende de racemisatie vrijwel niet verandert. Uit een kinetische studie werd 
geconcludeerd dat genoemde racemisatie-reacties eerste orde in substraat en base zijn. Op basis van 
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een studie van de racemisatie van amandelzuur 1 onder verschillende omstandigheden, werd een 
snelle en milde racemisatie in de smelt ontwikkeld. De sterke basen DBN 6 en TBD 7 gaven hierbij 
de beste resultaten. Een asymmetrische transformatie van amandelzuur 1, gebruikmakend van de 
snelle en milde racemisatie in de smelt, werd uitgevoerd volgens twee methoden. In de eerste 
methode werd een overmaat resolutie-base gebruikt om zowel de racemisatie als de resolutie te 
bewerkstelligen. Dit resulteerde echter in magere resultaten met enantiomere overmaten (ee's) van 
5%. In de tweede aanpak werden twee basen gebruikt, namelijk een chirale base voor de resolutie en 
een sterke achirale base voor de racemisatie. De beste resultaten werden behaald door gebruik van 
2 5 equivalent (S)-MBA 8 en 0.05 equivalent DBN 6 of TBD 7, hetgeen resulteerde in een bijna 
kwantitatieve opbrengst met ee's van 24-27% (Schema 1). 
O H
 2 5 (S)-MBA 8 9 H 
^ A c O O H OP* DBN 6 of TBD 7 . ^ ^ C Q O H 
I M I 1200C, 64 h K J J opbrengst = 91-97% 
^ ^ (RS)-l ^У (S)-l ее = 24-27% 
Schema 1. Kristallisatie-geïnduceerde asymmetrische transformatie van amandelzuur. 
Hoofdstuk 4 is gewijd aan de racemisatie en asymmetrische transformatie van profenen 2-4, 
uitgevoerd volgens de methodologie ontwikkeld in hoofdstuk 3. De bestudering van de base-
gekatalyseerde racemisatie in de smelt leverde DBN 6 als beste base op. Evenals in hoofdstuk 3, 
werden twee methoden toegepast voor de asymmetrische transformatie, namelijk (1) overmaat 
resolutie-base en (2) combinatie van een resolutie-base en een sterke achirale base. Alleen de laatste 
methode, die uitgebreid werd bestudeerd met Ibuprofen 3 als substraat en MBA 8 als resolutie-base, 
leverde goede resultaten op. Diverse factoren bleken een belangrijke invloed op het proces te 
hebben, namelijk base-sterkte, verhouding van achirale base/resolutie-base, reactietemperatuur, 
oplosbaarheid, reactietijd en oplosmiddel. Optimalisatie van deze parameters resulteerde in een 
asymmetrische transformatie van Ibuprofen 3 in een opbrengst van 85-95% en een ее van 60-70%. 
Verdere optimalisatie werd verkregen door zowel het resolutie als racemisatie proces te verbeteren, 
door middel van enten met optisch zuiver isomeer, uitgaan van isomeer-verrijkt substraten, heet 
affiltreren, controle van de roersnelheid en variëren van de hoeveelheid achirale base. De beste 
resultaten werden behaald door het toepassen van heet filtreren als isolatieprocedure. Reactie van 
(RS)-3 met 1.5-2.5 equivalent (S)-MBA 8 in combinatie met 0.05 equivalent DBN 6 resulteerde, na 
heet affiltreren, in de isolatie van (S)-3 in een opbrengst van 70-90% en een ее van 73-75% 
(Schema 2). 
1) 1 5-2 5(S)-MBA8 
COOH 0 0 5 D B N 6 „ , r ^ V ^ C O O H 
110-130OC, 64-112 h I K J J opbrenst = 70-90% 
2) warm affiltreren / " Ч / Ч ^ / (S)-3 ее = 73-75% 
Schema 2. Kristallisatie-geïnduceerde asymmetrische transformatie van Ibuprofen. 
Een verdere verbetering van de asymmetrische transformatie tot een ее van 100% is moeilijk, 
omdat MBA 8 een kwalitatief middelmatig resolutie-base is voor Ibuprofen 3, zoals werd bevestigd 
door een analyse van het fasediagram. 
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Knstallisatie-geinduceerde asymmetrische transformatie van hydratroopzuur 2 werd bereikt 
door toepassing van de optimale condities als beschreven voor Ibuprofen 3 Dit resulteerde in een 
opbrengst van 94% en een ее van 6 8 % Een goed systeem voor naproxen 5 is tot op heden nog niet 
gevonden Er werd echter wel een asymmetrische transformatie in de smelt van naproxen methyl 
ester, een conglomeraat, bewerkstelligd met behulp van een katalytische hoeveelheid DBN 6, 
hetgeen resulteerde in een kwantitatieve opbrengst met een ее van 2 7 % 
о н ! I 
NH2 OH | /-\^\Ь^\/К\ 
ОГПГ 0— ф^ e a r 
(S)-9 (S) 10 (-)-ll L ^ (+)-І2 
Figuur 2. Nieuwe resolutie-basen voor Ibuprofen en amandelzuur 
In hoofdstuk 5 wordt de studie naar nieuwe resolutie-basen voor Ibuprofen 3 en amandelzuur 
1 beschreven Diverse chirale basen werden getest voor deze substraten en gekwalificeerd met 
behulp van binair fasediagrammen De vorming van een conglomeraat, een primaire voorwaarde 
voor een goede resolutie, kon worden geconcludeerd uit het diagram Tevens kon de efficiency van 
een resolutie worden berekend aan de hand van de eutectische samenstelling, af te lezen uit het 
diagram Een kwalificatie van de resolutie is mogelijk door vergelijking van deze parameters voor 
diverse resolutie-basen voor hetzelfde substraat Twee nieuwe resolutie-basen, namelijk (S)-l-
(benzyloxymethyl)-propylamine (S)-9 en (S)-phenylglycinol (S)-10, werden met behulp van deze 
techniek gecertificeerd voor Ibuprofen 3 Vergelijking van de resultaten met die van bekende 
resolutie-basen, MBA 8 en lysine, leidde tot de conclusie dat (S)-phenylglycinol (S)-10 de beste 
resolutie-base is voor Ibuprofen 3 Via dezelfde procedure, werden twee nieuwe resolutie-basen, 
namelijk (-)-Ar-methylephednne (-)-ll en (+)-(2S,3R)-4-dimethylamino-3-methyl-l,2-di-phenyl-2-
butanol (+)-12, gevonden voor amandelzuur 1 De reeds bekende resolutie-base MBA 8 blijft 
echter zonder twijfel de beste resolutie-base, waarbij N-methyl-ephedrine 11 een goed alternatief is 
In hoofdstuk 6 wordt een methode beschreven voor de berekening van de efficiency van 
resoluties uitgaande van willekeurige conglomeraatsamenstelhngen Deze methode kan worden 
gebruikt voor een snelle selectie en kwalificatie van resoluties met minimale experimentele 
gegevens, volgens een beschreven protocol Hierbij wordt gebruik gemaakt van betrouwbare en 
essentiële deconvolutie software voor overlappende pieken in differential scanning calonmetry 
(DSC) thermogrammen 
In hoofdtuk 7 wordt een relatief milde en snelle racemisatie-methode voor a-gesubstitueerde 
carbonzuren via intermediaire anhydnden beschreven Activering met behulp van 
azijnzuuranhydride werd bij voorkeur uitgevoerd in combinatie met DBN 6 in aprotisch polaire 
oplosmiddelen, waarbij halfwaarde-tijden van minder dan een minuut mogelijk zijn Een externe 
base was met strikt nodig bij gebruik van dicyclohexylcarbodnmide (DCC) als racemisatie reagens 
Beide methoden werden toegepast bij kamer temperaturen en resulteerde in een snelle racemisatie 
Samenvattend kan worden gesteld dat met het onderzoek beschreven in dit proefschrift een 
beter inzicht is verkregen in de rationele ontwikkeling van asymmetrische transformaties 
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